

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC. and PFIZER INC.,
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,
Patent Owner.

Case No. IPR2018-01680
U.S. Patent No. 9,526,844 B2¹

**PATENT OWNER SANOFI-AVENTIS DEUTSCHLAND GMBH'S
NOTICE OF APPEAL UNDER 37 C.F.R. § 90.2(a)**

¹ Pfizer Inc. was joined as a petitioner in this proceeding.

Pursuant to 35 U.S.C. §§ 141–144, 319 and 37 C.F.R. § 90.2(a), notice is hereby given that Patent Owner Sanofi-Aventis Deutschland GmbH (“Sanofi”) appeals to the United States Court of Appeals for the Federal Circuit from the Final Written Decision (Paper No. 110) (the “Final Written Decision”), in IPR2018-01680, entered on May 29, 2020, by the United States Patent and Trademark Office, Patent Trial and Appeal Board (the “Board”), and from all orders, decisions, rulings, and opinions antecedent to the Final Written Decision. This appeal is timely under 35 U.S.C. § 142 and Rule 15(a)(1) of the Federal Rules of Appellate Procedure. A copy of the Final Written Decision is attached hereto as Exhibit A.

In accordance with 37 C.F.R. § 90.2(a)(3)(ii), Sanofi further indicates that the issues on appeal may include, but are not limited to, the Board’s determination that claims 21–30 of U.S. Patent Number 9,526,844 B2 have been shown to be unpatentable under 35 U.S.C. § 103 in view of the grounds of unpatentability identified in the Board’s Final Written Decision, the Board’s denial of Patent Owner’s contingent motion to amend to substitute amended claims 31–38, challenges to any findings supporting the Board’s determinations, the Board’s failure to properly consider evidence of record, the Board’s legal and factual errors in undertaking the obviousness and written description analyses, the Board’s failure to consider Sanofi’s arguments in support of patentability, the Board’s

failure to consider and address all arguments raised relating to the amended claims, the Board's procedural errors including its failure to strike and/or exclude certain of Petitioner's arguments and evidence and the Board's failure to provide Sanofi an opportunity to offer rebuttal argument and evidence, the Board's findings that conflict with the evidence of record and are not supported by substantial evidence, the Board's failure to provide Sanofi with sufficient due process, the Board's failure to provide Sanofi with just compensation, the constitutionality of the Administrative Patent Judges, and other issues decided adversely to Sanofi.

Simultaneous with this submission, a copy of this Notice of Appeal is being filed through the Patent Trial and Appeal Board End to End ("PTAB E2E") System. In addition, a copy of the Notice of Appeal, along with the required docketing fee, is being filed with the Clerk of Court for the United States Court of Appeals for the Federal Circuit.

Dated: July 23, 2020

Respectfully submitted,

/Elizabeth Stotland Weiswasser/

Elizabeth Stotland Weiswasser

Reg. No. 55,721

Anish R. Desai

Reg. No. 73,760

Sudip K. Kundu

Reg. No. 74,193

Anna Dwyer

Admitted *Pro Hac Vice*

Andrew Gesior

Reg. No. 76,588

Kathryn M. Kantha

Reg. No. 70,371

Weil, Gotshal & Manges LLP

767 Fifth Avenue

New York, NY 10153

Phone: 212-310-8000

elizabeth.weiswasser@weil.com

anish.desai@weil.com

sudip.kundu@weil.com

anna.dwyer@weil.com

andrew.gesior@weil.com

kathryn.kantha@weil.com

Adrian C. Percer

Reg. No. 46,986

Weil, Gotshal & Manges LLP

201 Redwood Shores Parkway

Redwood Shores, CA 94065

Phone: 650-802-3124

adrian.percer@weil.com

Robert T. Vlasis

Admitted *Pro Hac Vice*

William S. Ansley

Reg. No. 67,828

Matthew D. Sieger

Reg. No. 76,051

Weil, Gotshal & Manges LLP
2001 M Street NW, Ste. 600
Washington, D.C. 20036
Phone: 202-682-7000
sutton.ansley@weil.com
matthew.sieger@weil.com

W. Karl Renner
Reg No. 41,265
John S. Goetz
Reg. No. 54,867
Joshua A. Griswold
Reg. No. 46,310
Matthew S. Colvin
Reg. No. 66,843
Kenneth W. Darby, Jr.
Reg. No. 65,068
Fish & Richardson P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Phone: 202-783-5070
PTABInbound@fr.com

CERTIFICATE OF SERVICE

The undersigned certifies that, in addition to being filed electronically through the PTAB E2E System, the original version of Patent Owner Sanofi-Aventis Deutschland GmbH's Notice of Appeal, has been sent via priority mail on July 23, 2020, to the Director of the United States Patent and Trademark Office, at the following address:

Director of the United States Patent and Trademark Office
c/o Office of the General Counsel
United States Patent and Trademark Office
Madison Building East, Room 10B20
600 Dulany Street
Alexandria, VA 22314-5793

The undersigned also certified that a true and correct copy of Patent Owner Sanofi-Aventis Deutschland GmbH's Notice of Appeal and the required filing fee were filed electronically via CM/ECF on July 23, 2020, with the Clerk of Court for the United States Court of Appeals for the Federal Circuit.

The undersigned also certifies that a true and correct copy of Patent Owner Sanofi-Aventis Deutschland GmbH's Notice of Appeal was served on July 23, 2020, via electronic mail, upon the following counsel of record for Petitioner Mylan Pharmaceuticals Inc. and Pfizer Inc.:

Richard Torczon
Wesley Derryberry
Tasha Thomas
Lora Green

WILSON SONSINI GOODRICH & ROSATI
1700 K Street NW, 5th Floor
Washington, D.C. 20006
rtorczon@wsgr.com
wderryberry@wsgr.com
tthomas@wsgr.com
lgreen@wsgr.com

Douglas H. Carsten
Jeffrey W. Guise
Arthur Dykhuis
Elham F. Steiner

WILSON SONSINI GOODRICH & ROSATI
12235 El Camino Real, Suite 200
San Diego, CA 92130
dcarsten@wsgr.com
jguise@wsgr.com
adykhuis@wsgr.com
esteiner@wsgr.com

Lorelei Westin

WILSON SONSINI GOODRICH & ROSATI
650 Page Mill Road
Palo Alto, CA 94304
lwestin@wsgr.com

Nicole W. Stafford

WILSON SONSINI GOODRICH & ROSATI
900 South Capital of Texas Highway
Las Climas IV, Fifth Floor
Austin, TX 78746-5546
nstafford@wsgr.com

Jad Mills

WILSON SONSINI GOODRICH & ROSATI
701 Fifth Avenue, Suite 5100

Seattle, WA 98104
jmills@wsgr.com

Jovial Wong
Charles B. Klein
WINSTON & STRAWN LLP
1901 L Street, NW
Washington, DC 20036
jwong@winston.com
cklein@winston.com

Dan H. Hoang
WINSTON & STRAWN LLP
35 W. Wacker Drive
Chicago, IL 6061-9703
dhoang@winston.com

PfizerIPRs@winston.com

Dated: July 23, 2020

Respectfully submitted,

/Timothy J. Andersen/
Timothy J. Andersen
Case Manager
Weil Gotshal & Manges LLP
2001 M Street, NW, Suite 600
Washington, DC 20036
timothy.andersen@weil.com

Exhibit A

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC. and PFIZER INC.,¹
Petitioner,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,
Patent Owner.

IPR2018-01680
Patent 9,526,844 B2

Before HYUN J. JUNG, BART A. GERSTENBLITH, and
JAMES A. TARTAL, *Administrative Patent Judges*.

TARTAL, *Administrative Patent Judge*.

JUDGMENT
Final Written Decision
Determining All Challenged Claims Unpatentable
Denying Patent Owner's Motion to Amend
Denying Petitioner's Motion to Exclude
35 U.S.C. § 318(a)

¹ Pfizer Inc. was joined as a petitioner in this proceeding.

We have jurisdiction to conduct this *inter partes* review under 35 U.S.C. § 6. This Final Written Decision is issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73. For the reasons discussed herein, we determine that a preponderance of the evidence shows that claims 21–30 (the “Challenged Claims”) of U.S. Patent 9,526,844 B2 (Ex. 1004, “the ’844 patent”) are unpatentable. We deny the motion to amend claims filed by Sanofi-Aventis Deutschland GmbH (“Patent Owner”).² We also deny the motion to exclude.

I. INTRODUCTION

A. Summary of Procedural History

Mylan Pharmaceuticals Inc. (“Mylan”)³ filed a Petition (Paper 2, “Pet.”) requesting *inter partes* review of the Challenged Claims. Pet. 1. We instituted an *inter partes* review of the Challenged Claims on all grounds of unpatentability asserted in the Petition. Paper 22 (“Inst. Dec.”). After institution, Pfizer Inc. (“Pfizer”)⁴ separately filed a petition challenging the same claims of the ’844 patent on the same grounds asserted by Mylan, along with a motion for joinder to this case. *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-01022, Papers 2, 3 (May 2, 2019). We instituted *inter partes* review on Pfizer’s petition and granted Pfizer’s motion for joinder. Paper 47.

² Patent Owner identifies itself, Sanofi-Aventis U.S. LLC, and Sanofi Winthrop Industrie as real parties in interest. Paper 6, 2.

³ Mylan identifies itself, Mylan Inc., Mylan GmbH (Mylan N.V. subsidiaries), Biocon Research Ltd., Biocon Ltd., and Becton, Dickinson and Company as real parties in interest. Pet. 1; Paper 9, 2.

⁴ Pfizer identifies itself and Hospira, Inc., as real parties in interest. *Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH*, IPR2019-01022, Paper 2, 1.

Patent Owner filed a Patent Owner Response (Paper 32, “PO Resp.”). Mylan and Pfizer (collectively, “Petitioner”) filed a Reply to the Patent Owner Response (Paper 52, “Pet. Reply”), to which Patent Owner filed a Sur-reply (Paper 67, “PO Sur-reply”).

Patent Owner also filed a Corrected Revised Contingent Motion to Amend (Paper 73, “RMTA”).⁵ Petitioner filed an Opposition to the RMTA (Paper 80, “RMTA Opp.”), to which Patent Owner filed a Reply (Paper 90, “RMTA Reply”), and further to which Petitioner filed a Sur-reply (Paper 97, “RMTA Sur-reply”).

Patent Owner filed Observations on the Cross Examination of Mr. Karl Leinsing. Paper 84. Petitioner filed Observations Regarding the Testimony of Alexander Slocum, Ph.D. Paper 85. Patent Owner filed a Response to Petitioner’s Observations (Paper 86) and Petitioner filed a Response to Patent Owner’s Observations (Paper 87).

Petitioner filed a Motion to Exclude (Paper 92, “Mot.”). Patent Owner filed a Response in opposition to the Motion to Exclude (Paper 95, “Mot. Opp.”), to which Petitioner filed a Reply (Paper 96, “Mot. Reply”).

Oral argument was held and a transcript of the hearing appears in the record. Paper 104 (Tr.). We have jurisdiction under 35 U.S.C. § 6. This Final Written Decision is issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 (2017). Petitioner bears the burden of proving unpatentability of the Challenged Claims by a preponderance of the evidence, and the burden of persuasion never shifts to Patent Owner. *See*

⁵ Prior to filing its Corrected Revised Contingent Motion to Amend, Patent Owner filed a Contingent Motion to Amend (Paper 34), to which Petitioner filed an opposition (Paper 56), and further to which we issued Preliminary Guidance (Paper 65).

IPR2018-01680
Patent 9,526,844 B2

35 U.S.C. § 316(e) (2012); 37 C.F.R. § 42.1(d) (2017); *Dynamic Drinkware, LLC v. Nat'l Graphics, Inc.*, 800 F.3d 1375, 1378 (Fed. Cir. 2015).

B. Related Proceedings

Claims 21–30 of the '844 patent are also challenged by Mylan in IPR2018-01682, to which Pfizer was joined as petitioner based on its petition in IPR2019-01023. Patent Owner also filed a Corrected Revised Contingent Motion to Amend in IPR2018-01682 that, along with the related briefing of the parties, is substantively the same as the RMTA and related briefing filed in this case. Mylan also challenged the same claims of the '844 patent in IPR2018-01696, however, institution of *inter partes* review in that proceeding was denied.

The parties identify the following court proceedings as related matters:

Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, Sanofi Winthrop Industrie v. Mylan GmbH, Biocon Ltd., Biocon Research Ltd., Biocon Sdn. Bhd. and Biocon S.A., Case No. 2-17-cv-09105-SRC-CLW (D.N.J.) (the “NJ-9105 Case”);

Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie v. Merck Sharp & Dohme Corp., Case No. 1-16-cv-00812-RGA-MPT (D. Del.); and

Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH v. Eli Lilly and Company, Case No. 1-14-cv-00113-RGA-MPT (D. Del.).

Pet. 1–2; Paper 6, 2; Exs. 1029, 1030. On March 9, 2020, the court in the NJ-9105 Case issued an order finding that “Mylan has proven that [claims 21, 22, 25, and 30 of the '844 patent] are invalid for failure to satisfy the written description requirement stated in 35 U.S.C. § 112 ¶ 1.”

Ex. 1118, 1–2.

According to the parties, patents related to the '844 patent are challenged in IPR2018-01670, IPR2018-01675, IPR2018-01676, IPR2018-01677, IPR2018-01678, IPR2018-01679, IPR2018-01684, IPR2019-00122, IPR2019-00977, IPR2019-00978, IPR2019-00979, IPR2019-00980, IPR2019-00981, IPR2019-00982, and IPR2019-00987. Pet. 2; Paper 6, 2–3; Paper 9, 2–3; Paper 27, 2–4; Paper 60, 1–3. Patent Owner also identifies numerous U.S. patents and U.S. patent applications that claim priority to one or more of the same applications to which the '844 patent claims priority. Paper 6, 4–5; Paper 27, 5–6; Paper 60, 4–5.

C. The '844 Patent

The '844 patent, titled “Pen-Type Injector,” issued December 27, 2016, from an application filed May 17, 2016. Ex. 1004, codes (54), (45), (22). The '844 patent “relates to pen-type injectors . . . where a user may set the dose.” *Id.* at 1:25–29. We next provide a claim of the '844 patent to illustrate the subject matter followed by a description of the apparatus disclosed.

1. Illustrative Claim

Challenged claim 21 is independent. Challenged claims 22–30 depend from claim 21. Claim 21 is illustrative of the claimed subject matter and is reproduced below:

21. A drug delivery device comprising:
 - a housing comprising a dose dispensing end and a first thread;
 - a dose indicator comprising a second thread that engages with the first thread;
 - a driving member comprising a third thread;
 - a sleeve that is (i) disposed between the dose indicator and the driving member and (ii) releasably connected to the dose indicator;
 - a piston rod comprising either an internal or an external fourth thread that is engaged with the third thread;

a piston rod holder that is rotatably fixed relative to the housing and configured to (i) prevent the piston rod from rotating during dose setting and (ii) permit the piston rod to traverse axially towards the distal end during dose dispensing;

wherein:

the housing is disposed at an outermost position of the drug delivery device;

the dose indicator is disposed between the housing and the sleeve and is configured to (i) rotate and traverse axially away from the dose dispensing end during dose setting and (ii) rotate and traverse axially towards the dose dispensing end during dose dispensing;

the driving member is configured to rotate relative to the piston rod;

the sleeve is rotatably fixed relative to the driving member and configured to traverse axially with the dose indicator; and


the piston rod and the driving member are configured to rotate relative to one another during dose dispensing; and

the piston rod is configured to traverse axially towards the dose dispensing end during dose dispensing.

Ex. 1004, 8:16–49.

2. Description of the Apparatus Disclosed

Figures 1 and 2 of the '844 patent are reproduced below, as annotated by Petitioner with color-coding of certain components that Petitioner contends correspond to the features recited in claim 21 of the '844 patent.



Pet. 6–7. Figure 1 (left) and Figure 2 (right) illustrate “a sectional view of a pen-type injector” in a “cartridge full” position in Figure 1 and in a “maximum first dose dispensed” position in Figure 2. Ex. 1004, 2:60–62. As explained by Petitioner, the injector includes main housing part 4 (grey) (the recited “housing”), dose-dial sleeve 70 (green) (the recited “dose indicator”), drive sleeve 30 (red) (the recited “driving member”), clutch 60 (blue) (the recited “sleeve”), piston rod 20 (yellow) (the recited “piston rod”), and insert 16 (purple) (the recited “piston rod holder”).⁶ Pet. 4–7;

⁶ Petitioner notes that the ’844 patent refers to the needle-end of the device as the “first end” or “distal end” and to the button-end as the “second end” or “proximal end.” Pet. 8 n.2 (citing Ex. 1004, 3:8–14, claim 1).

Ex. 1004, 3:37–38, 3:59–62, 4:13–23, 4:42–44. Patent Owner similarly provides a summary of the components shown in Figures 1 and 2, further highlighting medicament cartridge 8, cartridge piston 10, clicker 50, externally-grooved dose dial sleeve 70, dose dial grip 76, and button 82. PO Resp. 7–8.

As shown in Figures 1 and 2, insert 16 is at a first end of housing part 4 and is fixed rotationally and axially to housing part 4. Ex. 1004 at 3:58–59. Insert 16 includes threaded circular opening 18, through which piston rod 20 extends. *Id.* at 3:59–62. Piston rod 20 includes first thread 19 that engages threaded circular opening 18. *Id.* at 3:65–4:1. Piston rod 20 also includes pressure foot 22 that abuts piston 10 of cartridge 8. *Id.* at 4:1–3. Drive sleeve 30 extends about piston rod 20, and second thread 24 of piston rod 20 engages internal helical groove 38 of drive sleeve 30. *Id.* at 4:13–23.

Clicker 50 and clutch 60 are disposed between drive sleeve 30 and dose-dial sleeve 70. *Id.* at 4:42–44. Clicker 50 is generally cylindrical and includes, at one end, extending arm 52 and, at the other end, saw teeth 56. *Id.* at 4:46–53. Clutch or clutch means 60 includes, at one end, saw teeth 66, which interface with saw teeth 56. *Id.* at 4:59–61, Fig. 7. Clutch 60 is generally cylindrical and includes a radially inwardly directed flange 62 and dog teeth 65 at the end opposite of saw teeth 66. *Id.* at 4:63–67. Clutch 60 is keyed to drive sleeve 30 by splines to prevent relative rotation between clutch 60 and drive sleeve 30. *Id.* at 5:2–4.

Dose-dial sleeve 70 is outside of clutch 60 but within housing 4. *Id.* at 5:12–14. Dose-dial sleeve 70 has helical groove 74 on its outer surface, and helical rib 46 of housing 4 is seated in helical groove 70 to allow relative motion. *Id.* at 5:14–20. Dose-dial grip 76 is disposed about the second end

of dose-dial sleeve 70 and secured to dose-dial sleeve 70 to prevent relative motion. *Id.* at 5:34–39.

In operation, a user rotates dose-dial grip 76 to set a dose and to cause dose-dial sleeve 70, clutch 60, and drive sleeve 30 to rotate together out of housing part 4. *Id.* at 5:60–64, Fig. 9. The dose can be reduced by turning dose-dial grip 76 in the opposite direction. *Id.* at 6:28–30, Fig. 10.

Clicker 50 and clutch 60 provide audible and tactile feedback of the dose being dialed, as torque is transmitted through the saw teeth 56, 66. *Id.* at 5:64–66. Flexible arm 52 deforms and drags toothed member 54 over splines 42 to produce a click. *Id.* at 5:67–6:2. Splines 42 may be configured such that each click corresponds to a unit dose. *Id.* at 6:2–2. Once the proper dose is set, the user then presses button 82, which causes clutch 60 to disengage from dose-dial sleeve 70 so that clutch 60 moves axially and dose-dial sleeve 70 rotates back into housing part 4. *Id.* at 6:38–45, Fig. 11. Drive sleeve 30 also moves axially and causes piston rod 20 to rotate through threaded opening 18 to dispense medicine from cartridge 8. *Id.* at 6:55–57. Drive sleeve 30 is prevented from rotating by the deformation of flexible arm 52, such that saw teeth 56, 66 are not overhauled during dispense. *Id.* at 6:46–48.

D. References and Expert Testimony

Below we provide an abbreviated summary of the qualifications of each expert that provides testimony on behalf of one of the parties in this case. We also provide a table identifying the references relied upon, as well as the exhibits corresponding to the declarations and deposition testimony in the record for each expert.

Petitioner's contentions are supported by Mr. Karl R. Leinsing, MSME, PE; Dr. William C. Biggs; and Dr. DeForest McDuff, Ph.D.

Mr. Leinsing is the President of a company that develops medical devices, previously worked as a Director of Biomedical Engineering at a company that developed implants for heart valve repair, previously worked as a Senior Principal Design Engineer on medical drug infusion products from 1992 to 2002, and has Bachelor of Science and Master of Science degrees in mechanical engineering. Ex. 1011 ¶¶ 2–6.

Dr. Biggs has been “Board Certified by the American Board of Internal Medicine in Internal Medicine since 1985,” is a Clinical Assistant Professor in the Department of Internal Medicine at Texas Tech School of Medicine, is the Medical Director of the Diabetes Center at Northwest Texas Hospital, and works “as the Principal Investigator for numerous clinical research trials involving diabetes for type 1 and type 2 diabetes, including trials that look specifically at the effect of insulins, devices, patient education, and healthcare costs.” Ex. 1048 ¶¶ 3–13.

Dr. McDuff has undergraduate degrees in economics and mathematics and a Ph.D. in economics, is a Partner at an economics consulting firm, and has “provided expert analysis and consulting in over 50 cases involving pharmaceuticals and related products, including evaluations of economic damages, competition, commercial success, irreparable harm, and other issues.” Ex. 1060 ¶¶ 1–4.

Patent Owner’s arguments are supported by Dr. Alexander H. Slocum, Ph.D.; Dr. Henry G. Grabowski, Ph.D.; and Dr. Robin S. Goland. Dr. Slocum is a Professor of Mechanical Engineering at the Massachusetts Institute of Technology, has “taught courses on mechanical design, including precision machine design, continuously since 1991,” has “taught courses on medical device design continuously since 2001,” is a consultant “for companies to assist them with various types of design challenges,” is “an

inventor on approximately 133 United States patents, many of which relate to machine elements, tools, and medical devices,” and has Bachelor of Science and Master of Science degrees in mechanical engineering and a Doctor of Philosophy degree. Ex. 2107 ¶¶ 3–13.

Dr. Grabowski is Professor Emeritus of Economics and the Director of the Program in Pharmaceuticals and Health Economics at Duke University, much of his “research has focused on pharmaceutical competition and the economics of generic medications,” and he has a Bachelor of Science degree in engineering physics and a doctorate in economics. Ex. 2109 ¶¶ 1–4.

Dr. Goland is “board-certified in Internal Medicine and Endocrinology,” has been the Chief of the Diabetes Clinic at New York-Presbyterian Hospital/Columbia University since 1987, is a Professor of Clinical Medicine, Clinical Medicine and Clinical Pediatrics, and Clinical Diabetes, and is “an experienced clinical investigator and principal investigator in diabetes trials.” Ex. 2111 ¶¶ 2–7.

References and Expert Testimony	Date	Exhibit No.
US 6,932,794 B2 (“Giambattista”)	Aug. 23, 2005	Ex. 1016
US 6,235,004 B1 (“Steenfeldt-Jensen”)	May 22, 2001	Ex. 1014
US 6,582,404 B1 (“Klitgaard”)	June 24, 2003	Ex. 1017
US 2002/0053578 A1 (“Møller”)	May 2, 2002	Ex. 1015
WO 02/092153 (“Atterbury”)	Nov. 21, 2002	Ex. 1097
US 4,648,872 (“Kamen”)	Mar. 10, 1987	Ex. 2169
US 4,747,824 (“Spinello”)	May 31, 1988	Ex. 2170
US 6,248,093 B1 (“Moberg”)	June 19, 2001	Ex. 2171
Declaration of Karl R. Leinsing, MSME, PE	Sept. 9, 2018	Ex. 1011

References and Expert Testimony (con't)	Date	Exhibit No.
Reply Declaration of Karl R. Leinsing, MSME, PE	Sept. 18, 2019	Ex. 1095
Declaration of Karl R. Leinsing, MSME, PE, Supporting Opposition to Motion to Amend	Sept. 18, 2019	Ex. 1096
Declaration of Karl R. Leinsing, MSME, PE, Supporting Opposition to Revised Motion to Amend	Dec. 17, 2019	Ex. 1113
Deposition Transcript of Karl R. Leinsing, MSME, PE	June 3, 2019	Ex. 2163
Deposition Transcript of Karl R. Leinsing, MSME, PE	June 4, 2019	Ex. 2164
Deposition Transcript of Karl R. Leinsing, MSME, PE	Oct. 10, 2019	Ex. 2316
Deposition Transcript of Karl R. Leinsing, MSME, PE	Dec. 20, 2019	Ex. 2331
Declaration of Dr. William C. Biggs	Sept. 16, 2019	Ex. 1048
Deposition Transcript of Dr. William C. Biggs	Oct. 15, 2019	Ex. 2317
Declaration of DeForest McDuff, Ph.D.	Sept. 17, 2019	Ex. 1060
Deposition Transcript of DeForest McDuff, Ph.D.	Oct. 9, 2019	Ex. 2318
Declaration of Alexander H. Slocum, Ph.D. in Support of Patent Owner Response	June 24, 2019	Ex. 2107
Declaration of Alexander H. Slocum, Ph.D. in Support of Motion to Amend	June 24, 2019	Ex. 2302
Declaration of Alexander H. Slocum, Ph.D. in Support of Revised Motion to Amend	Oct. 30, 2019	Ex. 2325
Declaration of Alexander H. Slocum, Ph.D. in Support of Reply for Revised Motion to Amend	Jan. 7, 2020	Ex. 2332

References and Expert Testimony (con't)	Date	Exhibit No.
Deposition Transcript of Alexander H. Slocum, Ph.D.	Aug. 27, 2019	Ex. 1053
Deposition Transcript of Alexander H. Slocum, Ph.D.	Aug. 28, 2019	Ex. 1054
District Court Trial Testimony Transcript of Alexander H. Slocum, Ph.D.	Dec. 4, 2019	Ex. 1114
District Court Trial Testimony Transcript of Alexander H. Slocum, Ph.D.	Dec. 5, 2019	Ex. 1115
Deposition Transcript of Alexander H. Slocum, Ph.D.	Dec. 10, 2019	Ex. 1109
Deposition Transcript of Alexander H. Slocum, Ph.D.	Jan. 10, 2020	Ex. 1117
Declaration of Henry G. Grabowski, Ph.D.	June 22, 2019	Ex. 2109
Deposition Transcript of Henry G. Grabowski, Ph.D.	Sept. 5, 2019	Ex. 1055
Declaration of Dr. Robin S. Goland	June 24, 2019	Ex. 2111
Deposition Transcript of Robin S. Goland	Sept. 10, 2019	Ex. 1056

E. The Asserted Grounds of Unpatentability

Petitioner alleges unpatentability of the Challenged Claims on the following grounds:

Claim(s) Challenged	35 U.S.C. §	Reference(s)
21–29	102(a)	Giambattista
24–29	103	Giambattista, Steinfeldt-Jensen
30	103	Giambattista, Klitgaard

F. Date of Priority for the Challenged Claims of the '844 Patent

The '844 patent issued December 27, 2016, from U.S. Application No. 15/156,616 (“the '616 application”), filed May 17, 2016. Ex. 1004, codes (21), (22), (45). The '616 application was a continuation of U.S.

Application No. 14/946,203 (“the ’203 application”), filed November 19, 2015, which, itself, was one in a series of U.S. continuation and division applications dating back to March 2, 2004. *Id.* at code (60). The ’844 patent also identifies under “Foreign Application Priority Data” a filing date of March 3, 2003, for Great Britain patent application number 0304822.0 (Ex. 1026, “the GB application”). *Id.* at code (30).

The date of priority of the Challenged Claims is potentially determinative in this case because all of Petitioner’s unpatentability grounds rely on Giambattista, which issued from an application filed April 3, 2003 (one month after the date of the GB application). Ex. 1016, codes (54), (45), (22). “Under [35 U.S.C.] section 119, the claims set forth in a United States application are entitled to the benefit of a foreign priority date if the corresponding foreign application supports the claims in the manner required by section 112, ¶ 1.” *In re Gosteli*, 872 F.2d 1008, 1010 (Fed. Cir. 1989); *see also* 35 U.S.C. § 112, ¶ 1 (“[t]he specification shall contain a written description of the invention”).

We note that Petitioner may not argue in an *inter partes* review that claims of a challenged patent are unpatentable for lack of written description under 35 U.S.C. § 112, ¶ 1. *See* 35 U.S.C. § 311(b). Thus, whether the Challenged Claims of the ’844 patent have written description support in the ’616 application is not before us. Petitioner may, however, show that the Challenged Claims are not entitled to priority to an earlier filed application because of a lack of written description in the earlier application. As such, Petitioner contends in this proceeding that the earliest priority date to which the Challenged Claims are entitled is May 17, 2016, the filing date of the ’616 application. Pet. 15. Patent Owner contends that the priority date of

the Challenged Claims is the date of the GB application, March 3, 2003. PO Resp. 19–30; PO Sur-reply 3–10.

1. Principles of Law Regarding Written Description

When a priority claim involves a chain of priority documents, “each application in the chain leading back to the earlier application must comply with the written description requirement of 35 U.S.C. § 112.” *Lockwood v. Am. Airlines, Inc.*, 107 F.3d 1565, 1571 (Fed. Cir. 1997). The test for determining compliance with the written description requirement entails “an objective inquiry into the four corners of the specification from the perspective of a person of ordinary skill in the art,” and, “[b]ased on that inquiry, the specification must describe an invention understandable to that skilled artisan and show that the inventor actually invented the invention claimed.” *Ariad Pharm., Inc. v. Eli Lilly & Co.*, 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc). As the Federal Circuit has noted, however, “[i]n order to satisfy the written description requirement, the disclosure as originally filed does not have to provide *in haec verba* support for the claimed subject matter at issue.” *Purdue Pharma L.P. v. Faulding Inc.*, 230 F.3d 1320, 1323 (Fed. Cir. 2000). Rather, “the test for sufficiency is whether the disclosure of the application relied upon reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” *Ariad*, 598 F.3d at 1351. “The level of detail required to satisfy the written description requirement varies depending on the nature and scope of the claims and on the complexity and predictability of the relevant technology.” *Id.* A lower level of detail is required to satisfy the written description requirement in cases, such as this, where the field of the invention, a mechanical device, is a predictable art. *See Hologic, Inc. v. Smith & Nephew, Inc.*, 884 F.3d 1357, 1361 (Fed. Cir. 2018). However,

“[i]t is not sufficient for purposes of the written description requirement of § 112 that the disclosure, when combined with the knowledge in the art, would lead one to speculate as to modifications that the inventor might have envisioned, but failed to disclose.” *Lockwood*, 107 F.3d at 1572.

2. *Analysis of Priority*

The dispute of the parties over the priority date of the Challenged Claims is directed to certain limitations recited in claim 21. Claim 21 requires, *inter alia*, a “dose indicator,” “a driving member comprising a third thread,” “a sleeve that is . . . disposed *between* the dose indicator and the driving member,” and “a piston rod comprising either an *internal* or an external fourth thread that is engaged with the third thread.” Ex. 1004, 8:16–31 (emphases added).

There is no dispute that applications leading to the ’844 patent expressly describe a piston rod with external threads. *See* Pet. 17. By contrast, Petitioner explains that a limitation directed to an “internally-threaded piston rod” first appeared in a claim of the ’616 application in 2016. Pet. 16; Ex. 1011 ¶ 102. Petitioner states that no prior application to which the ’844 patent claims priority either “describes an internally threaded piston rod or engaging such internal threads with external threads of a driving member” or “contain[s] a disclosure that external threads can be replaced with internal threads generically, much less specifically on the piston rod.” Pet. 16 (citing Ex. 1011 ¶¶ 101–102).

In support of its contention that the Challenged Claims are not entitled to a priority date earlier than the ’616 application, Petitioner asserts that the preceding ’203 application “and each of the applications to which it claims priority repeatedly and uniformly describe the piston rod having external threads adapted to engage internal threads of two components (the drive

sleeve and insert) that are ‘located’ between the piston rod and the housing.” *Id.* at 17–18 (citing, *e.g.*, Ex. 1025, 79, 82, Figs. 1–7, 9–13; Ex. 1026, 2:1–5, 5:19–27, 11:9–11, Figs. 1–7, 9–13). Mr. Leinsing further explains that the ’203 application, and all earlier applications to which it claims priority, do not describe a piston rod “that includes an internal thread” or “that engages with external threads of a driving member.” Ex. 1011 ¶ 101–102. The absence of any express disclosure of an internally threaded piston rod in the GB application, as explained in more detail below, is for good reason—the GB application expressly teaches, illustrates, and recites a dose dial sleeve located “between” the housing and the piston rod, corresponding to an externally threaded piston rod. Mr. Leinsing explains, in this regard, that the ’203 application “exclusively describes an injector device that has a piston rod having external threading adapted to engage internal threading of a drive sleeve and an insert, both of which are located between the piston rod and the housing.” *Id.* (citing, *e.g.*, Ex. 1025, Figs. 1–7, 9–13).

Patent Owner does not dispute that every application from the ’203 application back to the GB application fails to expressly describe an internally threaded piston rod and fails to describe any embodiment that uses an internally threaded piston rod. Instead, Patent Owner argues that “a claim does not lack written description ‘simply because the embodiments of the specification do not contain examples explicitly covering the full scope of the claim language.’” PO Resp. 20 (quoting *Falkner*, 448 F.3d at 1366) (citations omitted). Further, Patent Owner argues that because written description is based on the perspective of a person of ordinary skill in the art, “it is unnecessary to spell out every detail of the invention in the specification.” PO Sur-reply 10 (quoting *Falkner v. Inglis*, 448 F.3d 1357, 1366 (Fed. Cir. 2006) (quoting *LizardTech, Inc. v. Earth Res. Mapping, Inc.*,

424 F.3d 1336, 1345 (Fed. Cir. 2005))). By narrowly focusing only on the word “threaded,” taken out of the broader context of the GB application, Patent Owner attempts to circumvent the focus of our written description analysis—whether “the four corners of the specification” demonstrate “the inventor actually invented the invention claimed.” *Ariad Pharm.*, 598 F.3d at 1351; *see also id.* at 1352 (“a description that merely renders the invention obvious does not satisfy the [written description] requirement”).

We find Patent Owner’s arguments unpersuasive, as explained below, because this is not a case where there is merely an absence of “every detail.” Rather, there is no persuasive evidence, viewed from the perspective of a person of ordinary skill in the art, that the inventors of the ’844 patent had possession of the claimed subject matter of an internally threaded piston rod employed in the claimed pen-type injector as of the filing date of the GB application. Patent Owner seeks to fill the absence of written description in the GB application for an internally threaded piston rod by arguing that: (1) the specification is “open-ended as to whether these threads are internal or external and there’s no requirement specified here,” and (2) the broad disclosure of “threaded” demonstrates to a person of ordinary skill in the art “that the inventors were in possession of the genus of threaded piston rods (internally and externally) that engage with threads of a drive sleeve.” Tr. 73:1–73:8; PO Resp. 23.

First, Patent Owner seeks to show that the GB application is “open ended” in regard to threading by focusing on a single disclosure from the GB application, reproduced below as annotated in the declaration of Dr. Slocum:

- 25 According to a first aspect of the present invention, a pen-type injector comprises
a housing;
a piston rod adapted to operate through the housing;
a dose dial sleeve located between the housing and the piston rod, the dose dial
sleeve having a helical thread of first lead;
- 30 a drive sleeve located between the dose dial sleeve and the piston rod, the drive
sleeve having a helical groove of second lead;
characterised in that the first lead of the helical thread and the second lead of the
helical groove are the same.
- Preferably, the piston rod has a first threaded portion at a first end and a second
threaded portion at a second end;
- an insert or radially inwardly extending flange is located in the housing and
- 5 through which the first threaded portion of the piston rod may rotate;
the dose dial sleeve being rotatable with respect to the housing and the insert;
the drive sleeve being releasably connected to the dose dial sleeve and
connected to the piston rod for rotation with respect thereto along the second
threaded portion of the piston rod;

PO Resp. 23 (illustrating Ex. 1026, 7:25–8:9). The excerpt of the GB application shown above states that “[p]referably, the piston rod has a first threaded portion at a first end and a second threaded portion at a second end.” *Id.* Dr. Slocum describes what is expressly shown above—“nowhere” in the “broad disclosure” he selectively identified from the GB application “does it say that the piston rod has external threads or that the drive sleeve has internal threads.” Ex. 2107 ¶ 92. That is readily apparent, because the excerpt Dr. Slocum selected does not contain the words “internal” or “external.” But to suggest that the GB application merely discloses a threaded piston rod, without regard to whether it is internal or external threading, is a mischaracterization of what the GB application discloses, as a whole, including through figures that illustrate a piston rod only with

external threads and a drive sleeve only with internal threads.⁷ As Mr. Leinsing explains, the applications leading to the '844 patent “exclusively” describe “an injector device that has a piston rod having internal threading adapted to engage internal threading of a drive sleeve and an insert, both of which are located between the piston rod and the housing.” Ex. 1011 ¶ 101. Mr. Leinsing includes extensive citations to the '203 application in support, which we do not reproduce here, and further explains that the same is true for the GB application, with additional citations. *Id.* ¶¶ 101, 102; *see also* Pet. 17 (citing Ex. 1026, 2:1–5, 5:19–27, 11:9–11, Figs. 1–7, 9–13). Because Dr. Slocum disregards the express disclosure of an externally threaded piston rod in the GB application, we find his opinion that the GB application “broadly discloses a piston rod with threads engaged to a drive sleeve with threads” neither credible nor consistent with the GB application.

Patent Owner and Dr. Slocum not only disregard the figures that show only an externally threaded piston rod in the GB application, but also claimed limitations that suggest the threading on the piston rod is limited to external threading. The GB application expressly teaches, illustrates, and recites a dose dial sleeve located “between” the housing and the piston rod, corresponding to an externally threaded piston rod. Patent Owner argues for an unreasonably broader interpretation of “between” and contends that a person of ordinary skill “would understand that the arrangement of a drive sleeve ‘between’ a dose dial sleeve and a piston rod *does not foreclose* an

⁷ Petitioner explains that, although the figures included in the GB application are of poor quality, there is no dispute that they illustrate the same embodiment of the invention using the same figures reproduced in higher quality in subsequent applications. Pet. 17 n.4.

internally threaded piston rod.” PO Resp. 25. Showing what is not foreclosed by the GB application is not equivalent to showing the necessary written description.

Specifically, Patent Owner asserts that the GB application uses the term “between” in such a broad way as to include both a dose dial sleeve located “between” the housing and the piston rod in a radial direction, which is illustrated in the GB application, and in an axial direction, which is not disclosed or described in the GB application. PO Resp. 24–25; *see also* Ex. 2107 ¶ 93. Patent Owner attempts to support its argument by asserting that when the GB application discusses other, unrelated components, such as threading “extending between the first flange 32 and the second flange 34,” the GB application is referring to elements “between” one another “in the axial direction (i.e., lengthwise),” not in the radial direction. *Id.* at 24. Thus, Patent Owner reasons that, because the drive sleeve and dose dial sleeve may include flanges, where the GB application “states that ‘a drive sleeve located between the dose dial sleeve and the piston rod,’ it must include the situation where the drive sleeve is located axially between the dose dial sleeve and the piston rod.” *Id.* at 25 (citing Ex. 1026, 2:19–24, 8:23–24).

We find not credible and unsupported Dr. Slocum’s opinion in support of Patent Owner that the plain and ordinary meaning for “between” is nothing more than that “one must encounter B as one goes from A to C,” and that “‘between’ by itself does not imply direction.” Ex. 2107 ¶ 94. We credit the testimony of Mr. Leinsing over Dr. Slocum in this regard because it is consistent with the description provided in the GB application. As Mr. Leinsing explained:

the [GB application] describes a dose dial sleeve that is “located between the housing and the piston rod” and a drive sleeve that

is “located between the dose dial sleeve and the piston rod.” *Id.*, 7 (1:28–30). A person of ordinary skill would have understood this disclosure as detailing a concentric arrangement of parts where the piston rod is disposed within the drive sleeve, which is disposed within the dose dial sleeve, which is disposed within the housing. Indeed, this concentric arrangement is one that is uniformly depicted and described in the GB application—that is, in describing the only embodiment shown in the figures, the GB application begins with the radially innermost component, the piston rod 20, followed by the drive sleeve 30 disposed around the piston rod 20, the clicker 50 and the clutch 60 disposed around the drive sleeve 30, and the dose dial sleeve 70 disposed around the clicker 50 and the clutch 60. *See id.*, 11-14 (5:25–8:7). Thus, a person of ordinary skill would have understood the GB application as contemplating that the threaded portions of the piston rod are external threads along its outer surface, which engage with internal threads on the internal surface of a component disposed concentrically around it (i.e., the “helical groove” on the drive sleeve). *See id.*, 7–8 (1:30–2:9); *see also id.*, 12 (6:12–14) (further explaining “a helical groove 38 extends along the internal surface of the drive sleeve 30” and a “second thread 24 of the piston rod is adapted to work within the helical groove 38”).

Ex. 1095 ¶ 11. In sum, for the reasons provided above, we determine that Petitioner shows that the GB application discloses only a piston rod with external threading.

The reason Patent Owner casts the GB application as broadly describing a threaded piston rod without regard to whether the threading is internal or external is linked to Patent Owner’s next argument:

Having established that the GB Application discloses a threaded piston rod, the relevant inquiry is whether this disclosure reasonably conveys to a POSA that the inventors had possession of an internally threaded piston rod – *i.e.*, whether the disclosure of the genus (threaded piston rod) includes disclosure of a particular species (internally threaded piston rod).

PO Resp. 26. Contrary to Patent Owner's assertion, a preponderance of the evidence shows that the GB application does not disclose a genus that Patent Owner calls "threaded piston rod." There is no dispute that the GB application discloses an externally threaded piston rod, but Patent Owner has not shown that the GB application discloses or suggests any equivalent structure corresponding to an internally threaded piston rod. In other words, the GB application does not provide the species – genus construct Patent Owner seeks to apply.

It is Dr. Slocum who provides Patent Owner the missing disclosure by asserting that a person of ordinary skill in the art "would understand that there are *two ways* to implement this threaded engagement: (1) the piston rod has external threads that engage internal threads of a drive sleeve; or (2) the piston rod has internal threads that engage external threads of a drive sleeve. Ex. 2107 ¶ 92. In this way, Patent Owner seeks to create and define a genus (threaded piston rods) with two species (externally threaded piston rods and internally threaded piston rods). Dr. Slocum reasons that "[b]oth drive mechanisms were conventional at the time the GB application was filed." Ex. 2107 ¶ 92. Dr. Slocum's opinion is not convincing because the piston rod is not an isolated feature, but a part of the entire device disclosed by the GB application, which Dr. Slocum fails to adequately address. For example, Dr. Slocum's opinion is premised on his view that in the GB application "between" means nothing more than that "one must encounter B as one goes from A to C," which we rejected for the reasons provided above. Ex. 2107 ¶ 94.

We also note that Patent Owner's attempt to construct a genus-species analysis that has only two species is inconsistent with the GB application, which discloses a piston rod that has threads on both ends. Indeed,

Patent Owner argues that the disclosure of “threaded” in the GB application is so broad as to provide written description support for a piston rod with (1) internal threads at both ends, (2) external threads at both ends, (3) an internal thread at the first end and an external thread at the second end, and (4) an external thread at the first end and an internal thread at the second end. *See* Tr. 72:25–73:2 (“nowhere here is it saying that they have to be a male/female thread, an internal or an external thread”).

Mr. Leinsing, however, explains persuasively why a person of ordinary skill in the art would have understood the GB application only discloses external threading on *both* ends of the piston rod. *See* Ex. 1095 ¶ 13. We presume that Dr. Slocum intends to address only one end of the piston rod in arriving at his opinion that there are only “two ways to implement this threaded engagement.” *See also* Ex. 1053, 109:11–14 (Dr. Slocum stating that “when you read ‘threaded,’ it’s just in your brain, it’s internal and external. There’s only two options. That’s the only thing you have. It’s in your brain.”).

However, by addressing only one end of the piston rod, Dr. Slocum provides an oversimplified explanation of the number of alternative configurations encompassed by Patent Owner’s contention that “threaded,” alone, provides written description support for both internal and external threads.

Notwithstanding our misgivings about the genus-species argument, as framed by Patent Owner, Patent Owner fails to show that a person of ordinary skill in the art would have known that the apparatus disclosed in the GB application could have alternatively employed a “conventional lead screw drive mechanism” featuring an internally threaded piston rod. PO Resp. 27.

Dr. Slocum, who concedes that he had no personal experience designing injector pens as of March 2003, opines that at “the time the GB

application was filed, driving mechanisms where an internally threaded piston rod is driven by externally threaded driver were well known” to a person of ordinary skill in the art. Ex. 2107 ¶ 95; Ex. 1115, 518:17–23; PO Resp. 26. In support, Dr. Slocum identifies Kamen as teaching a medical infusion pump with “externally threaded drive screw 14 that drives an internally threaded piston member 12.” Ex. 2107 ¶ 95 (citing Ex. 2169, 1:6–10, 2:55–61). Dr. Slocum also identifies Spinello, which is directed to “a hypodermic anesthetic injection method” that includes “an axially slidable ‘piston rod [that] is internally threaded to receive a drive screw 23.’” *Id.* ¶ 96 (quoting Ex. 2170, 6:33–41). According to Dr. Slocum, such “lead-screw drive” mechanisms were described in Moberg as a “conventional” mechanism and, thus, need not have been disclosed in the GB application, because it was well known in the art. PO Resp. 27–28 (citing, e.g., Ex. 2071, 5:17–21, Figs. 3a, 3b); *see also* Ex. 2071, 4:13–17 (describing Figures 3a and 3b as views of a “conventional lead-screw drive mechanism”). Dr. Slocum concludes that because the lead-screw drive mechanism was conventional, there was no need to “to explicitly show the arrangement of an internally threaded piston rod engaged to an externally threaded drive sleeve” in the GB application. Ex. 2107 ¶ 98.

In reply, Patent Owner argues, and we agree, that showing Kamen, Spinello, or Moberg would have rendered an internally threaded piston rod obvious, as Patent Owner’s arguments suggest, is not sufficient to show written description support for an internally threaded piston rod. *See* Pet. Reply 6 (citing *Ariad*, 598 F.3d at 1352 (“a description that merely renders the invention obvious does not satisfy the requirement”)).

More importantly, the reasoning employed by Dr. Slocum is fundamentally flawed, as explained by Mr. Leinsing, because the GB

application does not merely disclose a threaded piston rod in isolation.

Mr. Leinsing explains, in this regard, the following:

Nowhere does the GB application describe that the piston rod is driven by a leadscrew or a “stinger” having a drive sleeve disposed concentrically around it. Instead, the GB application makes clear that it is the sleeve, which is located between the piston rod and the housing that moves axially to drive the piston rod. *See, e.g.*, EX1026, 7 (1:30). A person of ordinary skill would not have understood a leadscrew or a stinger to be a drive sleeve, which, I note, was acknowledged by Dr. Slocum. *See, e.g.*, EX1053, 156:11–19.


...

Each of [Kamen, Spinello, and Moberg] discloses using an externally-threaded screw that is rotated by a motor to drive the piston. *See* EX2169, Abstract (stating “[a] motor rotates a short drive screw, which engages the threads of the drive member” also called a piston member); EX2170, 6:34–42 (describing a “drive screw 23 coupled to a reversible stepper motor 24”); EX2171, 2:26–27 (“As previously noted, these lead screw drive systems use gears which are external to the motor.”), 2:55–58 (“Thus the motor 306 rotates the drive screw 305 which engages the threads of the piston member 303 to displace the piston head 304 in the axial direction d.”). They do not describe a piston rod with internal threads that engage external threads of a drive sleeve in a concentrically-arranged injection device. As I noted above, lines 7:25–8:9 of EX1026 do not describe a “driving member”—they describe a “drive sleeve,” which, through clutch means, rotates relative to a dose dial sleeve when a button is depressed, allowing the piston rod to be driven. EX1026, 8:10–13. Thus, unlike the “conventional” motor-driven leadscrew mechanisms of EX2169–EX2171, a person of ordinary skill would have understood from the GB application that it must be the sleeve, arranged between the dose dial sleeve and the piston rod, that drives the piston rod.

Ex. 1095 ¶¶ 10, 14.

In support of his opinion that a lead-screw drive mechanism was conventional, Dr. Slocum also explained during his deposition how he

envisioned an internally threaded piston rod would interact with a drive sleeve. Ex. 1053, 112:19–114:10. The illustration Dr. Slocum created during his deposition is reproduced below, with annotations provided by Patent Owner:



EX1051 (annotated)

PO Sur-reply 6; Ex. 1051. The illustration shows only one half of a device that includes a “drive sleeve” in blue with an externally threaded “stinger” at the center of the drive sleeve that mates with a “piston” in red that has a hollow center with internal threads. PO Sur-reply 6–7; Ex. 1053, 112:19–114:10, 122:20–124:16. Dr. Slocum explained: “[t]hat kind of a long threaded rod or slender rod, that would be called a stinger in the art.” Ex. 1053, 112:19–113:8. Dr. Slocum further maintains that even though he added an externally threaded rod, which he called a “stinger,” to the center of the drive sleeve, it is merely a part of the “drive sleeve,” and, therefore, an “externally threaded drive sleeve.” *Id.* at 113:9–20. Dr. Slocum acknowledges that neither a “stinger” nor the corresponding arrangement he devised and illustrated is shown or described in the GB application beyond

the disclosure of a “threaded drive sleeve.” *Id.* at 113:21–114:10. Likewise, there is no evidence to show that a “stinger” or the corresponding arrangement Dr. Slocum devised and illustrated is shown or described in Kamen, Spinello, or Moberg, the prior art references that purportedly demonstrate a conventional lead screw drive mechanism. As such, we find the evidence that Dr. Slocum, a distinguished Professor of Mechanical Engineering at the Massachusetts Institute of Technology, was able to design and illustrate an apparatus during his deposition in 2019 sheds no credible light on what a person of ordinary skill in the art would have understood from the GB application during the relevant time frame. In this regard, we credit the testimony of Mr. Leinsing, who explains the following:

Nowhere does the GB application describe that the piston rod is driven by a leadscrew or a “stinger” having a drive sleeve disposed concentrically around it. Instead, the GB application makes clear that it is *the sleeve*, which is located between the piston rod and the housing, that moves axially to drive the piston rod. *See, e.g.*, EX1026, 7 (1:30). A person of ordinary skill would not have understood a leadscrew or a stinger to be a drive sleeve, which, I note, was acknowledged by Dr. Slocum. *See, e.g.*, EX1053, 156:11-19.

Ex. 1095 ¶ 10.

Dr. Slocum also opines with regard to written description that “[r]egardless of the overall arrangement of components . . . , in the end, physics does not care which element has the internal thread and which element has the external thread.” Ex. 2107 ¶¶ 98–99. Patent Owner broadly cites to Dr. Slocum’s testimony, but does not make any argument in its response that relies on or otherwise explains the relevance of this testimony to the issue of written description. *See* PO Resp. 22 (citing Ex. 2107 ¶¶ 86–100); 28 (citing Ex. 2107 ¶¶ 97–100); 30 (citing Ex. 2107 ¶¶ 95–100). We

have nonetheless considered Dr. Slocum’s opinion that a person of ordinary skill in the art would have understood “the underlying physics” and that “providing an externally threaded piston rod engaged with an internally threaded driver was interchangeable with an internally threaded piston rod engaged with an externally threaded driver.” Ex. 2107 ¶¶ 98–99. We find that opinion to be conclusory, unsupported by evidence, and contrary to Dr. Slocum’s explanation that additional components, including a “stinger,” would need to be added to purportedly make an internally threaded driver into an externally threaded driver. Ex. 1053, 112:19–114–10.

In sum, Petitioner demonstrates that the ’844 patent is not entitled to a priority claim prior to May 17, 2016, the filing date of the ’616 application. We are not persuaded that a person having ordinary skill in the art would have recognized from the disclosure of “threaded” that the inventors were in possession of a piston rod that was either internally or externally threaded. Patent Owner does not show that the GB application provides written description support for anything other than a single embodiment with an externally-threaded piston rod. *See* Ex. 1026, 12, 7–14. This disclosure expressly states that the drive sleeve extends about the piston rod and that internal groove 38 of the drive sleeve works with thread 24 of the piston rod. *See id.*; *see also id.* at Fig. 1 (showing, somewhat illegibly, that piston rod 20 is externally threaded); *id.* at 13–14 (describing clicker 50 and clutch 60 as disposed about the drive sleeve and between the drive sleeve and dose dial 70, which is provided outside the clicker and clutch and radially inward of the main housing).

II. ANALYSIS OF PETITION

In our analysis of Petitioner’s unpatentability contentions with respect to the Challenged Claims, we next address the applicable principles of law;

the level of ordinary skill in the art; the proposed construction of claim terms; the scope and content of the asserted prior art; and then further analyze Petitioner’s contentions with respect to each alleged ground of unpatentability for purposes of determining whether Petitioner shows by a preponderance of the evidence the unpatentability of the Challenged Claims.

A. Principles of Law

Petitioner’s first asserted ground of unpatentability is based on anticipation. Pet. 3. A “prior art reference—in order to anticipate under 35 U.S.C. § 102—must not only disclose all elements of the claim within the four corners of the document, but must also disclose those elements ‘arranged as in the claim.’” *Net MoneyIN, Inc. v. VeriSign, Inc.*, 545 F.3d 1359, 1369 (Fed. Cir. 2008) (quoting *Connell v. Sears, Roebuck & Co.*, 722 F.2d 1542, 1548 (Fed. Cir. 1983)). “A single prior art reference may anticipate without disclosing a feature of the claimed invention if such feature is necessarily present, or inherent, in that reference.” *Allergan, Inc. v. Apotex Inc.*, 754 F.3d 952, 958 (Fed. Cir. 2014) (citing *Schering Corp. v. Geneva Pharm.*, 339 F.3d 1373, 1377 (Fed. Cir. 2003)).

Petitioner’s two other asserted grounds of unpatentability are based on obviousness. Pet. 3. A patent claim is unpatentable as obvious if “the differences between” the claimed subject matter “and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.” 35 U.S.C. § 103(a).⁸ An invention “composed of

⁸ The Leahy-Smith America Invents Act (“AIA”), Pub. L. No. 112-29, 125 Stat. 284, 287–88 (2011), amended 35 U.S.C. § 103 effective March 16, 2013. We quote the AIA version of 35 U.S.C. § 103, which applies to applications with an effective filing date after March 16, 2013, however, the

several elements is not proved obvious merely by demonstrating that each of its elements was, independently, known in the prior art.” *KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 418 (2007).

The question of obviousness is resolved on the basis of underlying factual determinations, including: (1) the scope and content of the prior art; (2) any differences between the claimed subject matter and the prior art; (3) the level of skill in the art; and (4) objective evidence of nonobviousness. *Graham v. John Deere Co. of Kansas City*, 383 U.S. 1, 17–18 (1966). An obviousness determination “cannot be sustained by mere conclusory statements; instead, there must be some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.” *KSR*, 550 U.S. at 418 (quoting *In re Kahn*, 441 F.3d 977, 988 (Fed. Cir. 2006)); see *In re Magnum Oil Tools Int’l, Ltd.*, 829 F.3d 1364, 1380 (Fed. Cir. 2016). Rather, “it can be important to identify a reason that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does.” *Id.*

B. Level of Ordinary Skill in the Art

In determining whether an invention would have been obvious at the time it was made, 35 U.S.C. § 103 requires us to resolve the level of ordinary skill in the pertinent art at the time of the invention. *Graham*, 383 U.S. at 17. The person of ordinary skill in the art is a hypothetical person who is presumed to have known the relevant art at the time of the invention. *In re GPAC, Inc.*, 57 F.3d 1573, 1579 (Fed. Cir. 1995).

pre-AIA version of § 103 is nearly identical and any differences do not affect our analysis here.

Petitioner proposes that a person having ordinary skill in the art would have “had, through education or practical experience, at least the equivalent of a bachelor’s degree in mechanical engineering, or a related field” and “would have understood the basics of medical-device design and manufacturing, and basic mechanical elements (*e.g.*, gears, pistons) involved in drug-delivery devices.” Pet. 18 (citing Ex. 1011 ¶¶ 105–106). Patent Owner proposes a similar level of ordinary skill in the art and states that any difference from Petitioner’s proposal is immaterial to the arguments presented. PO Resp. 11. Based on the evidence provided, including the prior art of record, we agree with Petitioner’s proposed level of ordinary skill and also find that the prior art of record further reflects the level of ordinary skill in the art. *See Okajima v. Bourdeau*, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (noting that the prior art of record may reflect the level of ordinary skill in the art).

C. Claim Construction

In an *inter partes* review, “[a] claim in an unexpired patent . . . shall be given its broadest reasonable construction in light of the specification of the patent in which it appears.” 37 C.F.R. § 42.100(b) (2017); *Cuozzo Speed Techs., LLC v. Lee*, 136 S. Ct. 2131, 2142 (2016) (upholding the use of the broadest reasonable interpretation standard).⁹ “Under a broadest reasonable

⁹ Although the claim construction standard applied in *inter partes* review was changed to the federal court claim construction standard used in a civil action under 35 U.S.C. § 282(b), that change does not apply to this proceeding because the Petition was filed before November 13, 2018, the effective date of the change. *See Changes to the Claim Construction Standard for Interpreting Claims in Trial Proceedings Before the Patent Trial and Appeal Board*, 83 Fed. Reg. 51,340, 51,344 (Oct. 11, 2018) (now codified at 37 C.F.R. pt. 42 (2019)).

interpretation, words of the claim must be given their plain meaning, unless such meaning is inconsistent with the specification and prosecution history.” *TriVascular, Inc. v. Samuels*, 812 F.3d 1056, 1062 (Fed. Cir. 2016). If the Specification “reveal[s] a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess[,] . . . the inventor’s lexicography governs.” *Phillips v. AWH Corp.*, 415 F.3d 1303, 1316 (Fed. Cir. 2005) (en banc) (citing *CCS Fitness, Inc. v. Brunswick Corp.*, 288 F.3d 1359, 1366 (Fed. Cir. 2002)).

Petitioner asserts that “claim terms should be given their ordinary and accustomed meaning, consistent with the specification and how they would have been understood by” a person having ordinary skill in the art. Pet. 18. Petitioner also asserts that Patent Owner has taken claim construction positions for certain claim terms in district court proceedings, and that the broadest reasonable interpretation of those terms should at least encompass Patent Owner’s proposed constructions in district court. *Id.* at 19.

In particular, Petitioner identifies the terms in the table below and provides definitions based on Patent Owner’s district court contentions.

Claim Term	Proposed Meaning (supporting citation)
“driving member”	“A component releasably connected to the dose dial sleeve that drives the piston during dose dispensing.” (Ex. 1019, 28.)
“main housing”	“An exterior unitary or multipart component configured to house, fix, protect, guide, and/or engage with one or more inner components.” (<i>Id.</i> at 21.)
“piston rod”	“A rod that engages with the driving member to advance the piston during dose dispensing.” (<i>Id.</i> at 27.)

Claim Term	Proposed Meaning (supporting citation)
“the piston rod and the driving member are configured to rotate relative to one another during dose dispensing”	Plain and ordinary meaning such that “during dose dispensing, the piston rod rotates while the driving member does not rotate, the driving member rotates while the piston rod does not rotate, or both rotate at different rates and/or directions.” (<i>Id.</i> at 27 (citing Ex. 1004, 6:38–67, FIG. 11; claim 21)).
“thread”	“A rib or groove on a first structure that engages a corresponding groove or rib on a second structure.” (<i>Id.</i> at 30.)
“clutch”	“A structure that couples and decouples a moveable component from another component.” (<i>Id.</i> at 24.)
“clicker”	“A structure that provides audible and/or tactile feedback when the dose knob is rotated.” (<i>Id.</i> at 31.)
“holder”	Plain and ordinary meaning such that a person of ordinary skill in the art “would understand to be ‘a structure that holds a referenced structure’ (e.g., a piston rod holder holds a piston rod).” <i>Id.</i> at 33.

Pet. 19–20. Petitioner also states that, in district court proceedings, Mylan proposed means-plus-function constructions for the terms “clutch,” “clicker,” and “holder.” *Id.* at 20. Petitioner identifies the functions and structures related to these three terms. *See id.* at 20–22.

Patent Owner does not propose alternative constructions and maintains that “no express constructions are required” to demonstrate that the Challenged Claims are patentable over the asserted prior art. PO Resp. 11. We agree with Patent Owner that no claim term requires express construction. *See Wellman, Inc. v. Eastman Chem. Co.*, 642 F.3d 1355, 1361 (Fed. Cir. 2011) (“claim terms need only be construed ‘to the extent necessary to resolve the controversy’” (internal citation omitted)). In as much as claim 22, or any other claim, must be construed to some extent, we address it in our patentability analysis below.

D. Scope and Content of the Prior Art

Petitioner relies on Giambattista, Steinfeldt-Jensen, and Klitgaard to show the unpatentability of the Challenged Claims. Each of these references is summarized briefly below.

1. Summary of Giambattista

Giambattista, titled “Medication Delivery Pen,” issued August 23, 2005, from an application filed April 3, 2003. Ex. 1016, codes (54), (45), (22). Giambattista is directed to “medication delivery pens, such as those used in administering insulin.” Ex. 1016, 1:6–7.

Figure 2 of Giambattista is reproduced below:




Figure 2 illustrates “an exploded view of a medication delivery pen constructed in accordance with [Giambattista’s] invention.” *Id.* at 2:1–2. Giambattista’s medication delivery pen includes cap 12, cartridge holder 14,

spinner 16, body 18, dose knob 20, dosing ring 22, driver 24, leadscrew 26, dosing ring adaptor 28, and thumb button 30. *Id.* at 2:36–40. Spinner 16 is configured to engage plunger 38 to expel drug from drug cartridge 32. *Id.* at 2:47–50.

Body 18 is generally cylindrical and includes bulkhead 44, which extends across the interior of body 18 and contains aperture 46. Ex. 1016, 2:66–3:3. Aperture 46 allows leadscrew 26 to pass through, but has a rectangular shape to prevent leadscrew 26 from rotating when positioned through aperture 46. *Id.* at 3:3–6. Driver 24 is fixed axially relative to body 18, yet rotates relative to body 18. *Id.* at 3:21–22.

Dosing ring 22 and dosing ring adaptor 28 are mounted onto driver 24 with splines 86 extending into the keyways 74. Ex. 1016, 3:43–46, Fig. 9. As a result, dosing ring 22 cannot rotate relative to driver 24, yet splines 86 are formed to allow dosing ring 22 to axially move along the length of keyways 74. *Id.* at 3:46–49, Fig. 9.

Dose knob 20 is generally tubular and is used to set the dose for the pen. Ex. 1016, 3:56–60. Dose knob 20 rotates within body 18, translating that rotation to axial displacement of dose knob 20 relative to body 18 in setting a desired dosage. *Id.* at 3:63–66, Fig. 11. Dose knob 20 includes one or more ratchet arms 96, which are aligned with longitudinal ribs 80 so that rotation of dose knob 20 relative to dosing ring 22 results in ratchet arms 96 acting against ribs 80 to provide a user an audible signal of the dose being set. *Id.* at 4:1–8. Giambattista’s pen allows dose knob 20 to be “dialed back” if the user inadvertently passes the intended dose setting. Ex. 1016, 4:61–64.

2. *Summary of Steinfeldt-Jensen*

Steenfeldt-Jensen, titled “Injection Syringe,” issued May 22, 2001, from an application filed October 28, 1999. Ex. 1014, codes (54), (45), (22). Steinfeldt-Jensen relates to “injection syringes of the kind apportioning set doses of a medicine from a cartridge . . . [and] are mainly made for users who have to inject themselves frequently, e.g. diabetics.” *Id.* at 1:12–17.

Figures 15–17 of Steinfeldt-Jensen are reproduced below:




Figure 15 illustrates “a sectional side view” of an injection syringe, Figure 16 illustrates a “sectional side view perpendicular to the view in [Figure] 15,” and Figure 17 depicts “an exploded view of the syringe in [Figures] 15 and 16.” Ex. 1014; *Id.* at 5:23–28. The injection syringe includes tubular housing 1 that is partitioned so that a first division has ampoule holder 2. *Id.* at 5:38–40. Ampoule holder 2 has a central bore with

thread 5 that engages external thread 7 of piston rod 6. *Id.* at 5:55–58. Driver tube 85 is disposed about piston rod 6. *See id.* at Figs. 15–17. “The piston rod has a not round cross-section and fits through the driver tube bore which has a corresponding not round cross-section” so that “rotation is transmitted” and “the piston rod is allowed to move longitudinally through the driver tube.” *Id.* at 11:15–19.

Scale drum 80 within housing 1 has on its outer wall a helical track that engages a helical rib on the inner wall of housing 1. *Id.* at 11:20–22. One end of scale drum 80 has a larger diameter so as to form dose setting button 81. *Id.* at 11:22–24. Bushing 82 fits within scale drum 80 and over driver tube 85. *Id.* at 11:26–29. Bushing 82 is coupled to driver tube 85 so that both bushing 82 and driver tube 85 can rotate, but not move longitudinally. *Id.* at 11:30–33. Injection button 88 is rotatably mounted at an end of bushing 82. *Id.* at 49–51. A dose is set by rotating dose setting button 81, which causes scale drum 80 to rotate out of housing 1. *Id.* at 11:52–55. Injection button 88 is pressed to inject the set dose, and bushing 82 rotates with dose setting button 81, because of the engagement of the helical track of scale drum 80 with the rib of housing 1 when scale drum 80 is pressed into housing 1. *Id.* at 12:4–10. The rotation of bushing 82 rotates driver tube 85, causing piston rod 6 to rotate and screw into ampoule 89 in ampoule holder 2. *Id.* at 12:10–13.

Steenfeldt-Jensen also teaches audible and tactile clicks formed when setting the dose that represent one unit of dose. Specifically, Steenfeldt-Jensen states as follows:

To set a dose the ampoule holder 2 is rotated anticlockwise in the first division of the housing 1. This rotation is performed against a resistance presented due to the fact that a protrusion 30 on the outer wall of the ampoule holder rests in one of a number

of depressions 31 circumferentially provided in the inner wall of said first division of the housing as shown in the cross-sectional view in FIG. 3. The angular spacing of the depressions are appropriately made so that a dose of one unit is set when the protrusion is moved from one depression to the [neighboring] depression so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.

Id. at 6:42–53.

3. Summary of Klitgaard

Klitgaard, titled “Dose Setting Limiter,” issued June 24, 2003, from an application filed September 6, 2000. Ex. 1017, codes (54), (45), (22). Klitgaard is directed to “injection devices where[] the contents of a cartridge are injected as a number of individually set doses.” *Id.* at 1:13–15. Figure 3 of Klitgaard is reproduced below:




Fig. 3

Figure 3 illustrates “the dose setting member, the driver, and the track follower of an[] embodiment of an injection syringe.” *Id.* at 2:60–63. Relevant to our decision, Klitgaard discloses nut member 32, which is disposed between dose setting-member 30 and driver 31. *Id.* at 4:26–29. During dose setting, nut member 32 rotates with dose-setting element 30 relative to driver 31 because of the engagement between ridge 35 and

recess 34, such that the position of nut member 32 on driver 31 depends on the set dose. *Id.* at 4:33–37. When the medicine is injected, dose-setting member 30 is forced to rotate relative to the housing and transmits rotational force to driver 31, but nut member 32 maintains its position on driver 31, such that the position indicates the total injected dose. *Id.* at 4:37–58.

E. Alleged Anticipation by Giambattista

Petitioner contends that claims 21–29 of the '844 patent are anticipated by Giambattista. Pet. 27–66; Pet. Reply 7–12. Patent Owner argues that certain limitations of claims 22 and 24–29 are not disclosed by Giambattista. PO Resp. 30–35; PO Sur-reply 10–13. We address the Challenged Claims below and determine for the reasons provided that Petitioner shows by a preponderance of the evidence that Giambattista anticipates claims 21–24 and 26–28 of the '844 patent, but does not anticipate claims 25 and 29.


1. Differences Between the Subject Matter of Independent Claim 21 and Giambattista

Petitioner shows that Giambattista discloses every limitation of claim 21 through a claim chart which provides citations to the disclosures in Giambattista that correspond to each limitation of claim 21. Pet. 27–53. Petitioner's contentions are also supported by Mr. Leinsing. Ex. 1011 ¶¶ 544–575. Patent Owner does not dispute that Giambattista discloses every limitation of claim 21, and instead relies only on its argument that Giambattista is not prior art, which we find not persuasive as explained above. *See generally* PO Resp. Thus, Patent Owner does not identify any differences between the subject matter of claim 21 and the disclosures of Giambattista. We are persuaded that Petitioner shows by a preponderance of the evidence that Giambattista discloses every limitation of claim 21 for the

reasons identified in the Petition (pages 27–53 (citing Ex. 1016, Abstract; 1:8–19; 1:44–46; 2:26–40; 2:42–53, 2:66–3:25; 3:39–49; 3:56–67; 4:21–27; 4:37–64; 5:8–28; Figs. 1, 2, 3, 5, 7–12)), which we adopt as our own findings.

2. *Differences Between the Subject Matter of Dependent Claim 22 and Giambattista*

Claim 22 depends from claim 21 and further requires that “the piston rod has a circular cross-section.” Ex. 1004, 8:50–51. Petitioner relies on a portion of Figure 2 of Giambattista, which is reproduced below.



Pet. 54. The portion of Figure 2 of Giambattista reproduced above illustrates leadscrew 26 with threaded end 103 and spinner 16 with threaded aperture 105 “formed to threadedly engage the threaded end 103 in mounting spinner 16 onto the leadscrew 26.” *Id.* (quoting Ex. 1016, 4:28–33). Mr. Leinsing further explains that Figure 2 “depicts threaded end 103 having a circular cross-section configured to engage with circular threaded aperture 105 in spinner 16,” and that the opposite end of leadscrew 26 also has a circular cross-section. Ex. 1011 ¶ 577. Petitioner argues that claim 22 of the ’844 does not require a piston rod with a uniformly circular cross-section along its entire length, and that leadscrew 26 satisfies the limitation because it has a circular cross-section at each end. *Id.* Patent Owner does

not dispute that the ends of leadscrew 26 of Giambattista have a circular cross-section. PO Resp. 30–33.

Petitioner also contends that because leadscrew 26 has “circular helical threads along the majority of its length” it is “understood to have a ‘circular cross-section’ with flat sides.” *Id.* (citing Ex. 1011 ¶ 577). Mr. Leinsing provides no evidence in support of the assertion that a piston rod with circular helical threads and flat sides is “understood to have a ‘circular cross-section.’” Ex. 1011 ¶ 577. We, therefore, find that argument unsupported and conclusory. The only issue remaining is whether the claim language is satisfied if, as shown in Giambattista, only a portion of the piston rod has a circular cross-section.

Patent Owner first argues that leadscrew 26 has a non-circular cross-section. PO Resp. 31. That is only half true – portions of leadscrew 26 have a non-circular cross-section where the sides are flat and portions of leadscrew 26 have a circular cross-section, most notably at the ends. Patent Owner’s suggestion that leadscrew 26 “would not work for its intended purpose” if, presumably, its entire length had a circular cross-section is irrelevant to whether leadscrew 26 discloses what is claimed – a piston rod that “has a circular cross-section.” *See* PO Resp. 30–31. Likewise, Patent Owner’s argument that Steinfeldt-Jensen describes a piston rod similar to leadscrew 26 of Giambattista as having a “not round cross-section” is irrelevant because, as shown by Giambattista, a piston rod may have portions that have a circular cross-section and portions that do not have a circular cross-section. *Id.* at 31.

The only responsive argument advanced by Patent Owner is that Petitioner’s interpretation of the claim language “is not reasonable.” *Id.* at 32; PO Sur-reply 10–12. According to Patent Owner:

nowhere in the claim or specification is it suggested or described that the cross-section of the piston rod is defined by the very ends (e.g., the head) of the piston rod. Rather, the specification shows that the piston rod has a circular cross-section over its length because it is adapted to engage with and move rotationally and axially relative to the cylindrical bore in the drive sleeve. *See* Ex. 1004 at 3:65–66, 4:13-14, 6:55–58, Figs. 9–11; Ex. 2107, ¶¶ 418–19.

PO Resp. 32. Thus, Patent Owner argues that we should read into claim 22 a limitation that the entire piston rod must have a circular cross-section throughout (“over” or “along”) its length because (1) the specification doesn’t say where the cross-section of the piston rod is defined, and (2) an embodiment shown in the specification has a circular cross-section over its length.¹⁰

The plain language of the claim is not as limited as Patent Owner now suggests and requires only that “the piston rod has a circular cross-section.” The claim does not require a circular cross-section along the entire length of the piston rod and Patent Owner offers no persuasive reason for reading such a limitation into the claim. If Patent Owner’s narrow construction of the claim language were correct, a piston rod that had a circular cross-section along nearly its entire length would not have a “circular cross-section” within the scope of claim 22 if any portion of it did not have a circular cross-section. To the extent Patent Owner implies that the circular cross-section need not be throughout the “entire” length, such a construction would be inconsistent with the plain language of the claim, which does not recite a

¹⁰ Patent Owner belatedly suggests in its Sur-reply that “common sense and customary usage” would lead a person of ordinary skill to look to the “functional part of the piston rod” to determine the cross-section. PO Sur-reply 11. This argument was not raised in the Patent Owner Response and is unsupported by any evidence.

“circular cross-section” over “most” or “a majority” of the piston rod. It also would be unreasonably vague and ambiguous, because Patent Owner offers no explanation for how a person of ordinary skill in the art would have known whether any particular piston rod satisfied the claim language. Given the choice between construing “the piston rod has a circular cross-section” to mean either the entire piston rod has a circular cross-section or some portion of the piston rod has a circular cross-section, Petitioner has shown that the broadest reasonable construction is the latter. There is no dispute that portions of Giambattista’s leadscrew 26 have a circular cross-section. Therefore, we find that Petitioner shows by a preponderance of the evidence that Giambattista discloses every limitation of claim 22.

3. *Differences Between the Subject Matter of Dependent Claim 23 and Giambattista*

Claim 23 depends from claim 21 and further requires “a clutch.” Ex. 1004, 8:52–53. Petitioner shows how Giambattista discloses every additional limitation of dependent claim 23 through a claim chart, which provides citations to the disclosures in Giambattista that correspond to each limitation of claim 23. Pet. 55–56. Petitioner’s contentions are supported by Mr. Leinsing. Ex. 1011 ¶ 578. Specifically, Petitioner shows that dosing ring 22 and dosing ring adaptor 28 correspond to the recited “clutch,” because they couple and decouple a moveable component from another moveable component. Pet. 55–60 (citing Ex. 1016, 3:39–47, 4:21–36, 4:49–53, 5:8–19, 5:26–28; Ex. 1011 ¶ 578; *see also* Ex. 1019, 24 (Patent Owner construing “clutch” to mean a “structure that couples and decouples a moveable component from another component”). Patent Owner does not dispute that Giambattista discloses every limitation of claim 23. *See generally* PO Resp. We are persuaded that Petitioner shows by a

preponderance of the evidence that Giambattista discloses every limitation of claim 23 for the reasons identified in the Petition (pages 55–56 (citing Ex. 1016, 3:43–47; 4:21–36; 4:49–53; 5:8–19; 5:26–28)), which we adopt as our own findings.

4. *Differences Between the Subject Matter of Dependent Claims 24–29 and Giambattista*

Claim 24 depends from claims 23, which depends from claim 21, and further recites “where the clutch provides audible and tactile feedback *indicative* of unit doses of medicament.” Ex. 1004, 8:54–56 (emphasis added). Claim 25 depends from claim 24 and recites “where the clutch provides audible clicks during dose cancelling, where each click is *equal to* a unit dose of medicament.” *Id.* at 8:57–59 (emphasis added). Claims 26–28 also depend from claim 24. *Id.* at 8:57–9:3. Claim 29 depends from claim 21 and, similar to claim 25, recites “a clicker that provides audible clicks during dose setting, where each click is *equal to* a unit dose of medicament.” *Id.* at 9:4–7 (emphasis added).

Petitioner shows, and Patent Owner does not dispute, that dosing ring 22 and ring adaptor 28 of Giambattista operate as the recited “clutch” and provide “audible and tactile feedback.” Pet. 55–58 (citing, e.g., Ex. 1016, 3:43–47, 4:1–12, 4:49–53, 5:8–19, Fig. 8; Ex. 1011 ¶¶ 578–581). Giambattista expressly explains that “rotation of the dose knob 20 relative to the dosing ring 22 results in the ratchet arms 96 acting against ribs 80 in a ratcheting manner giving a user an audible signal of such rotation.” Ex. 1016, 4:5–8. Mr. Leinsing also explains that “the user necessarily would have tactile feedback as well as audible feedback because the audible feedback is created by the physical impact of the inwardly-biased ratchet arms 96 of dose knob 20 on longitudinal ribs 80 of dosing ring 22.”

Ex. 1011 ¶ 581. The only issues in dispute are whether the feedback provided by the clutch of Giambattista is “indicative of unit doses of medicament,” as required by claims 24 and 26–28, and whether each click is equal to a unit dose of medicament.

To show that Giambattista discloses the recited limitations, Petitioner relies on Mr. Leinsing, who explains that “rotation of dose knob 20 [of Giambattista] to set a dose occurs in discrete unit doses defined by each click,” and that “[o]nce a dose is set for a given number of unit doses, dose knob 20 will maintain that setting until a different dose is set comprising a different number of unit doses.” Ex. 1011 ¶¶ 582, 594; *see also* Pet. 59 (citing Ex. 1011 ¶¶ 582, 584, 585, 594). Mr. Leinsing further states that Figure 8 of Giambattista “demonstrates that ribs 80 are evenly spaced around dosing ring 22, which means that each unit dose represented by each audible signal is the same.” Ex. 1011 ¶ 585.

Patent Owner argues that “nowhere does Giambattista disclose audible or tactile feedback *indicative of unit doses*.” PO Resp. 34. According to Patent Owner, “Giambattista has no disclosure that one click corresponds to one unit dose or, for example, that five clicks correspond to one unit dose,” and that “Giambattista does not disclose that the number of ribs 80 corresponds to unit doses.” *Id.* at 35.

In reply, Petitioner argues that Giambattista need not use the term “unit dose” to anticipate the Challenged Claims, because Giambattista discloses “the tactile and audible feedback in each click equals a dose that qualifies as a unit dose.” Pet. Reply 11. Patent Owner responds that Petitioner still fails to identify any language, even if not identical, that discloses the limitation. PO Sur-reply 13.

Neither party directly addresses what is meant by “unit dose” or “unit doses.” In this regard, the ’844 patent states only that “[p]referably, the splines 42 are disposed such that each click corresponds to a unit dose,” and, in regard to an alternate embodiment, that “[p]referably the saw teeth 56,66 are so disposed that the circumferential extent of each saw tooth corresponds to a unit dose.” Ex. 1004, 6:2–3, 6:35–37. From this we understand that, at a minimum, a “unit dose” is not defined by the structure of the apparatus that is providing the feedback, i.e., a click. If that were the case there would be no need to “preferably” size the apparatus such that “each click corresponds to a unit dose.”

As to claims 24 and 26–28, which only require “feedback *indicative* of unit doses,” we find more persuasive Petitioner’s argument, supported by Mr. Leinsing, than Patent Owner’s unsupported argument, as we note that Dr. Slocum did not address this issue in his declaration. *See* Ex. 2109. Patent Owner does not dispute that rotation of dose knob 20 of Giambattista to set a dose occurs in discrete increments defined by each click, as explained by Mr. Leinsing. Ex. 1011 ¶ 582. Thus, for any “unit dose” there will be a corresponding number of clicks “indicative” of that dose because each click indicates some measure of medicament that corresponds to some portion of any dose defined as a unit dose. Patent Owner does not show that the recited claim language requires any more than that. Patent Owner’s assertion that Giambattista fails to disclose whether “one click corresponds to one unit dose or, for example, that five clicks correspond to one unit dose,” is beyond the scope of claims 24 and 26–28, which do not require any specific correspondence between the feedback and a unit dose.

Petitioner further shows how Giambattista discloses every additional limitation of dependent claims 24 and 26–28 through claim charts, which

provides citations to the disclosures in Giambattista that correspond to each limitation of claims 24–29. Pet. 56–66. Petitioner’s contentions are supported by Mr. Leinsing. Ex. 1011 ¶¶ 579–596. Beyond the arguments addressed above, Patent Owner does not otherwise dispute that Giambattista discloses every limitation of claims 24 and 26–28. We are persuaded that Petitioner shows by a preponderance of the evidence that Giambattista discloses every limitation of claims 24 and 26–28 for the reasons identified in the Petition (pages 56–66 (citing Ex. 1016, 3:19–21; 3:39–40; 3:56–60; 4:1–12; 4:21–27; 4:33–36; 4:49–5:3; 5:8–28, Figs. 2, 7, 8, 11, 12)), which, in addition to our findings above, we adopt as our own findings.

As to claims 25 and 29, a specific correspondence between the feedback and a unit dose is required, because the claims recite “each click is equal to a unit dose of medicament.” Petitioner implicitly seeks to define a “unit dose” by the operation of the apparatus: “the tactile and audible feedback in each click equals a dose that qualifies as a unit dose.” Pet. Reply 11. Petitioner offers no explanation for why each click necessarily “qualifies” as a unit dose. We find such an interpretation of the claim language unreasonably broad in light of the disclosures in the Specification of the ’844 patent discussed above, which make clear that a “unit dose” is not defined by the structure of the apparatus that is providing the feedback. Accordingly, we find that Petitioner does not show by a preponderance of the evidence that Giambattista discloses “each click is equal to a unit dose of medicament,” as required by claims 25 and 29.

5. Conclusion on Anticipation by Giambattista

For the reasons provided above, we determine that Petitioner shows by a preponderance of the evidence that Giambattista discloses every limitation and, therefore, anticipates claims 21–24 and 26–28 of

the '844 patent. Additionally, because Petitioner does not show that Giambattista discloses “each click is equal to a unit dose of medicament,” Petitioner does not show by a preponderance of the evidence that Giambattista anticipates claims 25 and 29.

F. Alleged Obviousness over Giambattista and Steinfeldt-Jensen

Petitioner contends that claims 24–29 of the '844 patent would have been obvious over the combination of Giambattista and Steinfeldt-Jensen. Pet. 66–69; Pet. Reply 12–14. Patent Owner argues that the asserted combination is based improperly on hindsight. PO Resp. 35–38; PO Sur-reply 13–14. We address each of these claims below and determine for the reasons provided that Petitioner shows by a preponderance of the evidence that the combination of Giambattista and Steinfeldt-Jensen teaches every limitation of claims 24–29 of the '844 patent and demonstrates a legally sufficient rationale in support of the combination.

1. Differences Between the Subject Matter of Claims 24–29 and the Teachings of Giambattista and Steinfeldt-Jensen

Petitioner contends that Giambattista discloses every limitation of claims 21–29, as discussed above in regard to anticipation, and that “[t]o the extent Giambattista’s disclosure regarding its clicking feature does not teach that each click is equal to a unit dose, Steinfeldt-Jensen’s express teaching of this feature was readily applicable to Giambattista.” Pet. 66. As explained above, we agree, and Patent Owner does not dispute, that Giambattista teaches every limitation of claims 24–29 other than “each click is equal to a unit dose of medicament.”

With regard to the clicking features, Petitioner shows, and Patent Owner does not dispute, that “Steenfeldt-Jensen taught a clicking system that, like the system disclosed in Giambattista, operates by having a

protrusion extend into a number of depressions such that the spacing of the depressions causes tactile and audible signal as the protrusion snaps into the depressions.” Pet. 66–67 (citing Ex. 1014, 6:48–54, 11:37–40, 11:62–67); *see also* Ex. 1011 ¶¶ 597–600 (explaining the operation of Steinfeldt-Jensen with respect to audible and tactile feedback during dose setting). There also is no dispute that Steinfeldt-Jensen teaches both “audible and tactile feedback *indicative* of unit doses of medicament,” as well as “audible clicks during dose setting, where each click is equal to a unit dose of medicament,” as recited in the claims challenged. *See* Pet. 66–67. In this regard, Steinfeldt-Jensen expressly states the following:

To set a dose the ampoule holder 2 is rotated anticlockwise in the first division of the housing 1. This rotation is performed against a resistance presented due to the fact that a protrusion 30 on the outer wall of the ampoule holder rests in one of a number of depressions 31 circumferentially provided in the inner wall of said first division of the housing as shown in the cross-sectional view in FIG. 3. The angular spacing of the depressions are appropriately made so that a dose of one unit is set when the protrusion is moved from one depression to the neighbouring depression so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.

Ex. 1014, 6:42–53. In sum, there is no dispute that the combination of Giambattista and Steinfeldt-Jensen teaches every limitation of claims 24–29.

2. Reasons for the Combination of Giambattista and Steinfeldt-Jensen

Petitioner relies on the teaching of Steinfeldt-Jensen, reproduced above, as providing “a reason to a [person of ordinary skill in the art] to likewise arrange longitudinal ribs 80 so that a dose of one unit is set for each click so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.” Pet. 67–68 (citing Ex. 1011 ¶ 601); *see also id.* at 68–69 (stating that “it would have been obvious to a

[person of ordinary skill in the art] to place the splines of Giambattista such that each click corresponds to a set dose so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose”). In support of Petitioner’s rationale, Mr. Leinsing explains that “Steenfeldt-Jensen expressly teaches it is ‘appropriate,’ or beneficial, to arrange the clicker so that a dose of one unit is set for each click and so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.” Ex. 1011 ¶ 601. Petitioner also contends that a person of ordinary skill in the art would have had a reasonable expectation of success in applying Steenfeldt-Jensen to Giambattista because it is a simple calculation to calibrate the device to a desired unit dose. Pet. 68 (citing Ex. 1011 ¶ 602).

Patent Owner argues that Petitioner “fails to provide a motivation for a [person of ordinary skill in the art] to modify Giambattista in view of Steenfeldt-Jensen, which is required to support obviousness.” PO Resp. 36. Specifically, Patent Owner first contends that the “Giambattista pen was not designed to solve the problem of providing audible or tactile feedback indicative of unit doses,” and, therefore, “does not disclose or suggest that its pen could be modified to provide audible or tactile feedback indicative of unit doses.” *Id.* at 37. Patent Owner’s argument cites no legal authority in support and has no discernable merit. In an obviousness analysis the art to be modified need not be “designed to solve the problem” addressed by the modification and need not “disclose or suggest” it could be modified.

Second, Patent Owner argues that the “only justification for the modification is the limitation itself,” and that Petitioner fails to explain “why” a person of ordinary skill in the art would be motivated to make the modification, not simply that such a person was able to make the

modification. *Id.* at 37–38 (citing *Polaris Indus. v. Arctic Cat, Inc.*, 882 F.3d 1056, 1068 (Fed. Cir. 2018)). Patent Owner attempts to further support its argument by contending that where “Steenfeldt-Jensen” states that “the depressions are appropriately made,” it is to accommodate the protrusion and “does not provide a motivation for making the feedback indicative of unit doses.” PO Sur-reply 14. Although expert testimony is not required, we note that Dr. Slocum does not provide an opinion in support of Patent Owner’s arguments in this regard.

We credit the testimony of Mr. Leinsing over the insufficiently supported arguments of Patent Owner and find the reason provided by Petitioner in support of the asserted combination persuasive. *See* Ex. 1011 ¶ 601. Petitioner demonstrates that a person of ordinary skill in the art would have understood from Steenfeldt-Jensen that the benefit of “appropriately” sizing the apparatus was “so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.” Ex. 1014, 6:42–53. That the clicks “correspond” to the dose setting is the clear benefit taught by Steenfeldt-Jensen for “appropriately” sizing the apparatus. In sum, we find that Petitioner demonstrates that the combination of Giambattista and Steenfeldt-Jensen teaches every limitation of claims 25–29 and establishes a legally sufficient rationale in support of the combination.

3. *Objective Indicia of Nonobviousness*

We next consider evidence of objective indicia of nonobviousness related to a product that Patent Owner asserts practices claims of the ’844 patent and “satisfied a long-felt need in the industry,” received industry praise, and attained “overwhelming commercial success.” PO Resp. 2–3, 46–57; PO Sur-reply 19–25. Petitioner argues in response that

Patent Owner fails to show a nexus between the purported evidence of objective indicia of nonobviousness and the Challenged Claims and that the offered evidence fails to support Patent Owner's contentions. Pet.

Reply 17–31.

As background to Patent Owner's arguments, Patent Owner sold an insulin glargine solution administered as a once-daily subcutaneous injection for patients diagnosed with either Type 1 or Type 2 diabetes under the tradename Lantus[®] in three different forms. Ex. 2109 ¶¶ 6, 17. The first form launched in the United States in 2001 as “Lantus[®] vial” and is administered through a syringe. *Id.* ¶¶ 6, 18. The second form launched in the United States in 2005 in a pen injector form as “Lantus[®] OptiClik[®],” but was subsequently discontinued and allegedly did not practice the '844 patent. *Id.* ¶¶ 19, 36; Ex. 2107 ¶¶ 644–648. The third form launched in the United States in 2007 in a pen injector form as “Lantus[®] SoloSTAR[®].” Thereafter, in addition to Lantus[®], a “long-acting insulin analog,” Patent Owner also sold “fast-acting” injectable insulin with the SoloSTAR[®] pen injector, including Apidra[®] SoloSTAR[®] and Admelog[®] SoloSTAR[®]. *Id.* ¶¶ 6, 17, 22; Ex. 1048 ¶ 39. Patent Owner also explains that at the time of the invention of the '844 patent “there were already several pen-type injectors known in the art,” including the commercially available Novo Nordisk FlexPen[®] which “closely corresponds” to an embodiment described in Steinfeldt-Jensen and which was marketed for administering an insulin analog as the “Levemir[®] FlexPen[®].” PO Resp. 3 (citing Ex. 1014, Figs. 1–17; Ex. 2107 ¶ 28), 49, 54.

According to Patent Owner, the SoloSTAR[®] pen injector practices claims 21 and 30 of the '844 patent. PO Resp. 2–3; Ex. 2109 ¶ 20; Ex. 2107 ¶¶ 551–610. Patent Owner's contention is persuasively supported by Dr.

Slocum’s unrebutted testimony that the SoloSTAR[®] pen injector practices claims 21 and 30 of the ’844 patent. Ex. 2107 ¶¶ 551–610; *see id.* ¶ 551 (stating that “it is my opinion that the SoloSTAR[®] device practices at least claims 21 and 30 of the ’844 patent”). Accordingly, based on Dr. Slocum’s testimony, Patent Owner shows that SoloSTAR[®] practices claims 21 and 30 of the ’844 patent.

Patent Owner, however, does not focus its arguments of objective evidence of nonobviousness on SoloSTAR[®] alone (with the exception of industry praise), but instead proceeds to argue that “Sanofi’s Lantus[®] SoloSTAR[®] practices claims 21 and 30” of the ’844 patent. PO Resp. 47 (footnote omitted). Importantly, none of the Challenged Claims of the ’844 patent recite Lantus[®] or any other medication as a required limitation. Presumably, Patent Owner implicitly reasons that because SoloSTAR[®], a pen injector for administering a medication, practices the Challenged Claims, the same pen injector sold as a combination product with medication, Lantus[®], necessarily also practices the claimed invention. Petitioner does not dispute Patent Owner’s contention and we are persuaded that Lantus[®] SoloSTAR[®] practices claims 21 and 30 of the ’844 patent for the same reasons Patent Owner sufficiently established that SoloSTAR[®] practices the same claims.

As a brief summary of the legal standards we apply with regard to evidence of objective indicia of nonobviousness, we emphasize that such indicia are “only relevant to the obviousness inquiry ‘if there is a nexus between the claimed invention and the [objective indicia of nonobviousness].’” *In re Affinity Labs of Tex., LLC*, 856 F.3d 883, 901 (Fed. Cir. 2017) (quoting *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1312 (Fed. Cir. 2006)). A patentee is entitled to a presumption of nexus

“when the patentee shows that the asserted objective evidence is tied to a specific product and that product ‘embodies the claimed features, and is coextensive with them.’” *Fox Factory, Inc. v. SRAM, LLC*, 944 F.3d 1366, 1373 (Fed. Cir. 2019) (quoting *Polaris Indus., Inc. v. Arctic Cat, Inc.*, 882 F.3d 1056, 1072 (Fed. Cir. 2018) (quoting *Brown & Williamson Tobacco Corp. v. Philip Morris Inc.*, 229 F.3d 1120, 1130 (Fed. Cir. 2000))). If the patented invention is only a component of a commercially successful machine or process, the patentee is not entitled to a presumption of nexus. *Id.* (reaffirming the importance of the “coextensiveness” requirement). “[T]he purpose of the coextensiveness requirement is to ensure that nexus is only presumed when the product tied to the evidence of secondary considerations ‘is the invention disclosed and claimed.’” *Id.* at 1374 (quoting *Demaco Corp. v. F. Von Langsdorff Licensing Ltd.*, 851 F.2d 1387, 1392 (Fed. Cir. 1988)). “[T]he degree of correspondence between a product and a patent claim falls along a spectrum. At one end of the spectrum lies perfect or near perfect correspondence. At the other end lies no or very little correspondence.” *Id.* “A patent claim is not coextensive with a product that includes a ‘critical’ unclaimed feature that is claimed by a different patent and that materially impacts the product’s functionality.” *Id.* at 1375.

Patent Owner does not argue that Lantus[®] SoloSTAR[®] is coextensive (or nearly coextensive) with any of the Challenged Claims, which do not require medication. Accordingly, to the extent that Patent Owner relies on evidence based on Lantus[®] SoloSTAR[®] to show objective indicia of nonobviousness, Patent Owner does not show that it is entitled to a presumption of nexus.

However, “[a] finding that a presumption of nexus is inappropriate does not end the inquiry into secondary considerations.” *Fox Factory*,

944 F.3d at 1375. “To the contrary, the patent owner is still afforded an opportunity to prove nexus by showing that the evidence of secondary considerations is the ‘direct result of the unique characteristics of the claimed invention.’” *Id.* at 1373–74 (quoting *In re Huang*, 100 F.3d 135, 140 (Fed. Cir. 1996)). “Where the offered secondary consideration actually results from something other than what is both claimed and *novel* in the claim, there is no nexus to the merits of the claimed invention,” meaning that “there must be a nexus to some aspect of the claim not already in the prior art.” *In re Kao*, 639 F.3d 1057, 1068–69 (Fed. Cir. 2011) (emphasis in original). Additionally, there is no requirement that “objective evidence must be tied exclusively to claim elements that are not disclosed in a particular prior art reference in order for that evidence to carry substantial weight.” *WBIP, LLC v. Kohler Co.*, 829 F.3d 1317, 1331 (Fed. Cir. 2016). A patent owner may show, for example, “that it is the claimed combination as a whole that serves as a nexus for the objective evidence; proof of nexus is not limited to only when objective evidence is tied to the supposedly ‘new’ feature(s).” *Id.*

Indeed, Patent Owner argues, as to the claimed invention of the ’844 patent, that the components recited in the Challenged Claims “work together” to provide a device that is “easy to use” and that yields “a combination of desirable features and properties, such as (i) low injection force, (ii) short injection stroke length or higher maximum dose per injection, and (iii) a relatively small number of components that decrease the complexity of the device.” PO Resp. 47 (citing Ex. 2107 ¶ 651). To be clear, these alleged “features and properties” do not correspond to any recited limitation in any of the Challenged Claims. As Petitioner explains, Lantus® SoloSTAR® “is not ‘the invention’ of these claims,” because “the

claims do not require Lantus[®]] (or insulin at all), an 80-unit cartridge, a particular stroke length or injection force.” Pet. Reply 18. Moreover, Patent Owner offers no objective definition or explanation of what constitutes an “easy to use” pen injector, a “low injection force,” a “short injection stroke length,” a “higher maximum dose,” or a “relatively small number of components.”

Ultimately, the fact finder must weigh the secondary considerations evidence presented in the context of whether the claimed invention as a whole would have been obvious to a skilled artisan. *WBIP*, 829 F.3d at 1331–32. Once the patentee has presented a *prima facie* case of nexus, the burden of coming forward with evidence in rebuttal shifts to the challenger “to adduce evidence to show that the commercial success was due to extraneous factors other than the patented invention.” *Demaco*, 851 F.2d at 1393. Below we consider in more detail the evidence and argument provided by the parties with regard to any purported long-felt need, industry praise, and commercial success in light of the alleged nexus to the required features of the Challenged Claims of the ’844 patent.

a) Long-Felt, Unmet Need

Patent Owner contends that “Lantus[®] SoloSTAR[®] satisfied long-felt, but unresolved needs existing in commercially available pen injectors.” PO Resp. 48–52; PO Sur-reply, 24–25; *see also* Pet. Reply 26–28 (disputing Patent Owner’s contentions of long-felt need). Specifically, Patent Owner contends its product “satisfied a long-felt but unmet need for an easy-to-use pen that was particularly well suited to administer medication with a low injection force.” *Id.* at 52.

Based on Dr. Goland’s testimony, Patent Owner asserts that “diabetic patients need an easy-to-use injection device with a low injection force to

reduce the burden on the patient and increase the likelihood of the patient adhering to their prescribed therapy.” *Id.* at 49 (citing Ex. 2111 ¶¶ 24–26). Patent Owner further explains that “[p]rior to the launch of Lantus[®] SoloSTAR[®], there were multiple injection pens on the market for administering insulin or an insulin analog,” but they all required “significant injection force” and that “made the devices difficult to use and thus increased the risk of patients not adhering to their insulin and insulin-analog therapy.” *Id.* at 49 (citing Ex. 2107 ¶ 646; Ex. 2109 ¶¶ 52–55; Ex. 2111 ¶¶ 23–25, 33–35; Ex. 2143; Ex. 2144).

Patent Owner argues that “Lantus[®] SoloSTAR[®] revolutionized the injection pen market, in large part because the Lantus[®] SoloSTAR[®] was easy to use,” and attributes that ease of use to the “reduced injection force,” which Patent Owner characterizes as “a primary concern.” *Id.* at 49–50 (citing Ex. 2111 ¶ 33; Ex. 2116, 7; Ex. 2142). According to Patent Owner, “the primary intent of the invention” of the ’844 patent is described in the patent as an embodiment that “helps reduce the overall force required for a user to cause medicinal product to be dispensed.” *Id.* at 50 (quoting Ex. 1004, 4:7–9). Patent Owner also identifies a “related patent” that describes presumably the same “drive mechanism” as the one taught in the ’844 patent as “an alternative for drive mechanisms, wherein reduced force is needed to actuate the mechanism.” *Id.* (quoting Ex. 1005, 1:66–2:3).

In support of its contention that “Lantus[®] SoloSTAR[®] satisfied a long-felt, unmet need, Patent Owner argues that “[t]he industry extensively recognized SoloSTAR[®] for solving the problem of needing to deliver high doses with a short dial extension and with low injection force,” and that patients “expressed a preference for SoloSTAR[®] for its low injection force.”

Id. at 51 (citing Ex. 2117; Ex. 2121, 2, 9; Ex. 2123, 6; Ex. 2128; Ex. 2143; Ex. 2144; Ex. 2184, 2; Ex. 2185, 1).

(1) Patent Owner Fails to Show a Nexus Between the Purported Evidence of Alleged Long-felt Need and Any Challenged Claim of the '844 Patent

There is no dispute that none of the Challenged Claims recite or otherwise require a low injection force, the ability to deliver high doses, or a short dial extension. Thus, to show that the Challenged Claims satisfied a long-felt, unmet need for an injection pen with these features, Patent Owner must show that the purported low injection force, ability to deliver high doses, and/or short dial extension is the direct result of the unique characteristics of the claimed invention. *Fox Factory*, 944 F.3d at 1373–74. Patent Owner fails to carry this burden. The entirety of Patent Owner’s argument and evidence on this specific issue consists essentially of the assertion that Dr. Slocum explained that “the inventions in the challenged claims describe a set of components that elegantly work together.” PO Resp. 47 (citing Ex. 2107 ¶ 651¹¹); *see also id.* at 48 (stating that “due to the contributions of the above features described by” Dr. Slocum, “the Lantus[®] SoloSTAR[®] satisfied long-felt, but unresolved needs existing in commercially available pen injectors”); *see also* PO Sur-reply 21 (stating that “the challenged claims enable SoloSTAR[®]’s low injection force and other features identified in the Response”).

We have considered Dr. Slocum’s testimony and find it insufficient to support Patent Owner’s contentions. In his declaration, Dr. Slocum

¹¹ Patent Owner’s citation to Exhibit 2107 ¶ 651, the “CONCLUSION AND JURAT,” appears to be in error and we assume Patent Owner intended to cite the prior paragraph which we reproduce below.

addressed how SoloSTAR[®] practices claims of *four different patents*, including the '844 patent. Ex. 2107 ¶¶ 439–649. Dr. Slocum then addresses in a single paragraph, reproduced below, the “Benefits of the Claims of the Challenged Patents”:

In my opinion, the claimed components and interfaces, such as the threaded engagements, piston rod, drive sleeves/driving members, dose stops, and clutch enable an injection device with (i) low injection force, (ii) short or long injection stroke length for low or high dose per injection, and (iii) a relatively small number of components that decrease the complexity and cost of the device. The arrangement of components limits the frictional losses in the mechanism, thereby providing an efficient force transmission from the user's hand to the injection piston in the ampoule that contains the medicament. The challenged claims also enable a device without a “resetting” operation, thereby making the injection pen easier to use. The challenged claims further enabled an injection device with a shorter dial extension, providing additional benefits for patients lacking dexterity. Specifically, the SoloSTAR[®] has a maximum of 80 units, while the FlexPen[®] only has a maximum of 60 units. While the SoloSTAR[®]'s dial would extend to 25.5mm to inject 60 units, the FlexPen[®] must extend to 33mm to inject 60 units. All of these features are evidenced in the SoloSTAR[®] injector pen which practices the inventions of the challenged claims. The embodiments described in the challenged patents also show that these advantages can be realized by a small number of components, thereby enabling a device that can be manufactured at lower cost. Also, because the pen is disposable, the components can be made of inexpensive materials, thereby further reducing the production costs.

Id. ¶ 650. Dr. Slocum fails to explain which “claimed components and interfaces” of which patents he is specifically referring to among the four patents discussed in his declaration, and fails to address how any of the purported benefits are the “the direct result” of any “unique characteristics of the claimed invention.” We agree with Mr. Leinsing that Dr. Slocum

“provides no analysis as to how these claims supposedly enabled the benefits identified in paragraph 650 of his declaration, including low injection force, dose dial stroke length, and a small number of components.” Ex. 1095 ¶ 156 (further explaining that “a person of ordinary skill would have understood that the components recited in the claims would not have necessarily provided any of these benefits, either alone or collectively,” and “would have understood the claims as broadly including embodiments lacking all of these supposed benefits”).

More critically, Dr. Slocum’s opinion that some set of components recited in the ’844 patent “enable an injection device” with certain features, such as “low injection force” is, on its face, insufficient to establish the necessary nexus. As we explained above, the evidence of secondary considerations, here the “low injection force,” must be shown to be the “direct result of the unique characteristics of the claimed invention.” *Fox Factory*, 944 F.3d at 1373–74 (quoting *In re Huang*, 100 F.3d 135, 140 (Fed. Cir. 1996)). Merely “enabling” a “low injection force” means that the injection force may, or may not be “low,” depending upon some other consideration, and, therefore, it is not “the direct result” of any claimed feature. In other words, setting aside the ambiguity of what constitutes a “low injection force,” Patent Owner provides no evidence that a pen injector made in accordance with any Challenged Claim will necessarily result in a device with a “low injection force.”

The same is true of the other purported benefits identified by Dr. Slocum. For example, Dr. Slocum states that some set of components recited in the ’844 patent “enable an injection device” with “a relatively small number of components that decrease the complexity and cost of the device.” The Challenged Claims do not require a “small number of

components,” and Patent Owner provides no evidence that a pen injector made in accordance with any Challenged Claim will necessarily result in a device with a “a relatively small number of components that decrease the complexity and cost of the device.” Likewise, “injection stroke length” and “dose per injection” are unclaimed features purportedly “enabled,” but not shown to be a “direct result” of any set of elements recited by any Challenged Claim. Thus, we find that Patent Owner fails to establish a nexus between the purported evidence of alleged long-felt need for a pen with a low or reduced injection force (or the ability to deliver high doses or a short dial extension) and any claim of the ’844 patent at issue in this proceeding.

(2) Patent Owner Fails to Show the Existence of a Long-felt, but Unresolved Need

Patent Owner does not show that a long-felt, but unresolved need existed at the time of the invention for “an easy-to-use pen that was particularly well suited to administer medication with a low injection force.” See PO Resp. 52. The Federal Circuit has explained that “[l]ong-felt need is closely related to the failure of others,” and that “[e]vidence] is particularly probative of obviousness when it demonstrates both that a demand existed for the patented invention, and that others tried but failed to satisfy that demand.” *Eurand, Inc. v. Mylan Pharms., Inc. (In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.)*, 676 F.3d 1063, 1082 (Fed. Cir. 2012). Establishing a long-felt need requires objective evidence that the invention has provided a long-awaited, widely accepted, and promptly adopted solution to a problem existent in the art, or that others had tried but failed to solve that problem. See *In re Mixon*, 470 F.2d 1374, 1377 (CCPA 1973). Furthermore, one must demonstrate that “widespread

efforts of skilled workers having knowledge of the prior art had failed to find a solution to the problem.” *In re Allen*, 324 F.2d 993, 997 (CCPA 1963). Patent Owner’s contentions and evidence fail to establish any failure of others, any unsatisfied demand, any long-awaited solution to a problem, or any other persuasive basis to show the existence of a long-felt need at the time of invention.

As an initial matter, Patent Owner fails to identify an objective means to measure or compare the ease of use of pen injectors to support the notion that a long-felt need existed for an “easy-to-use” injection device. *See* PO Resp. 48–52; PO Sur-reply 24–25. Dr. Goland suggests that “prior injection pen devices available prior to the launch of Lantus[®] SoloSTAR[®] were more difficult to use than Lantus[®] SoloSTAR[®] and had a higher injection force, meaning the devices required significantly more force by the patient’s thumb to depress the button to administer the medication.” Ex. 2111 ¶ 15. Dr. Goland does not quantify to what degree SoloSTAR[®] was easier to use and merely suggests that “[m]y patients overall prefer Lantus[®] SoloSTAR[®] over all other available pen injection devices.” *Id.* ¶ 16; *see also id.* ¶¶ 27–30 (stating that OptiClik[®] “had a much higher injection force,” that FlexPen[®] “has a relatively high injection force,” and that “other devices suffered from the same shortcomings”).

By contrast, Dr. Biggs highlights that “affordability” is more important to “ease of use” for patients than injection force, particularly in terms of patient adherence. Ex. 1048 ¶¶ 34, 35. Dr. Biggs states that SoloSTAR[®] was “welcomed by Lantus[®] users as a significant improvement over Sanofi’s defective OptiClik[®] pen but was not recognized as an unusually good pen in itself.” *Id.* ¶ 43; *see also id.* ¶¶ 49, 50 (discussing reasons the OptiClik[®] pen was unsatisfactory). According to Dr. Biggs,

“insulin drives the prescription, with the delivery mode being determined by the modes available from the prescribed insulin’s manufacturer,” and Lantus[®] SoloSTAR[®] “is prescribed frequently” because Lantus[®] “is a popular insulin,” not because SoloSTAR[®] “is a remarkable pen.” *Id.* ¶ 44. The notion of a long-felt need for an “easy-to-use” device is, at best, ambiguous in application. Dr. Goland, on behalf of Patent Owner, demonstrates the ambiguity and lack of objective evidence inherent in Patent Owner’s argument by explaining that “the primary reason that the SoloSTAR[®] pen is so easy-to-use is because of the low injection force,” but then stating that SoloSTAR[®] is “easier” because of a “short dial extension length,” is “also easy to use because it includes the ability to dial up and dial back a desired dose, and provides tactile and audible feedback, portability, and ease of handling,” has a “last dose stop” that “patients have found . . . contribute[s] to the device being easy to use,” and is “disposable.” Ex. 2111 ¶ 33–39. Patent Owner fails to demonstrate any established measure of what constitutes a device that is “easy-to-use,” but rather shows that there are many considerations that account for the ease of use of any device.

The evidence developed demonstrates that SoloSTAR[®] was not the first “easy to use” injection pen or that all of the competing pen injectors were not easy to use because they lacked a sufficiently “low” injection force. In fact, Patent Owner concedes that “[p]rior to the launch of Lantus[®] SoloSTAR[®], there were multiple injection pens on the market for administering insulin or an insulin analog – *e.g.*, Levemir[®] FlexPen[®] and Lantus[®] OptiClik[®] in the long-acting category, and the Humalog KwikPen in the rapid-and intermediate-acting categories, among many others.” PO Resp. 49. Likewise, Dr. Biggs explained that other insulin pens were

available and fungible with Lantus® SoloSTAR®. *See* Pet. Reply 26–27 (citing Ex. 1046, 9, 37, 39, 57, 62, 63, 75; Ex. 1048 ¶¶ 27, 29, 32–44–47, 51–53, 56; Ex. 2126, 1, 3; Ex. 2143, 1, 5, 9, 10, 70; Ex. 2145, 26).

Dr. Biggs also persuasively establishes that “[a]vailable pens at the 2003 filing date were already considered “easy-to-use, convenient, and accurate.” Ex. 1048 (citing Ex. 1046, 57, 62). Further, Petitioner establishes that:

- “other insulin pens were already considered easy to use both generally and for patients with special challenges like age or dexterity issues,” (Pet. Reply 27 (citing Ex. 1048 ¶¶ 45–47, 52; Ex. 1046, 57, 62, 63))¹²;
- “Sanofi’s studies confirm that both SoloSTAR® and FlexPen® were ‘very easy to use,’” (*id.* (quoting Ex. 2145, 26); *see also id.* (citing Ex. 1048 ¶ 55; Ex. 2126, 1157 (stating that “the SoloSTAR® and FlexPen® were more user-friendly”); Ex. 2143, 650, 659 (stating that “both the SoloSTAR® pen and FlexPen® were found to have high patient usability”), 656 (stating that “the FlexPen® was also found to be user-friendly”)));
- “Sanofi’s studies concluded both the SoloSTAR® and FlexPen® were suitable in both elderly and younger patients and those with visual and dexterity impairments, and ‘were associated with comparable usability’” (*id.* (quoting Ex. 2126, 1159); *see also id.* (citing Ex. 1048 ¶ 56; Ex. 2143, 654, 658)); and that,

¹² Unless otherwise noted, citations rely on the pagination of the original document for articles and studies.

- SoloSTAR[®] was a “best-performing pen device *in a statistical tie with FlexPen*” (*id.* (quoting Ex. 2146, 9); *see also id.* (citing Ex. 1048 ¶ 52; Ex. 2146, 37, 39, 75)).

We find the evidence provided by Petitioner of no long-felt, unmet need discussed above more credible than Dr. Goland’s insufficiently supported statement that “other pen devices . . . had too high of an injection force for my patients.” *See* Ex. 2111 ¶ 42.

In sum, Patent Owner’s evidence may demonstrate acceptance of Lantus[®] SoloSTAR[®] (*see, e.g.*, Ex. 2184, 1; Ex. 2185, 1; Ex. 2121, 6), but it does not show any failure of others, any unsatisfied demand, or any long-awaited solution to any problem. The mere fact that a pen injector with a lower injection force might, or might not, be preferable over other readily available and effective pen injectors, depending upon various considerations, including cost and medication, fails to show a long-felt, unmet need for a pen injector with a lower injection force. Accordingly, the evidence provided by Patent Owner does not demonstrate a long-felt need existed for an “easy-to-use” injection device corresponding to any of the features Patent Owner attributes to SoloSTAR[®].

(3) Patent Owner Fails to Show that Lantus[®] SoloSTAR[®] Satisfied a Purported Long-felt, but Unresolved Need

As discussed above, Patent Owner contends its product “satisfied a long-felt but unmet need for an easy-to-use pen that was particularly well suited to administer medication with a low injection force.” PO Resp. 52. Given the ambiguity in Patent Owner’s identification of any purported “long-felt, but unmet need,” it is virtually impossible to determine whether SoloSTAR[®] met the need. What we can conclude is that Patent Owner does not show that the injection force of SoloSTAR[®] made it the easiest-to-use

pen “particularly well suited to administer medication” ever invented at the time. Whether SoloSTAR[®] even provides a “low injection force” is in dispute and depends upon what study is relied upon and what other devices are compared.

Patent Owner relies on the opinions of Dr. Slocum and Dr. Goland, who, in turn, cite studies and internal marketing materials produced by Patent Owner to show that SoloSTAR[®] provides a reduced injection force, at least with respect to certain devices to which it was compared. PO Resp. 49; (citing Ex. 2111 ¶¶ 23–25; Ex. 2109 ¶¶ 52–55); *see also* Ex. 2111 ¶¶ 32, 33 (citing Ex. 2116, 9; Ex. 2123, 6; Ex. 2143, 7; Ex. 2144, 5, 9–11). For example, Dr. Grabowski states that “[o]ne study found that, with respect to injection force, ‘SoloSTAR[®] was preferred by a significantly greater number of patients as their first choice (65%) compared with other pens assessed,’ including Novolog[®] FlexPen[®] and Lilly's disposable pen.” Ex. 2109 ¶ 53 (citing Ex. 2126, 1159). The study Dr. Grabowski cites, however, characterizes its finding as “[r]egarding injection performance,” not “injection force” as indicated by Dr. Grabowski, who does not otherwise explain whether the terms are coextensive or whether “injection performance” includes features other than “injection force.” Dr. Grabowski also states that another study “compared the injection force of the SoloSTAR[®] pen to competitor pens” and “concluded that ‘SoloSTAR[®] stands out because of its low injection force, even when compared with newer insulin pen devices such as the KwikPen and NGFP [Next Generation FlexPen[®]].’” *Id.* (citing Ex. 2100, 150). The study relied upon by Dr. Grabowski was limited to “Other Disposable Insulin Pen Devices” and states that it was authored by “an employee of sanofi-aventis” and

acknowledges that “[e]ditorial support was provided by Global Publications group of sanofi-aventis.” Ex. 2100, 150, 155.

Petitioner argues that, in contrast to the “Sanofi-sponsored injection force studies” relied upon by Patent Owner (e.g., Ex. 2143; Ex. 2144; Ex. 2100; Ex. 2126; Ex. 2116; Ex. 2123), other studies found that SoloSTAR[®] did not have a lower injection force. Pet. Reply 27 (citing Ex. 2145, 15 (the “US Lantus SoloSTAR Launch Book,” stating in regard to SoloSTAR[®] that “[e]asier to inject’ was not supported by two studies showing data versus FlexPen[®] and Lilly pen”); 20–21 (stating that “SoloSTAR[®] has one of the lowest injection forces of all pens, but not the lowest,” that the “Innolet disposable pen has the lowest injection force of all disposable and reusable pens,” and that “NovoPen 4 injection force is very similar to SoloSTAR[®]”). Dr. Biggs also raised issues with the methodology of at least some of the studies relied on by Patent Owner. Ex. 1048 ¶ 58 n.3.

With regard to Dr. Slocum’s opinion that SoloSTAR[®] provided “a shorter dial extension,” “has a maximum of 80 units, while the FlexPen[®] only has a maximum of 60 units,” and has a dial that “would extend to 25.5mm to inject 60 units, [whereas] the FlexPen[®] must extend to 33mm to inject 60 units,” we find no sufficient evidence to show that any of these purported features provided a benefit over prior art pen injectors that satisfied any purported long-felt need. See Ex. 2107 ¶ 650. Dr. Biggs characterizes any difference between the maximum extension of SoloSTAR[®] compared to FlexPen[®] as “difficult to discern visually” and “too slight to be of practical consequence.” *Id.* ¶ 55.

We further find unpersuasive Patent Owner’s argument that “[t]he industry extensively recognized SoloSTAR[®] for solving the problem of needing to deliver high doses with a short dial extension and with low

injection force.” PO Resp. 51. As support, Patent Owner relies not on an industry publication, but on a study “supported by Sanofi-Aventis” that received “[e]ditorial support” from “Global Publications group of Sanofi-Aventis.” Ex. 2128, 121. Under the heading “Unmet needs,” the study states that “many patients need to administer doses of insulin exceeding 60 units, the maximum dose of many insulin pens.” *Id.* at 115. Dr. Biggs explains that there was “no unmet need in 2003 for an 80U pen” because “the Disetronic pen offered this feature years earlier.” *Id.* (citing Ex. 1046, 82–83). We agree.

We have considered all of the additional “industry” recognition cited by Patent Owner, including Exhibit 2123 (a study funded by Sanofi that found that, when compared to a limited set of certain other pens, Lantus[®] pens, KlikSTAR[®] and SoloSTAR[®], “require a significantly lower injection force compared with the reusable or prefilled insulin pens containing the insulin glargine copies”) and Exhibit 2184 (an article from the “Philippine Daily Inquirer” stating “the Lantus[®] SoloSTAR[®] operates with a low injection force?31 [sic] percent less than other insulin pens ?that [sic] allows a gentle injection.”).¹³ PO Resp. 51. Patent Owner also cites Exhibit 2185 as reflecting a statement from a Professor of Endocrinology in France that “[i]nsulin injection with SoloSTAR[®] brings flexibility, satisfaction for the patients, and an opportunity for earlier initiation of insulin therapy which may contribute to better long term glycemic control.” PO Resp. 51 (quoting Ex. 2185, 1). Patent Owner fails to explain how that statement supports the

¹³ Patent Owner alters the statement from what appears in Exhibit 2184 and also attributes it to a particular individual, however, the article does not make clear from whom the information is coming. *Compare* PO Resp. 51 *with* Ex. 2184, 2.

contention that SoloSTAR[®] satisfied any long-felt, unmet need. The same applies to Patent Owner's purported evidence of patient preferences. *Id.* (citing Ex. 2121, 2, 9; Ex. 2143; Ex. 2144).

We have further considered and find not persuasive all of Patent Owner's additional arguments, including that SoloSTAR[®] was preferred over OptiClik, that earlier FlexPens were hard to push, that some patients did not take their insulin because prior art devices were problematic, and that patients were transitioned to SoloSTAR[®] because of its lower injection force. PO Sur-reply 24–25 (citing Ex. 1056, 34:3–17, 35:7–12; 66:9–15; Ex. 2100; Ex. 2111 ¶¶ 31–43; Ex. 2113; Ex. 2116; Ex. 2121; Ex. 2123; Ex. 2126; Ex. 2128; Ex. 2140; Ex. 2143; Ex. 2144; Ex. 2184; Ex. 2185). Patent Owner also argues that Mr. Leinsing acknowledges a focus on reducing injection force (*id.* (citing Ex. 2316, 80:24–81:1)); that patients would have disliked Dr. Biggs suggestion that “any long-felt need was satisfied by the Lantus[®] vial and syringe, that patients complaining of injection force could have caregivers . . . administer their treatments, and that patients could carry around . . . preloaded syringes” (*id.* (citing Ex. 1048 ¶¶ 31–32; Ex. 1056, 52:23–53:25, 58:18–59:24; Ex. 2317, 70:10–19, 84:24–85:14)), and that Dr. Biggs's testimony is undermined by his admission that his suggestions may not be covered under Medicare or insurance and that the majority of his patients switched from Lantus[®] vial to Lantus[®] SoloSTAR[®], which most patients preferred (*id.* (citing Ex. 2317, 38:7–39:3, 115:23–116:6, 118:19–22)).

Based on the entirety of the evidence provided by both parties, we conclude for the reasons provided above that the evidence does not support Patent Owner's argument that SoloSTAR[®] satisfied a long-felt but unmet need for a pen with “a low injection force,” because there were other

injection pens that operated with similar and even lower injection forces than SoloSTAR[®]. Likewise, Patent Owner does not show persuasively that the dial extension or maximum dosing of SoloSTAR[®] exceeded any other injection pen available when it was introduced or at the time of the invention of the '844 patent to support the contention that it satisfied a long-felt, but unmet, need.

b) Industry Praise

Patent Owner contends that the “nonobviousness of the [']844 patent is further demonstrated by the high level of praise and industry recognition that Sanofi and DCA, the design firm with whom Sanofi partnered in creating SoloSTAR[®], received for the designs embodied in the SoloSTAR[®] device.” PO Resp. 52.

First, Patent Owner states that SoloSTAR[®] “won the Gold, International Export, and Grand Prix awards at the Design Business Association (DBA) Design Effectiveness Awards” in 2009. *Id.* (citing Ex. 2121). According to Patent Owner, “[t]he DBA is a design organization based in the UK that is interested in how a design commercially impacts a company’s business.” *Id.* Patent Owner asserts that “[t]he case study of SoloSTAR[®] for the DBA Awards describes the SoloSTAR[®]’s inventiveness as ‘suitably ambitious’ and explains that ‘SoloSTAR[®] is the first disposable insulin pen to combine very low injection force (which provides a smooth injection experience for patients) with 80 units maximum dose capability, an important breakthrough.’” *Id.* (citing Ex. 2121, 3).

Petitioner responds that the “case study of SoloSTAR[®]” Patent Owner relies upon was “written, funded, and sponsored by Sanofi” with DCA, and is “self-praise, not industry praise.” Pet. Reply 28–29 (citing Ex. 1055, 79:6–81:19). Consistent with Petitioner’s argument, the document Patent

Owner relies upon in support of its contentions, Exhibit 2121, bears the names “DCA” and “Sanofi Aventis” at the top of each page and reflects information they provided for consideration as part of the “DBA Design Effectiveness Awards 2009.” Ex. 2121, 1; *see also* Ex. 1060 (according to Dr. McDuff, the “DBA web site gives applicants like Sanofi and DCA tips on how to prepare the case studies applicants write”). Exhibit 2121 does not indicate any award was given to SoloSTAR[®], much less why any award was given to SoloSTAR[®].

The only evidence of actual industry praise offered by Patent Owner in this regard is Dr. Grabowski’s statement that “[i]n 2009, at the Design Business Association (“DBA”) Design Effectiveness Awards, Sanofi won the Gold, International Export, and Grand Prix awards.” Ex. 2109 ¶ 72. Dr. Grabowski fails to offer any explanation or evidence to show what these awards mean, how they were awarded, or why they were awarded for SoloSTAR[®]. Dr. Grabowski instead refers back to the case study prepared by Patent Owner and DCA, Exhibit 2121. *Id.* We find that Exhibit 2121 does not constitute “industry praise” because it was prepared by Patent Owner and DCA and does not reflect the opinion of the industry or even the receipt of praise. Nor can we reach any conclusion about the “Design Effectiveness Awards” Dr. Grabowski states were given for SoloSTAR[®] in the absence of any evidence explaining what any of the awards entail.

Second, Patent Owner states that “SoloSTAR also won the Good Design Award by the Chicago Athenaeum Museum of Architecture and Design.” PO Resp. 52 (citing Ex. 2201). According to Dr. Grabowski, “[t]he criteria for this award are ‘quality design of the highest form, function, and aesthetics a standard beyond ordinary consumer products and graphics.’” Ex. 2109 ¶ 73 (purporting to quote a website affiliated with The

Chicago Athenaeum Museum of Architecture and Design). Dr. Grabowski also states that “Christian K. Narkiewicz-Laine, President of the Chicago Athenaeum Museum of Architecture and Design noted that ‘SoloSTAR[®] represents a design for social good and for humanitarian concerns.’” *Id.* Petitioner correctly argues that Exhibit 2201, upon which Patent Owner relies, does not attribute any award to “inventiveness,” and we further note that Exhibit 2201 provides no explanation for how or why an award was given to SoloSTAR[®]. *See* Pet. Reply 29.

Dr. Grabowski also states that “the Lantus[®] and Apidra[®] SoloSTAR[®] devices were put into the permanent Design Collection of the Chicago Athenaeum Museum of Architecture and Design, as recognition of its inventiveness.” Ex. 2109 ¶ 73. Dr. McDuff explains that the document Dr. Grabowski cites in support of his contention that SoloSTAR[®] was placed in the permanent Design Collection of the Chicago Athenaeum Museum of Architecture and Design (*see* Ex. 2109 ¶ 73 n.95) is a DCA press release that does not state that this placement resulted from “recognition of its inventiveness” and contains no statements attributed to the Chicago Athenaeum. Ex. 1060 ¶ 59.

Third, Patent Owner submits that “at the Prix Galien USA 2009 Award, which ‘recognize[s] innovative biopharmaceutical drugs and medical technologies’ and ‘is considered the industry’s highest accolade for pharmaceutical research and development — equivalent to the Nobel Prize,’ Sanofi and DCA were both finalists.” PO Resp. 64 (citing Ex. 2109 ¶ 74). Patent Owner offers no further explanation of how this constitutes industry praise, but asserts without citation that “Patent Owner did not make up the SoloSTAR[®] awards or bestow upon itself industry praise.” PO Sur-reply 25.

Patent Owner's evidence of industry praise appears to be directed to SoloSTAR[®], and not Lantus[®] SoloSTAR[®]. Because Patent Owner shows sufficiently that SoloSTAR[®] practices Challenged Claims, Patent Owner would be entitled to a presumption of nexus if Patent Owner shows that SoloSTAR[®] "embodies the claimed features, and is coextensive with them." *Fox Factory*, 944 F.3d at 1373 (internal quotations omitted). Patent Owner does not argue SoloSTAR[®] is coextensive with any of the Challenged Claims. For example, the case study of SoloSTAR[®] Patent Owner relies upon to show industry praise states that an "important breakthrough" was the combination of "very low injection force . . . with 80 units maximum dose capability." Ex. 2121, 3; *see also id.* at 5 (emphasizing the attention given to "visual design" during the development of SoloSTAR[®] and asserting that it provides "a total of five differentiation features for improved safety: body colour, dial colour, button colour, label design and a tactile feature on the injection button"). None of the Challenged Claims require any maximum dose capability or "differentiation features." As with the proffered evidence of long-felt need discussed above, Patent Owner fails to demonstrate nexus between the purported evidence of industry praise and the claims at issue in this proceeding.

Moreover, even if we assume Patent Owner demonstrates nexus between the alleged industry praise and the claims at issue, much of the praise was generated by DCA, Sanofi's affiliate. *See, e.g.*, Ex. 1055, 76–79. Such self-generated praise is not persuasive industry praise. Further, evidence independent of DCA, such as consideration of Lantus[®] SoloSTAR[®] for the Prix Galien USA 2009 award, only generally specifies the criteria used to judge the nominees. Ex. 2042, 2. It does not evidence industry praise of any specific feature of the claimed invention. *Id.*

c) Commercial Success

Patent Owner contends that the “tremendous commercial success of Lantus[®] SoloSTAR[®] is further objective evidence of non-obviousness.” PO Resp. 53. According to Patent Owner, “commercial success is demonstrated by the contribution of Lantus[®] SoloSTAR[®] to the growth of the Lantus[®] franchise overall,” and by the strong performance of Lantus[®] SoloSTAR[®] when compared to other long-acting insulin and insulin analog pens.” *Id.* at 53–54; *see also id.* at 55–57; PO Sur-reply 22–23.

(1) Patent Owner Fails to Show a Nexus Between the Purported Evidence of Commercial Success and Any Challenged Claim of the '844 Patent

First, Patent Owner fails to show that the asserted evidence of commercial success of Lantus[®] SoloSTAR is a “direct result of the unique characteristics of the claimed invention,” and, therefore, fails to show the necessary nexus. *Fox Factory*, 944 F.3d at 1373–74 (internal quotation omitted). Patent Owner argues that “each of the features of the device disclosed and claimed in the 844 Patent and used in Lantus[®] SoloSTAR[®] contributed to its commercial success.” PO Resp. 55 (citing Ex. 2109 ¶ 53; Ex. 2107 ¶¶ 551–610, 651); *see also* PO Sur-reply 22 (asserting that the commercial success of Lantus[®] SoloSTAR[®] “is due at least in part to the elegant features that the challenged claims enable, such as low injection force”). Specifically, Patent Owner argues that SoloSTAR[®] satisfied a long-felt but unfulfilled need for an easy-to-use pen device with low injection force. *Id.*; *see also id.* at 57 (arguing that “[t]he tremendous success of Lantus[®] SoloSTAR[®], as compared to pens with long-acting insulins that failed to address the long-felt but unfilled need for a low injection force device, therefore shares a strong nexus with the claimed invention”).

Patent Owner does not show that the alleged “tremendous success” may fairly be attributed to the claimed invention, which does not require low injection force or insulin, let alone the long-acting insulin formulation of Lantus. Patent Owner’s argument does not show the necessary nexus, and for the reasons provided above, we found no persuasive evidence in support of Patent Owner’s allegations of long felt need. We likewise find unpersuasive Patent Owner’s argument that, because OptiClik[®] also dispensed Lantus, but had a “higher injection force” and “performed significantly worse than SoloSTAR[®]” such that it was discontinued, the “nexus between SoloSTAR[®]’s lower injection force and its commercial success is further confirmed.” PO Sur-reply 22 (citing Ex. 2109 ¶¶ 19, 35–30; Ex. 2111 ¶ 28). While the parties appear to agree that the OptiClik[®] was an inferior device, Patent Owner’s implication that it was discontinued only due to its higher injection force is not even supported by Patent Owner’s own expert, Dr. Goland, who explained that “Lantus[®] OptiClik[®] was thus a mechanically inferior design to Lantus[®] SoloSTAR[®]” because, in addition to a higher injection force, OptiClik[®] “did not automatically reset after injection and thus required additional steps by the user prior to its next,” and “was also relatively large, making it less convenient to carry.” Ex. 2111 ¶ 28. Dr. Biggs described OptiClik[®] as “difficult to refill and unreliable about delivering accurate doses” (citing Ex. 1045, 528, Table 2), and a “truly bad pen,” but noted that “injection force” was not a concern with OptiClik[®] expressed by his patients. Ex. 1048 ¶¶ 42, 49.

Next Patent Owner asserts that “the SoloSTAR[®] device won numerous design awards, and achieved significant industry praise.” PO Resp. 55. Again, Patent Owner’s argument does not show the necessary nexus, and for the reasons provided above, we found no persuasive evidence

in support of Patent Owner's allegations of industry praise. The only remaining arguments Patent Owner makes is that "the SoloSTAR[®] device embodies the challenged claims of the 844 patent," and "[t]hus, there is a nexus between the claimed invention in the 844 patent and the commercial success of Lantus[®] SoloSTAR[®]." *Id.* Patent Owner is wrong with regard to what must be shown to establish nexus.

There is no dispute that Lantus[®] SoloSTAR[®] is not coextensive with any of the Challenged Claims. Patent Owner relies on Lantus[®] SoloSTAR[®] to show commercial success, but merely showing that SoloSTAR[®] "embodies" any of the Challenged Claims fails to establish the necessary nexus between the evidence of commercial success and any claim challenged. Patent Owner suggests that "the success of SoloSTAR[®] is attributable at least in part to its unique design covered by the 844 patent." PO Resp. 57. Contrary to Patent Owner's argument, Patent Owner does not show persuasively that any "feature" purportedly disclosed and claimed in the '844 patent contributed to the commercial success of Lantus[®] SoloSTAR[®]. To be clear, that does not mean that the design of SoloSTAR[®], including unclaimed features and aesthetics, was irrelevant to the purported commercial success of Lantus[®] SoloSTAR[®]. Rather, Patent Owner does not show that the asserted evidence of commercial success of Lantus[®] SoloSTAR is a "direct result of the unique characteristics of the claimed invention."

(2) Patent Owner Fails to Show Commercial Success of Lantus[®] SoloSTAR[®]

Patent Owner argues that the following demonstrate the commercial success Lantus[®] SoloSTAR[®]:

- “fast and long-sustained growth in terms of dollar sales, new prescriptions, and total prescriptions”;
- “the overall levels and shares of dollar sales, new prescriptions, and total prescriptions, as well as the profitability and formulary placement”;
- “sales and prescriptions . . . remained strong despite the entry of several competing long-acting insulin and insulin analog drugs (all in pen form) starting in 2015”;
- “the highest level of sales among long-acting insulin and insulin analog pens even though it launched after several other long-acting insulin and insulin analog pens, including the Levemir[®] FlexPen[®]”; and
- “substantial growth relative to Lantus[®] OptiClik[®]” based on new prescriptions and total prescriptions.

PO Resp. 54–55 (citing Ex. 2109 ¶¶ 12, 37). Additionally, Patent Owner contends that marketing does not explain the commercial success because “marketing expenditures for Lantus[®] SoloSTAR[®] were in line with, or were lower than, many other long-acting insulin products.” *Id.* at 56 (citing Ex. 2109 ¶¶ 16, 64–69). Regarding “alleged ‘blocking patents’ covering the glargine molecule that is used in the production of the active ingredient in Lantus[®],” Patent Owner argues that “the law does not mandate across-the-board-discounting of commercial success simply because other patents cover components of the product,” and that the Board should “weigh the evidence on a case-by-case basis, in light of the specific commercial success argument being made.” *Id.* at 56–57. According to Patent Owner, “the success of Lantus[®] SoloSTAR[®] cannot be attributed solely to the insulin glargine

molecule because Lantus[®] OptiClik[®] used the exact same Lantus[®] formulation” and did not achieve SoloSTAR[®]’s success, thus the design of SoloSTAR[®] must have attributed at least in part to the success. *Id.* at 57. Patent Owner further argues that “Sanofi’s earlier patents on the insulin glargine molecule did not prevent others from entering the market for non-glargine, long-acting insulin products and competing with Lantus[®] SoloSTAR[®].” *Id.* Patent Owner identifies Levemir[®] FlexPen[®] with its long-acting insulin as an example of a disposable pen device with long-acting insulin. *Id.*

Petitioner disputes Patent Owner’s contentions, arguing, *inter alia*, that Patent Owner does not address profitability and “provides no benchmarks for evaluating success, applies a faulty ‘pens-only’ market definition, and [that] formulary status does not separately demonstrate commercial success.” Pet. Reply 29–30 (citing Ex. 1048 ¶¶ 17–28). Petitioner also argues that “Lantus[®] SoloSTAR[®] enjoyed the benefit of a Lantus[®] franchise that predated the Levemir[®] franchise by five years and the foundation of earlier Lantus[®] pen (OptiClik[®]),” which had “twice as many prescriptions in 2007 as Levemir[®] FlexPen[®].” Pet. Reply 31 (citing Ex. 2186, 2; Ex. 2198). Petitioner contends that “Lantus[®] SoloSTAR[®] overtook Levemir[®] FlexPen[®] not because of any unique SoloSTAR[®] attributes,” but because Patent Owner “selected it as the exclusive Lantus[®] pen in the United States.” *Id.* (citing Ex. 1075 ¶¶ 20–22, 30–35).

Patent Owner replies that Petitioner’s own data shows that Lantus[®] SoloSTAR[®] has been commercially successful (citing Ex. 1060, Attachment B-10; Ex. 2318, 31:14–17, 31:25–32:8), that the diabetes community has widely adopted Lantus[®] SoloSTAR[®]; that Dr. McDuff acknowledged the large Lantus[®] SoloSTAR[®] sales and admitted that

profitability analysis is not required (citing Ex. 2318, 15:10–13, 28:7–19, 29:20–30:18), and that Lantus® SoloSTAR® has the largest market share in Petitioner’s asserted broader market (citing Ex. 1060, Attachment B-10; Ex. 2318, 31:14–17, 31:25–32:8). PO Sur-reply 19–20. Patent Owner further contends that Lantus® SoloSTAR® prescriptions more than quadrupled that of OptiClik® in the first four years of each product’s respective launch and that Lantus® SoloSTAR® grew the Lantus® market and remains the number one product. *Id.* at 20 (citing Ex. 1060, Attachment B-10; Ex. 2318, 18:23–19:20, 21:22–22:8). Patent Owner asserts that “SoloSTAR® enjoys favorable placement in health,” due, in part as admitted by Dr. McDuff, to its “mechanical features and attributes.” *Id.* at 20–21 (citing Ex. 2318, 33:7–36:3).

Having considered all of the evidence of commercial success presented by the parties, we find that the data presented in Attachment B-10 of Exhibit 1060 to be the most pertinent evidence regarding the purported commercial success of Lantus® SoloSTAR® provided in this proceeding. Attachment B-10 presents total prescription data by year for 40 insulin delivery products for the 20-year period 1999–2019. Ex. 1060, Attachment B-10. It also provides corresponding market share data for that same time period. *Id.*

Attachment B-10 shows that from the introduction of Lantus® Vial in 2002, until 2019, Lantus® delivery products (i.e., Lantus® Vial, Lantus® OptiClik®, and Lantus® SoloSTAR®) were by far the most proscribed insulin delivery devices. Ex. 1060, Attachment B-10. As shown, from 2002 to 2011 prescriptions of Lantus® Vial grew from roughly 1.3 to 11 million prescriptions, while the most successful competing products (Humulin and Novolog) each grew to prescription levels of roughly 5 million prescriptions.

Id. Thus, Attachment B-10 clearly demonstrates the commercial success of Lantus[®] Vial during that time period. Attachment B-10 also demonstrates that once Lantus[®] OptiClik[®] was introduced, prescriptions of Lantus[®] Vial decreased as prescriptions of Lantus[®] OptiClik[®] increased, with the overall number of Lantus[®] OptiClik[®] prescriptions slowly, but steadily climbing.

Id. We note that during the time period that Lantus[®] OptiClik[®] was the only Lantus[®] alternative to Lantus[®] Vial, the number of Lantus[®] Vial prescriptions essentially stayed the same.

In 2008, Lantus[®] SoloSTAR[®] was introduced. Ex. 1060, Attachment B-10. From 2008–2011, prescriptions of Lantus[®] SoloSTAR[®] steadily rose while prescriptions of Lantus[®] OptiClik[®] declined. *Id.* During this time period, prescriptions of Lantus[®] Vial continued to remain steady. *Id.* Then in 2012, things changed. *Id.* First, prescriptions of Lantus[®] OptiClik[®] dropped off significantly. *Id.* By 2014, prescriptions of Lantus[®] OptiClik[®] dropped to a mere 382 prescriptions. *Id.* During the time period from 2011–2016 (when prescriptions of Lantus[®] SoloSTAR[®] hit their peak), prescriptions of Lantus[®] Vial began to decrease at a rate of about 500,000 prescriptions per year. It is unknown why prescriptions of Lantus[®] Vial began to decline starting in 2012, but it appears that they declined as the prescriptions of Lantus[®] SoloSTAR[®] increased. Regardless of the reason for the decline, the evidence clearly shows that the number of Lantus[®] SoloSTAR[®] prescriptions peaked in 2016 and that most of the increase in prescriptions for Lantus[®] SoloSTAR[®] merely offset the decline in prescriptions for Lantus[®] Vial. Thus, the evidence does not support a showing of commercial success for Lantus[®] SoloSTAR[®]. Rather, it appears to show a fairly stable number of prescriptions for Lantus[®] products from 2009–2016, with a decline in those prescriptions from 2017–2019.

4. *Collective Consideration of the Graham Factors*

Having considered each of the *Graham* factors individually, we now consider them collectively. The scope and content of the prior art, the differences between the prior art and claims 24–29 of the '844 patent, and the level of ordinary skill in the art heavily favor Petitioner's contention that claims 24–29 would have been obvious over the combination of Giambattista and Steinfeldt-Jensen. Claims 24–29 depend from claim 21, and Patent Owner does not dispute that Giambattista anticipates, and, therefore, teaches every limitation of claim 21. There also is no dispute that both Giambattista and Steinfeldt-Jensen teach dose tracking mechanisms that provide audible and tactile feedback. To the extent there is any ambiguity in whether Giambattista teaches such feedback to be “indicative of unit doses,” or fails to teach that “each click is equal to a unit dose,” Petitioner shows, and Patent Owner does not dispute, that Steinfeldt-Jensen expressly teaches these limitations. Petitioner also provides a persuasive rationale in support of the asserted combination of prior art, which is to provide the device taught by Giambattista the readily apparent benefit taught by Steinfeldt-Jensen: “so that the number of clicks heard and felt during the dose setting rotation corresponds to the size of the set dose.” Ex. 1014, 6:42–53.

Having considered all the evidence of indicia of nonobviousness, Patent Owner does not show the requisite nexus between the alleged objective indicia of nonobviousness and the Challenged Claims of the '844 patent. Moreover, even if Patent Owner had shown nexus, the objective evidence of nonobviousness identified by Patent Owner fails to show persuasive evidence of a long-felt, unmet need satisfied by the invention of any of the Challenged Claims. Patent Owner also fails to show

persuasive evidence of either industry praise of SoloSTAR[®] or of commercial success of Lantus[®] SoloSTAR[®]. Thus, Patent Owner's evidence of indicia of nonobviousness provides very little, if any, support for nonobviousness of the Challenged Claims.

On the whole, we find that the information provided by Petitioner and Patent Owner in consideration of the *Graham* factors collectively demonstrates by a preponderance of the evidence that the subject matter of claims 21–29 of the '844 patent would have been obvious over the combination of Giambattista and Steinfeldt-Jensen.

G. Alleged Obviousness over Giambattista and Klitgaard

Petitioner contends that claim 30 of the '844 patent would have been obvious over the combination of Giambattista and Klitgaard. Pet. 69–72; Pet. Reply 14–17. Claim 30 depends from claim 21 and further recites “a nut that tracks each set dose of medicament delivered.” Ex. 1004, 9:8–10. Patent Owner argues that the asserted combination does not fall within the scope of claim 30 and that a person of ordinary skill in the art would have been dissuaded from making the combination. PO Resp. 38–46; PO Sur-reply 14–19.

1. Differences Between the Subject Matter of Claim 30 and the Teachings of Giambattista and Klitgaard

Petitioner relies on Klitgaard as teaching the expressly recited limitation of claim 30 and on Giambattista as teaching the limitations of claim 21 from which claim 30 depends. Pet. 69–72. As explained above, Petitioner shows and Patent Owner does not dispute that Giambattista teaches every limitation of claim 21. As further shown by Petitioner, Klitgaard teaches an injection device with nut member 32 that, “[d]uring the setting of a dose” rotates “with the dose setting member 30 relative to the

driver 31 so that the position of the nut member 32 on this driver is dependent on the dose set.” *Id.* at 70 (quoting Ex. 1017, 4:33–37). The injector of Klitgaard operates such that “the nut member 32 on the driver 31 will always indicate the total sum of set and injected doses.” *Id.* (quoting Ex. 1017, 4:52–54). Patent Owner does not dispute that Klitgaard teaches nut member 32 corresponding to “a nut that tracks each set dose of medicament delivered,” as required by claim 30. Instead, Patent Owner argues that, as applied by Petitioner to Giambattista, the combination “would not satisfy claim 30.” PO Resp. 38–44.

In response, Patent Owner first argues that the asserted combination would not “satisfy claim 30” if the teachings of Klitgaard were applied to Giambattista as proposed by Petitioner. PO Resp. 39–44; PO Sur-reply 15–18. Specifically, Patent Owner asserts that with the proposed combination of references “a user could still dial a dose beyond the amount of medicament remaining in Giambattista’s drug cartridge 32” and, therefore, “the proposed adapted nut member would not ‘track[] each set dose of medicament delivered,’” as required by claim 30. *Id.* at 39. Contrary to Patent Owner’s argument, we agree with Petitioner that claim 30 does not require that a user be prevented from dialing “a dose beyond the amount remaining.” Pet. Reply 14.

Petitioner explains, and we agree, that Patent Owner is attempting to add an additional limitation, a “dose stop,” that is not required by claim 30. *Id.* We find persuasive Petitioner’s explanation because it is consistent with the claims of the ’844 patent. Unchallenged claim 14, which depends from claim 1, recites “a nut that tracks each set dose of medicament delivers,” which is identical language as set forth in claim 30. Ex. 1004, 7:63–64. Claim 18 depends from claim 14 and further recites “where the nut further

comprises a corresponding final dose stop.” *Id.* at 8:6–8. Unlike claim 18, claim 30 has no corresponding requirement that the nut “further comprises” a “dose stop.”

In its Sur-reply, Patent Owner fails to address this issue of claim differentiation and argues instead that we should construe the language of claim 30 as requiring a dose stop. PO Sur-reply 15. Patent Owner reasons that if a user may dial a dose beyond the amount of medicament remaining, then the device does not track “each set dose of medicament delivered.” *Id.* We find Patent Owner’s construction of the claim language inconsistent with the disclosure in claims 14 and 18 that make clear that a “nut that tracks each set dose of medicament delivers” does not necessarily include a “final dose stop.” Moreover, even in the absence of the disclosures in the ’844 patent, we are not persuaded by Patent Owner’s unsupported argument that a dose stop must be present to track “each set dose of medicament delivered.” Patent Owner does not dispute that the device would operate to track each set dose of medicament delivered up to and including the last dose. That is all that is required by the plain language of claim 30. Whether the device continues to track set doses of medicament “not delivered” beyond the last dose is irrelevant to and not precluded by claim 30.

Alternatively, if claim 30 were construed to require a dose stop, the evidence shows that the asserted combination includes this feature. Specifically, Patent Owner argues that Giambattista describes an embodiment that operates to provide “a measure of protection against unwanted rearward movement of the leadscrew.” PO Resp. 43 (quoting Ex. 1016, 3:32–37); *see also id.* (citing Ex. 2107 ¶¶ 431–32). Patent Owner suggests that the “measure of protection” described by Giambattista is not a “dose stop” because the “measure of protection” is “low” such that “if a user

continued to dial a dose, the applied torque would overcome the ‘measure of protection.’” *Id.* at 43–44. Patent Owner’s argument is not persuasive because, even if claim 30 were construed to require a dose stop, it does preclude a “low” dose stop that might be overcome by a user. Moreover, Petitioner shows that Patent Owner’s characterization of the “measure of protection” taught by Giambattista as “low” is unsupported by the express teachings of Giambattista. Pet. Reply 15 (citing Ex. 1016, 1:4–45, 3:44–47, 3:33–38, 5:31–35, Figs. 4, 5). In this regard, we credit the testimony of Mr. Leinsing that a “person of ordinary skill would have understood Giambattista as teaching a ratchet mechanism . . . would also be capable of preventing such movement when a user attempts to rotate the driver 24 in the same direction due to the tracking nut reaching the end of its helical track,” over the testimony of Dr. Slocum, because Mr. Leinsing’s explanation is supported by the cited teachings of Giambattista. Ex. 1095 ¶ 133 (citing, e.g., Ex. 1016, 5:31–35).

2. *Reasons for the Combination of Giambattista and Klitgaard*

Petitioner further contends a person of ordinary skill in the art would have had a reasonable expectation of success in incorporating nut member 32 of Klitgaard into the Giambattista pen injector, because the nut “could easily be adapted and disposed between dosing ring adapter 28 and dose knob 20 [of Giambattista] to track each set dose of medicament delivered.” Pet. 71 (citing Ex. 1011 ¶ 608). According to Petitioner, the components of Giambattista “have the concentric arrangement and relative movement identified by Klitgaard as the foundation for applying its nut.” *Id.* (citing Ex. 1011 ¶¶ 59, 60, 149, 608). Petitioner relies on Klitgaard’s explanation that the nut indicates “the total sum of set and injected doses” and prevents “setting a dose that exceeds the remaining available supply of

medication in the cartridge” as the reasons a person of ordinary skill in the art would have modified Giambattista. *Id.* (citing Ex. 1017, 4:52–58, Abstract).

Patent Owner argues that a person of ordinary skill in the art would not have been motivated to modify Giambattista to include a nut that tracks each set dose of medicament delivered, as taught by Klitgaard, because it would increase the overall diameter of the device and would increase the force required to inject a dose. PO Resp. 44–46; PO Sur-reply 18–19; *see also* PO Resp. 45 (alleging the proposed modification would “increase the overall diameter of the pen by approximately 25%, which is not ergonomic and would impair the user’s ability to handle and operate the dispensing apparatus” (citing Ex. 2107 ¶ 435)). According to Patent Owner, a person of ordinary skill in the art would have understood these undesirable effects “would decrease the usability of the injection pen and make it harder for patients to use, especially in view of the various hand and wrist conditions frequently experienced by diabetic patients.” *Id.* (citing Ex. 2107 ¶¶ 44–61, 435). In this regard, we note that the Challenged Claims are not limited to a device directed to diabetic patients and that Patent Owner does not argue that the modified device would be rendered inoperable. Additionally, according to Patent Owner, Mr. Leinsing agreed that a wider pen would be undesirable because it would be difficult to use, would increase the force needed to dispense medication, and would increase the cost of manufacture. *Id.* Based on those considerations, Patent Owner asserts a person of ordinary skill “would not have been motivated” to make the modification. *Id.* at 46.

In reply, Petitioner argues a person of ordinary skill in the art would not have been dissuaded from making the proposed modifications, because

an increase in width and injection force would have been “a reasonable tradeoff for the benefit of tracking doses.” Pet. Reply. 17 (citing Ex. 1095 ¶ 134); *see also id.* at 16 (asserting that the Giambattista pen, modified as proposed, would not necessarily be 25% wider and that any increase in injection force could be mitigated, for example, with lubrication (citing Ex. 1095 ¶ 134)). Petitioner also notes that a wider pen may assist patients with gripping. *Id.* (citing Ex. 1048 ¶ 50).

Patent Owner replies that the evidence shows that the modifications would “result in an undesirable pen.” PO Sur-reply 18–19. We disagree. We find that the evidence shows that modifying the Giambattista pen based on the teachings of Klitgaard would satisfy all limitations of claim 30 and would be beneficial because the modified pen would indicate the total sum of set and injected doses and would prevent setting a dose that exceeds the remaining available supply of medication in the cartridge. Patent Owner does not show that these are insubstantial benefits, but instead shows that they may come at the cost of an increased pen width and increased injection force, which may be detrimental to at least some patients. The Federal Circuit addressed just such a situation and explained that the “fact that the motivating benefit comes at the expense of another benefit, however, should not nullify its use as a basis to modify the disclosure of one reference with the teachings of another. Instead, the benefits, both lost and gained, should be weighed against one another.” *Winner Int’l Royalty Corp. v. Wang*, 202 F.3d 1340, 1349 n.8 (Fed. Cir. 2000).

In weighing the benefits, lost and gained, we note that Dr. Slocum’s opinion that the diameter of the modified pen would be increased by approximately 25%, as opposed to a lesser amount, is unexplained and unsupported. *See* Ex. 2107 ¶ 434. Likewise, Dr. Slocum’s opinion that the

proposed modification would increase the injection force fails to quantify the magnitude of any increase. *Id.* ¶ 435. We are persuaded by Petitioner that the clear and undisputed benefit of providing a device that indicates the total sum of set and injected doses and that prevents setting a dose that exceeds the remaining available supply of medication in the cartridge outweighs the more speculative and imprecise lost benefits of a smaller diameter and lower injection force. *See* Pet. Reply 16–17 (citing Ex. 1095 ¶ 134). In sum, Petitioner demonstrates that the combination of Giambattista and Klitgaard teaches every limitation of claim 30 and establishes a legally sufficient rationale in support of the combination.

3. *Objective Indicia of Nonobviousness*

Patent Owner relies on the same evidence of objective indicia of nonobviousness as discussed above with regard to the asserted obviousness of claims over Giambattista and Steinfeldt-Jensen.

4. *Collective Consideration of the Graham Factors*

With regard to claim 30 of the '844 patent, having considered each of the *Graham* factors individually, we now consider them collectively. The scope and content of the prior art, the differences between the prior art and claim 30, and the level of ordinary skill in the art heavily favor Petitioner's contention that claim 30 would have been obvious over the combination of Giambattista and Steinfeldt-Jensen. Claim 30 depends from claim 21, and Patent Owner does not dispute that Giambattista anticipates, and, therefore, teaches every limitation of claim 21. Petitioner shows by a preponderance of the evidence that the combination of Giambattista and Klitgaard teaches every limitation of claim 30. Petitioner's reliance on Klitgaard's explanation that the nut indicates the total sum of set and injected doses and prevents setting a dose that exceeds the remaining available supply of medication in

the cartridge provides a persuasive rationale for why a person of ordinary skill in the art would have modified Giambattista. *See* Ex. 1017, 4:52–58.

Additionally, as explained in detail above, having considered all the evidence of indicia of nonobviousness, Patent Owner does not show the requisite nexus between the alleged objective indicia of nonobviousness and the Challenged Claims of the '844 patent. Moreover, even if Patent Owner had shown nexus, the objective evidence of nonobviousness identified by Patent Owner fails to show persuasive evidence of a long-felt, unmet need satisfied by the invention of any of the Challenged Claims. Patent Owner also fails to show persuasive evidence of either industry praise of SoloSTAR[®] or of commercial success of Lantus[®] SoloSTAR[®]. Thus, Patent Owner's evidence of indicia of nonobviousness provides very little, if any, support for nonobviousness of claim 30.

On the whole, we find that the information provided by Petitioner and Patent Owner in consideration of the *Graham* factors collectively demonstrates by a preponderance of the evidence that the subject matter of claim 30 of the '844 patent would have been obvious over the combination of Giambattista and Klitgaard.

III. ANALYSIS OF PATENT OWNER'S CORRECTED REVISED CONTINGENT MOTION TO AMEND

Patent Owner's Corrected Revised Contingent Motion to Amend seeks entry of substitute claims 31–38 to the extent that we find the Challenged Claims unpatentable. RMTA 1–2. As discussed above, Petitioner shows by a preponderance of the evidence that the Challenged Claims are unpatentable. We now turn to consider whether to enter any of the substitute claims proposed by Patent Owner. For the reasons that follow, we deny Patent Owner's motion because the substitute claims it proposes

lack written description support, as required by 35 U.S.C. § 316(d) and 37 C.F.R. § 42.121.

A. Principles of Law Concerning a Motion to Amend

In an *inter partes* review, amended claims are not added to a patent as of right, but rather must be proposed as a part of a motion to amend. 35 U.S.C. § 316(d). The Board must assess the patentability of proposed substitute claims “without placing the burden of persuasion on the patent owner.” *Aqua Prods., Inc. v. Matal*, 872 F.3d 1290, 1328 (Fed. Cir. 2017) (en banc); see also *Lectrosonics, Inc. v. Zaxcom, Inc.*, IPR2018-01129, Paper 15 at 3–4 (PTAB Feb. 25, 2019) (precedential). Subsequent to the issuance of *Aqua Products*, the Federal Circuit issued a decision in *Bosch Automotive Service Solutions, LLC v. Matal*, 878 F.3d 1027 (Fed. Cir. 2017) (“*Bosch*”), as well as a follow-up order amending that decision on rehearing. See *Bosch Auto. Serv. Sols., LLC v. Iancu*, No. 2015-1928 (Fed. Cir. Mar. 15, 2018) (Order on Petition for Panel Rehearing).

In accordance with *Aqua Products*, *Bosch*, and *Lectrosonics*, a patent owner does not bear the burden of persuasion to demonstrate the patentability of the substitute claims presented in the motion to amend. Rather, ordinarily, “the petitioner bears the burden of proving that the proposed amended claims are unpatentable by a preponderance of the evidence.” *Bosch*, 878 F.3d at 1040 (as amended on rehearing); *Lectrosonics*, Paper 15 at 3–4. In determining whether a petitioner has proven unpatentability of the substitute claims, the Board focuses on “arguments and theories raised by the petitioner in its petition or opposition to the motion to amend.” *Nike, Inc. v. Adidas AG*, No. 2019-1262, 2020 WL 1802796, at *5 (Fed. Cir. Apr. 9, 2020). The Board itself also may justify any finding of unpatentability by reference to evidence of record in the

proceeding. *Lectrosonics*, Paper 15 at 4 (citing *Aqua Products*, 872 F.3d at 1311 (O’Malley, J.)).

“Before considering the patentability of any substitute claims” we “first must determine whether the motion to amend meets the statutory and regulatory requirements set forth in 35 U.S.C. § 316(d) and 37 C.F.R. § 42.121.” *Lectrosonics*, Paper 15 at 4. Accordingly, a patent owner must demonstrate: (1) the amendment proposes a reasonable number of substitute claims; (2) the proposed claims are supported in the original disclosure (and any earlier filed disclosure for which the benefit of filing date is sought); (3) the amendment responds to a ground of unpatentability involved in the trial; and (4) the amendment does not seek to enlarge the scope of the claims of the patent or introduce new subject matter. *See* 35 U.S.C. § 316(d); 37 C.F.R. § 42.121.

B. Substitute Claims 31–38

Patent Owner submits substitute claims 31–38, set forth below, with additions to the original claim shown in underlining and deletions shown in brackets or strikethroughs.¹⁴ Substitute claim 31 is independent. Substitute claims 32, 35, and 36 depend from substitute claim 31. Substitute claims 33, 37, and 38 depend from original claim 21, and substitute claim 34 depends from substitute claim 33.

¹⁴ Patent Owner provides its substitute claims in Appendix A to its Revised Contingent Motion to Amend (Paper 66, App. A (“Claims Appendix”)), but did not provide such an appendix of substitute claims with its subsequent Corrected Revised Contingent Motion to Amend (Paper 73). Patent Owner confirmed that references to a claims appendix in the Corrected Revised Contingent Motion to Amend are intended to refer to the claims appendix provided with the earlier filed Revised Contingent Motion to Amend. Ex. 1110, 17:14–19:17. We, therefore, rely on and refer to the same earlier-filed claims appendix.

1. *Substitute claim 31 (to replace claim 21)*

31. A drug delivery device comprising:
a housing comprising a dose dispensing end and a first thread;
a dose indicator comprising a second thread that engages with the first thread;
a driving member comprising a third thread;
a sleeve that is (i) disposed between the dose indicator and the driving member and (ii) releasably connected to the dose indicator;
a piston rod comprising ~~either an internal or an external~~ a fourth thread that is engaged with the third thread;
a piston rod holder that is rotatably fixed relative to the housing and configured to (i) prevent the piston rod from rotating during dose setting and (ii) permit the piston rod to traverse axially towards the distal end during dose dispensing; wherein:
the housing is disposed at an outermost position of the drug delivery device;
the dose indicator is disposed between the housing and the sleeve and is configured to (i) rotate and traverse axially away from the dose dispensing end during dose setting and (ii) rotate and traverse axially towards the dose dispensing end during dose dispensing;
the driving member is configured to rotate relative to the piston rod;
the sleeve is rotatably fixed relative to the driving member and configured to traverse axially with the dose indicator; and
the piston rod and the driving member are configured to rotate relative to one another during dose dispensing; and
the piston rod is configured to traverse axially towards the dose dispensing end during dose dispensing.

Claims Appendix 1–2.

2. *Substitute claim 32 (to replace claim 23)*

32. The drug delivery device of claim ~~[[21]]~~ 31 wherein the sleeve ~~further comprising~~ is a clutch;

wherein the drug delivery device has only one arc shaped body that is both within the housing and configured to track each set dose of medicament as said dose indicator is rotated relative to the arc shaped body, the arc shaped body comprising proximal and distal surfaces, end-most side surfaces, and inner and outer curved surfaces, the end-most side surfaces being circumferentially spaced apart, one of the curved surfaces comprising a fifth thread that is engaged with a sixth thread, and wherein the arc shaped body is configured to (i) during dose setting, move axially relative to the housing without rotating relative to the housing, and (ii) abut a radial stop when at a final dose position, said radial stop disposed separate from the sixth thread;

wherein said drug delivery device further comprises:

a first clicker feature comprising teeth configured to provide audible clicks (i) by dragging the teeth over corresponding teeth on said clutch and (ii) only during dialing down of a dose without dispensing medicament, where each click relates to a unit dose of medicament; and

a second clicker feature spaced axially apart from the first clicker feature and disposed adjacent an end of the dose indicator that is nearest the dose dispensing end, the second clicker feature comprising a flexible arm configured (i) to move axially relative to splines in only a first axial direction during dialing up of a dose and to move axially relative to the splines in only a second, opposite, axial direction during dose dispensing and (ii) to provide audible clicks by dragging a tooth member over the splines while rotating and moving axially relative to the splines; and

a zero dose stop on the housing, wherein the zero dose stop protrudes radially inward and prevents the dose indicator

from rotating in a dialing down direction past an end position.

Id. at 2–3.

3. *Substitute claim 33 (to replace claim 24)*

33. The drug delivery device of claim ~~[[23]]~~ 21

wherein the sleeve is a clutch;

wherein the device comprises a first clicker feature with teeth configured to provide audible clicks by dragging the teeth over corresponding teeth on the clutch and provide[[s]] audible and tactile feedback only during dose correction that is indicative of unit doses of medicament; and

wherein the device comprises a second clicker feature spaced axially apart from the first clicker feature and disposed adjacent an end of the dose indicator that is nearest the dose dispensing end, the second clicker feature comprising a flexible arm configured (i) to move axially relative to splines in only a first axial direction during dialing up of a dose and move axially relative to the splines in only a second, opposite, axial direction during dose dispensing and (ii) to provide audible clicks by dragging a tooth member over the splines while rotating and moving axially relative to the splines.

Id. at 3.

4. *Substitute claim 34 (to replace claim 26)*

34. The drug delivery device of claim ~~[[24]]~~ 33

wherein the clutch allows the dose cancelling without dispensing medicament; and

wherein the drug delivery device has only one arc shaped body that is both within the housing and configured to track each set dose of medicament as said dose indicator is rotated relative to the arc shaped body, the arc shaped body comprising proximal and distal surfaces, end-most side surfaces, and inner and outer curved surfaces, the end-most side surfaces being circumferentially spaced apart, one of the curved surfaces comprising a fifth thread that is engaged with a sixth thread, and wherein the arc shaped body is

configured to (i) during dose setting, move axially relative to the housing without rotating relative to the housing, and (ii) about a radial stop when at a final dose position, said radial stop disposed separate from the sixth thread.

Id. at 3–4.

5. *Substitute claim 35 (to replace claim 27)*

35. The drug delivery device of claim ~~[[24]]~~ 31

wherein the sleeve is a clutch; and

the drug delivery device further comprising a button seated in an annular recess of a dose dial grip on a proximal end of the dose indicator, where the button is rotatable relative to the dose indicator[.];

a first clicker feature comprising teeth configured to provide audible and tactile feedback (i) by dragging the teeth over corresponding teeth on said clutch and (ii) only during dialing down of a dose without dispensing medicament, the feedback being indicative of unit doses of medicament; and

a second clicker feature spaced axially apart from the first clicker feature and disposed adjacent an end of the dose indicator that is nearest the dose dispensing end, the second clicker feature comprising a flexible arm configured (i) to move axially relative to splines in only a first axial direction during dialing up of a dose and to move axially relative to the splines in only a second, opposite, axial direction during dose dispensing and (ii) to provide audible clicks by dragging a tooth member over the splines while rotating and moving axially relative to the splines.

Id. at 4–5.

6. *Substitute claim 36 (to replace claim 29)*

36. The drug delivery device of claim ~~[[21]]~~ 31

further comprising a clicker that provides audible clicks during dose setting, where each click is equal to a unit dose of medicament, wherein said clicker comprises:

a flexible arm extending from a fixed end circumferentially to a free end thereof, the flexible arm

comprising a tooth on the free end, the flexible arm configured to: (i) provide audible clicks while rotationally fixed relative to the sleeve, which is a clutch, and while the clicker is moving axially relative to the housing in a first direction during dialing up of a dose, where each click relates to a unit dose of the medicament, and (ii) not provide audible clicks while the clicker is moving axially relative to the housing in a second, opposite, direction during dialing down of a dose without dispensing the medicament; and

one-way teeth configured to: (i) provide audible clicks by dragging over corresponding teeth of the clutch while the clicker is moving axially relative to the housing in the second direction during dialing down of a dose without dispensing the medicament, where each click relates to a unit dose of the medicament and, (ii) not provide audible clicks while the clicker is moving axially relative to the housing in the first direction during dialing up of a dose; and

wherein the drug delivery device has only one arc shaped body that is both within the housing and configured to track each set dose of medicament as said dose indicator is rotated relative to the arc shaped body, the arc shaped body comprising proximal and distal surfaces, end-most side surfaces, and inner and outer curved surfaces, the end-most side surfaces being circumferentially spaced apart, one of the curved surfaces comprising a fifth thread that is engaged with a sixth thread, and wherein the arc shaped body is configured to (i) during dose setting, move axially relative to the housing without rotating relative to the housing, and (ii) abut a radial stop when at a final dose position, said radial stop disposed separate from the sixth thread.

Id. at 5–6.

7. *Substitute claim 37 (to replace claim 29)*

37. The drug delivery device of claim 21

further comprising a clicker that provides audible clicks during dose setting, where each click is equal to a unit dose of medicament, wherein said clicker comprises:

a flexible arm extending from a fixed end, circumferentially to a free end thereof, the flexible arm comprising a tooth on the free end, the flexible arm configured to: (i) provide audible clicks while rotationally fixed relative to the sleeve, which is a clutch, and while the clicker is moving axially relative to the housing in a first direction during dialing up of a dose, where each click relates to a unit dose of the medicament, and (ii) not provide audible clicks while the clicker is moving axially relative to the housing in a second, opposite, direction during dialing down of a dose without dispensing the medicament; and

one-way teeth configured to: (i) provide audible clicks by dragging over corresponding teeth of the clutch while the clicker is moving axially relative to the housing in the second direction during dialing down of a dose without dispensing the medicament, where each click relates to a unit dose of the medicament and, (ii) not provide audible clicks while the clicker is moving axially relative to the housing in the first direction during dialing up of a dose; and

wherein the drug delivery device has only one arc shaped body that is both within the housing and configured to track each set dose of medicament as said dose indicator is rotated relative to the arc shaped body, the arc shaped body comprising proximal and distal surfaces, end-most side surfaces, and inner and outer curved surfaces, the end-most side surfaces being circumferentially spaced apart, one of the curved surfaces comprising a fifth thread that is engaged with a sixth thread, and wherein the arc shaped body is configured to (i) during dose setting, move axially relative to the housing without rotating relative to the housing, and (ii) abut a radial stop when at a final dose

position, said radial stop disposed separate from the sixth thread.

Id. at 6–7.

8. *Substitute claim 38 (to replace claim 30)*

38. The drug delivery device of claim 21 further comprises comprising:

a nut that tracks each set dose of medicament delivered; and
a clicker that provides audible clicks during dose setting, where each click relates to a unit dose of medicament, wherein said clicker comprises:

a flexible arm extending from a fixed end, circumferentially to a free end thereof, the flexible arm comprising a tooth on the free end, the flexible arm configured to: (i) provide audible clicks while rotationally fixed relative to the sleeve, which is a clutch, and while the clicker is moving axially relative to the housing in a first direction during dialing up of a dose, where each click relates to a unit dose of the medicament, and (ii) not provide audible clicks while the clicker is moving axially relative to the housing in a second, opposite, direction during dialing down of a dose without dispensing the medicament; and

one-way teeth configured to: (i) provide audible clicks by dragging over corresponding teeth of the clutch while the clicker is moving axially relative to the housing in the second direction during dialing down of a dose without dispensing the medicament, where each click relates to a unit dose of the medicament and, (ii) not provide audible clicks while the clicker is moving axially relative to the housing in the first direction during dialing up of a dose.

Id. at 7–8.

C. Written Description and New Matter Under 35 U.S.C. § 316(d)(3) and 37 C.F.R. § 42.121(a)(2)(ii) and (b)

An amendment may not enlarge the scope of the claims of the patent or introduce new matter. 35 U.S.C. § 316(d)(3); 37 C.F.R. § 42.121(a)(2)(ii). In connection with its motion to amend, a patent owner must set forth “support in the original disclosure of the patent for each claim that is added or amended,” and “support in an earlier-filed disclosure for each claim for which benefit of the filing date of the earlier filed disclosure is sought.” 37 C.F.R. § 42.121(b). Patent Owner’s motion fails to set forth adequate written description support for the proposed substitute claims.

Patent Owner contends substitute claims 31–38 are fully supported by the original disclosure of the ’616 application and “the line of priority documents noted on the face of the ’844 Patent, which extend back to” the GB application. RMTA 5; *see also* Ex. 2304; Ex. 2313. In support of its contentions, Patent Owner provides a table of pin citations to the ’616 application and the GB application, pin citations to Dr. Slocum’s declaration (Ex. 2302), which purportedly provides “explanatory analysis of certain disclosures” from the perspective of a person of ordinary skill in the art, and additional discussion of certain features of the substitute claims. RMTA 5–18.

Petitioner argues that Patent Owner does not sufficiently identify written description support for each substitute claim, because Patent Owner provides “analysis for only a few limitations” and otherwise relies on “a

table of citation without analysis.”¹⁵ RMTA Opp. 1. More specifically, Petitioner contends four limitations lack support. RMTA Opp. 2–8. We address only one of the four limitations addressed by Petitioner, because we find it dispositive of the motion, reproduced below as originally provided in claim 21 and as proposed in substitute claim 31:

Claim 21: “*a driving member comprising a third thread*” and “*a piston rod comprising either an internal or an external fourth thread that is engaged with the third thread*”

Substitute Claim 31: “*a driving member comprising a third thread*” and “*a piston rod comprising a fourth thread that is engaged with the third thread*”

Patent Owner proposes substitute claim 31 as an amendment of challenged claim 21. Challenged claim 21 recites “a driving member comprising a third thread” and “a piston rod comprising *either an internal or an external* fourth thread that is engaged with the third thread.” Ex. 1004, 8:36–49 (emphasis added). Patent Owner proposes amending claim 21 by deleting the phrase “either an internal or an external,” whereby substitute claim 31 then recites “a piston rod comprising *a* fourth thread that is engaged with the third thread.” Claims Appendix 1 (Element 31[e]) (emphasis added to show “a” was added to substitute claim 31). Patent Owner proposes no other amendments to claim 21. Thus, substitute claim 31 is identical to challenged claim 21, but for the *omission* of “either

¹⁵ Petitioner notes that the restriction on grounds of unpatentability that may be raised to challenge issued claims in an *inter partes* review under § 311(b) does not “limit the grounds of unpatentability that can be raised in response to proposed substitute claims presented in a motion to amend.” RMTA Opp. 2 n.1 (quoting *Amazon.com, Inc. v. Uniloc Luxembourg S.A.*, IPR2017-00948, Paper 34 at 5 (PTAB Jan. 18, 2019) (precedential)).

an internal or an external” from claim 21 (and the addition to substitute claim 31 of “a” prior to “fourth thread”). *See* RMTA 3.

As explained above, because the GB application does not provide written description support for a “piston rod comprising . . . an internal . . . fourth thread” (i.e., an internally threaded piston rod), as recited in claim 21, claim 21 was not entitled to priority to the GB application. *See supra* § I.F. (explaining that the GB application discloses an externally threaded piston rod, but not an internally threaded piston rod or a genus of threaded piston rods). As a result, Giambattista is prior art to claim 21, and Petitioner shows that Giambattista anticipates claim 21. *See supra* §§ I.F., II.E.

In discussing substitute claim 31, Patent Owner begins by seeking “to be clear at the outset” that the written description analysis of claim 21 “does not dictate the outcome for *amended* claim 31,” because substitute claim 31 “is different” and there is no requirement for written description support of “an un-recited feature.” RMTA 8–9. We emphasize, again, that the only claim language that is “different” between claim 21 and substitute claim 31 is the omission of “either an internal or an external” from claim 21 (and the addition of “a”). Claims Appendix 1 (Element 31[e]). We agree with Patent Owner that an analysis of written description support for claim 21 does not “dictate” the same outcome with respect to substitute claim 31.

Patent Owner further maintains that by manipulating the language of claim 21 to eliminate any specific reference to either “an internal” or “an external” fourth thread in substitute claim 31, Patent Owner can: (1) have the scope of substitute claim 31 be *identical* to the scope of claim 21, and (2) “eliminate[] Giambattista from consideration as a prior art reference” to substitute claim 31, because a lack of written description for an internally

threaded piston rod is purportedly no longer an issue. RMTA 3, 18–19. Patent Owner further asserts that “while the test for written description support of claim 21 requires possession of both external and internal threads, for [substitute] claim 31, the test only requires possession of a thread.” PO Sur-reply 3–4. We disagree with Patent Owner that possession by the inventors of “a thread” provides sufficient written description to support substitute claim 31 with a scope identical to claim 21, which, as explained above, is an unpatentable claim. *See supra* § II.E. Indeed, Patent Owner recognizes that a “proper written description inquiry” is focused on “whether ‘the four corners of the specification’ demonstrate ‘the inventor actually invented the invention claimed.’” RMTA 9 (quoting *Ariad Pharm.*, 598 F.3d at 1351). The “four corners” of the GB application make clear that Patent Owner did not invent what Patent Owner now seeks to claim in substitute claim 31, for the reasons provided below.

The error in Patent Owner’s argument that it need show no more than possession of a “thread” mirrors the insufficiencies in Patent Owner’s showing addressed above in our priority analysis with respect to claim 21. *See supra* § I.F. In sum, the GB application discloses only an externally threaded piston rod, not an internally threaded piston rod. A preponderance of the evidence further shows that the GB application, in light of the knowledge of a person of ordinary skill in the art, does not disclose or suggest any alternative to an externally threaded piston, much less that the internally threaded piston rod, as applied in the GB application, was but a member of a “genus” of threaded piston rods with well-known, interchangeable options. *See id.* To the contrary, as discussed above, there is no disclosure or suggestion in the GB application that an internally

threaded piston rod would be functional in light of the required arrangement of other features of the pen injector disclosed. *See id.*

For substantially the same reasons, to the extent that Patent Owner seeks through substitute claim 31 to claim all threaded piston rods as a “genus” (with purportedly only two species—internally and externally threaded piston rods),¹⁶ Patent Owner does not show that the GB application provides any broad disclosure of a “thread” sufficient to provide written description for substitute claim 31. Further, to the extent that Patent Owner alternatively seeks through substitute claim 31 to claim all threaded piston rods as a “genus,” based on the disclosure in the GB application of only one species (an externally threaded piston rod), Patent Owner does not show sufficient written description support. To be clear, we agree with Patent Owner that it is *possible* that the disclosure of a species may provide written description support for a genus claim. *See* RMTA 11 (citing *In re Rasmussen*, 650 F.2d 1212, 1215 (C.C.P.A. 1981) (“[t]hat a claim may be broader than the specific embodiment disclosed in a specification is in itself of no moment”); *see also id.* at 10–12 (discussing *Hologic*, 884 F.3d at 1362, and *Bilstad v. Wakalopulos*, 386 F.3d 1116, 1124–25 (Fed. Cir. 2004)). Thus, although a narrow disclosure of a species (externally threaded piston rods) theoretically may provide written description support for a claim directed to a broader genus (threaded piston rods), such reasoning does not apply to substitute claim 31, because a preponderance of the evidence: (1) shows that Patent Owner was in possession of only one of

¹⁶ Assuming only two species ignores, again, the fact that the piston rod is threaded at both ends, corresponding to what would seem to be four species of threaded piston rods under Patent Owner’s own reasoning, as discussed above. *See supra* § I.F.

the two species (externally threaded piston rods) in the supposed genus of threaded piston rods Patent Owner seeks to claim, and (2) does not show that the second species (internally threaded piston rods) was well-known in the art or interchangeable with the first species. *See* RMTA 10–11; *see also Hologic*, 884 F.3d at 1362 (explaining that disclosure of a species (a “fibre optics bundle”) provided written description support for a genus (a “light guide”) where there was no “dispute that various types of light guides were well-known in the art”).

More specifically, turning to the evidence of written description Patent Owner provides in support of substitute claim 31 in its motion, Patent Owner identifies in a table certain portions of the ’616 application and corresponding portions of the GB application that Patent Owner asserts provide written description support for the recited “piston rod comprising a fourth thread that is engaged with the third thread.”¹⁷ RMTA 5–6 (citing Ex. 2304 ¶¶ 6, 7, 39–41; Ex. 1026, 1:25–2:13, 5:25–6:14, cls. 2, 6 (regarding Element 31[e] of Claims Appendix at 1); *see also* Ex. 2325 ¶ 23 (providing the same table). Rather than address the disclosures Patent Owner cited as

¹⁷ Patent Owner explains that citations to the GB application (Ex. 1026) “are equivalent to the same disclosure” in the ’616 application (Ex. 2304). RMTA 6 n.5. To the extent the parties and their experts discuss what was disclosed in either the GB application or the ’616 application, unless noted otherwise, our understanding is that each application provides an equivalent disclosure to the other. *See also* Ex. 2325 ¶ 25 n.7 (Dr. Slocum stating that he cites “to the US ’616 Application throughout simply as a matter of convenience, and by doing so, [he does] not mean to imply that the corresponding disclosure in the GB Application is not also relevant,” and noting that with regard to disclosures in the ’616 application, the “same disclosure exists in the GB Application”). We follow the same approach in that our discussion of either the GB application or the ’616 application pertains to what both applications equivalently disclose.

purportedly providing written description support, Patent Owner instead proceeds to address “original claim 1” of the GB application, which it did not identify as providing written description support for the piston rod limitation of substitute claim 31 at issue. *See id.* Specifically, Patent Owner argues that “original claim 1” of the GB application “recites a piston rod but does not specify that it is threaded internally or externally.” RMTA 9 (citing Ex. 1026). Patent Owner’s argument implicitly mischaracterizes claim 1 of the GB application, which states as follows:

1. A pen-type injector comprising a housing;
a piston rod adapted to operate through the housing;
a dose dial sleeve located between the housing and the piston rod,
the dose dial sleeve having a helical thread of first lead;
a drive sleeve located between the dose dial sleeve and the piston
rod, the drive sleeve having a helical groove of second lead;
characterised in that the first lead of the helical thread and the
second lead of the helical groove are the same.

Ex. 1026, 12. Patent Owner neglects to explain that not only does “original claim 1” of the GB application “not specify” whether the piston rod “is threaded internally or externally,” as Patent Owner asserts, “original claim 1” does not even specify that the piston rod is “threaded.” *See also* Ex. 2325 ¶ 28 (Dr. Slocum noting that original claim 1 “describes the piston rod without reference to threads”). Yet from this absence of disclosure, Patent Owner asserts a person of ordinary skill in the art would have “gleaned that the inventors considered their invention broader than the externally-threaded piston rod.” RMTA 9 (citing Ex. 2325 ¶¶ 25–32). Patent Owner’s explanation, on its face, fails to show written description support for substitute claim 31, even if the disclosure would have suggested some undisclosed “broader” invention. Moreover, Dr. Slocum’s opinion that the *absence* of *any* disclosure of “threads” in “original claim 1”

constitutes a “signal to a person of ordinary skill that the inventors had not intended their invention to be limited to external threads” is unsupported and not credible, because it is inconsistent with the entirety of the GB application, which expressly describes only an externally threaded piston rod. *See* Ex. 2325 ¶ 28.

The remaining evidence Patent Owner presents is duplicative of the arguments Patent Owner raised with respect to whether claim 21 was entitled to priority to the GB application, which we address and reject in Section I.F. above. Specifically, Patent Owner asserts again the following:

- a person of ordinary skill in the art would have known that “it does not matter which thread (whether on the piston rod or drive sleeve) is internal or external,” and that the location of these threads were “interchangeable” (RMTA 9 (citing Ex. 2107 ¶¶ 98–99); *see also* PO Resp. 22 (citing Ex. 2107 ¶¶ 97–100));
- a person of ordinary skill in the art would have understood “that the threads of a piston rod could *only* be either internal or external” and “would have immediately understood that the piston rod could have either internal threads or external threads” in “each instance where the specification discloses that the piston rod has a ‘thread’” (RMTA 9–10 (citing Ex. 2325 ¶¶ 21, 28); *see also* PO Resp. 23 (describing the “genus of threaded piston rods (internally and externally)” (citing Ex. 2107 ¶ 92))); and
- a person of ordinary skill in the art would have had “the prior knowledge of internally threaded piston rods in other related contexts” (RMTA 10 (citing Ex. 2107 ¶¶ 95–97 (citing Exs. 2169–2171); Ex. 2325 ¶¶ 25–32); *see also* PO Resp. 26–28 (arguing that “driving mechanisms implementing an internally threaded piston rod driven by an externally threaded driver were well known”) (citing Ex. 2107 ¶ 95–97; Exs. 2169–2171)).

According to Patent Owner, the above “understandings” would have led a person of ordinary skill in the art “to conclude that the inventors here had

possession of a threaded piston rod, without limitation to the specific position of the threads.” RMTA 10.

We have also considered additional testimony provided by Dr. Slocum in support of Patent Owner’s motion.¹⁸ *See* Ex. 2325 ¶¶ 23–32. Dr. Slocum states that the ’616 application describes an externally threaded piston rod 20. *Id.* ¶ 27 (citing Ex. 2304 ¶¶ 39–40, Fig. 1). We agree that the ’616 application (and the GB application) expressly disclose an externally threaded piston rod. Dr. Slocum also suggests that, because he was able to draw what he characterizes as “an exemplar of an internally threaded piston rod interacting with a drive sleeve” during his deposition, “a person of ordinary skill would read the GB Application and understand that the inventors were in possession of an invention with a drive sleeve connected to a piston rod, and that such connection could be with internal or external threads on the piston rod.” *Id.* ¶¶ 29–31. The exemplar Dr. Slocum refers to (Ex. 1051) includes a “stinger” and is discussed above. *See supra* § I.F. We find that Dr. Slocum’s drawing in a deposition in 2019 does not provide persuasive evidence of what a person of ordinary skill in the art would have understood from the ’616 application or the GB application during the relevant time frame.

In this regard, we credit the testimony of Mr. Leinsing, who explains that Dr. Slocum’s drawing does not reflect what a person of skill in the art would have considered a “routine or commonly-used component in pen injectors” and that “it was not conventional for pen injectors to use a drive with an internal ‘stinger’ that engages an internally thread piston rod.”

¹⁸ Dr. Slocum also provided a declaration (Ex. 2332) in support of Patent Owner’s reply to RMTA, which we address below.

Ex. 1113 ¶ 40; *see also id.* (noting that Steinfeldt-Jensen, Burroughs, Moller, and Giambattista all teach an externally threaded piston rod and demonstrate what would have been viewed as conventional and routine). Mr. Leinsing’s opinion that the ’616 application “provides no discussion on how to configure, much less describe, an internally threaded piston ‘rod’ with an internal ‘stinger’ that would work” is persuasive as Mr. Leinsing explains that “a person of ordinary skill would have understood the piston rod to be already very thin,” and that “additional structural concerns, such as buckling, would arise by hollowing out an already-thin component to introduce an even thinner threaded component within its space, thus requiring a larger size to address those concerns.” *Id.* ¶ 43.

In opposition to the motion, Petitioner also argues that “substitute claim 31 suffers the same deficiencies as original claim 21” and that substitute claims 31–38 lack written description support in the ’616 application. RMTA Opp. 2–4. Petitioner presents substantially similar arguments as discussed above with respect to whether claim 21 was entitled to priority to the GB application, relying on testimony from Mr. Leinsing.¹⁹ *Id.* (citing Ex. 1096 ¶¶ 25–27). Petitioner argues that a person of ordinary skill in the art would have understood from the ’616 application “that external threads on the piston rod are required to permit connection with the drive sleeve,” because the ’616 application “discloses a drive sleeve located

¹⁹ Mr. Leinsing provided a declaration (Ex. 1096) in support of Petitioner’s opposition to Patent Owner’s initial motion to amend, as well as a declaration (Ex. 1113) in support of Petitioner’s opposition to Patent Owner’s RMTA. Both declarations are relevant to Petitioner’s arguments against substitute claim 31, which is identical in both the motion to amend and the revised motion to amend. *Compare* Paper 34, App. A. at 1–2, *with* Paper 66, App. A at 1–2.

between the dose dial sleeve and the piston rod,” and “notes that the drive sleeve connects to the piston rod for rotation along the piston rod’s second threaded portion.” *Id.* at 3 (citing Ex. 2304 ¶¶ 6, 7; Ex. 1096 ¶¶ 25–27). Petitioner also explains that the only “driving member” disclosed by the ’616 application is a “drive sleeve” with inner helical groove 38, which works with external threading on piston rod 20. *Id.* at 4 (citing Ex. 1096 ¶¶ 25–27; Ex. 2304 Fig. 1). Petitioner argues that Patent Owner “fails to explain” how a person of ordinary skill in the art would have immediately discerned that the thread could also be on the inner surface of the piston rod and still interact with the drive sleeve.” *Id.* (citing *Waldemar Link GmbH & Co. v. Osteonics Corp.*, 32 F.3d 556, 558 (Fed. Cir. 1994)).

In regard to the disclosures of the ’616 application Patent Owner identifies as providing written description support (i.e., Ex. 2304 ¶¶ 6, 7, 39–41), Mr. Leinsing states as follows:

As I explained previously, while paragraphs 6 and 7 of the ’616 application do not explicitly specify whether the threading on the piston rod is internal or external, the paragraphs, like the rest of the specification, provides crucial context as to the concentric nature of the components by disclosing a drive *sleeve* that is located between the dose dial sleeve and the piston rod (and the dose dial sleeve is located between the housing and the piston rod), where the drive *sleeve* is connected to the piston rod for rotation with respect thereto along the second threaded portion of the piston rod. *See* EX 1095, ¶¶ 9–12; *see also* EX1109, 45:24–46:11.

The ordinary artisan would not read those paragraphs of the ’616 application as suggesting that the threading on the piston rod could be on either the inner surface or the outer surface of the piston rod and, similarly, that the threading on the drive sleeve could be either on the inner surface or the outer surface of the drive sleeve. That is, given the position of the piston rod relative to the drive sleeve, such that the drive sleeve is located

between the dose dial sleeve (which is located between the housing and the piston rod) and the piston rod, the ordinary artisan would understand that the threads of the piston rod are necessarily on the outer surface so as to allow for connection with the inner surface of the drive sleeve. Paragraphs 39-41 of the '616 application also do not disclose an internally threaded piston rod but reinforce the use of an externally threaded piston rod. Specifically, the piston rod is described as having a second thread 24 that is adapted to work within helical groove 38 that extends along the internal surface of the drive sleeve. EX2304, ¶¶ 39-41, 59; *see also* FIG. 1 (showing external thread 24 on piston rod 20); EX2325, ¶ 27 (noting that paragraphs 39 and 40 describe a specific embodiment that includes an externally threaded piston rod 20). Dr. Slocum's "stinger" approach overlooks the consistent terminology used in the '616 application—where a hollow, cylindrical, concentric component is a "sleeve" and that which is not is a "rod"—and instead sets forth a configuration where the "piston rod" is now an internally-threaded "sleeve" and the drive sleeve includes an externally-threaded "rod" attached to it.

Ex. 1113 ¶¶ 41–42.

Patent Owner's additional arguments fail to provide evidence that the inventors of the '844 patent were in possession of an internally threaded piston rod. *See* RMTA Reply 3–8; Ex. 2332 ¶¶ 11–33. Patent Owner argues that the GB application "places no special importance" on whether the piston rod threading is internal or external, refers to the piston rod as "threaded," and merely provides one illustrated embodiment with preferable features that shows an externally threaded piston rod, such that the "thread location is a mere implementation detail. RMTA Reply 4–5. We disagree, as Mr. Leinsing explains, the injector pen disclosed in the GB application includes components, including a drive sleeve, that essentially only function with an externally threaded piston rod, notwithstanding Dr. Slocum's attempt to redesign the device disclosed in the GB application to add a

“stinger” to the drive sleeve to then add an internally threaded piston rod. Patent Owner also argues in reply at length that Dr. Slocum’s design proves what a person of ordinary skill in the art “would have ‘immediately discerned’” because “Dr. Slocum readily envisioned such a device when prompted by Mylan’s counsel during deposition.” RMTA Reply 6–8.

For the many reasons provided above, we are not persuaded that what Dr. Slocum envisioned during a deposition in 2019 accurately reflects the understanding of a person of ordinary skill in the art at the time of the invention. Dr. Slocum’s declaration in support of the RMTA Reply highlights the very problem with his opinion—it is not based on sufficient evidence of what was known to a person of ordinary skill in the art at the time of the invention, but is instead a reflection of his personal knowledge and experience as of 2019. *See* Ex. 2332 ¶ 13–33. Dr. Slocum claims to show “how simple it is to accomplish” an internally threaded piston rod and externally threaded drive sleeve, which he calls his “‘stinger’ embodiment” by literally creating “a CAD model with engineering design calculations of the design to . . . more clearly show the arrangement of components.” Dr. Slocum does not rely on what was disclosed in the GB application, but instead shows what he has designed in 2019, including in “parallel with the CAD modeling,” a “spreadsheet to assess force loop of the drawn embodiment” to evaluate “the efficiency of the system, reasonable stresses in components, and material/geometry considerations.” *Id.* ¶¶ 13–15, 33. Dr. Slocum even suggests that “[w]ith the CAD model of the drawn embodiment complete, it was easy for me, acting as a person of ordinary skill, to evolve the model to show the “stinger” design using an internally threaded piston rod.” *Id.* ¶ 17. Dr. Slocum does not explain how he was able to set aside his superior knowledge to act “as a person of ordinary skill”

as he used the model he created to “evolve” it into his “stinger embodiment.” *See id.* Dr. Slocum proceeds to attempt to refute Dr. Leinsing’s opinion that the addition of a stinger would have presented structural concerns by discussing the properties of polyoxymethylene and how he “added the details for mechanically joining the stinger to the modified drive sleeve via a snap fit design.” *Id.* ¶¶ 19–24. Dr. Slocum also provides a table showing dozens of entries for “geometries and analysis” and an illustration comparing the “GB App. Model” (disclosed in the GB application) to his “‘Stinger’ Model.” *Id.* ¶¶ 25–33.

On the back of the extensive work Dr. Slocum performed creating a “Stinger Model,” Patent Owner proceeds to argue that it is “unsurprising” that a person of ordinary skill in the art “would have immediately discerned an internally-threaded piston rod in view of the GB Application’s disclosure,” because such a person would have been “well-versed on threaded engagements” and would have been familiar with “devices utilizing an internally-threaded piston rod driven by an externally-threaded driver.” RMTA Reply 7–8 (citing Kamen, Spinello, Moberg). We note Patent Owner does not suggest that Kamen, Spinello, or Moberg actually teaches the use of a stinger as shown in Dr. Slocum’s Stinger Model. Patent Owner concludes that Petitioner “fails to account for the real world fact that ‘[a] patent specification is written for a person of skill in the art, and such a person comes to the patent with the knowledge of what has come before.’” *Id.* at 8 (quoting *LizardTech*, 424 F.3d at 1345).

Petitioner argues in Sur-reply that “it is the specification itself that must demonstrate possession,” and that “a description that merely renders the invention obvious does not satisfy the requirement.” RMTA Sur-reply 1 (quoting *Ariad*, 598 F.3d at 1352). Petitioner further argues that Patent

Owner identifies no guidance or “blaze marks” from the specification indicating possession of the undisclosed embodiment, and that Patent Owner’s argument that a person of ordinary skill in the art could have made the undisclosed embodiments is insufficient. *Id.* at 1–2. Petitioner also argues, again, that the GB application “only shows possession of an external thread,” that “having a threaded drive sleeve necessarily means there is an externally-threaded piston rod,” and that “having an internally threaded piston rod requires an entirely different (and definitely undescribed) driving structure, like a ‘stinger.’” *Id.* at 3. According to Petitioner, whether Dr. Slocum can create “a functional stinger does not show written description support,” even if it “supports the obviousness of the configuration.” *Id.* at 3–4. Finally, Petitioner argues that Patent Owner “fails to direct the Board to any pen-injector art disclosing a stinger embodiment because it cannot,” and that the references cited “disclose devices that (1) are not pen injectors, and (2) operate differently, with an axially-fixed screw rotating (via, e.g., a motor) to move a rotationally-fixed nut,” not the drive mechanism of the ’844 patent. *Id.* at 4 (citing Ex. 2332 ¶ 18).

While we acknowledge Dr. Slocum apparently conceived of an attenuated way to add a “stinger” to the device disclosed in the GB application to redesign it in a way that arguably creates a functioning piston rod with internal threading, that design was not disclosed in the GB application and no evidence provided by Patent Owner sufficiently shows that a “Stinger Model” was well known or interchangeable with an externally threaded piston rod, as applied to the device disclosed in the GB application. We credit the testimony of Mr. Leinsing over the testimony of Dr. Slocum in this regard.

For these reasons, we find that Patent Owner does not show adequate support in the '616 application or the GB application for proposed substitute claim 31. Substitute claims 32, 35, and 36 depend from substitute claim 31. Proposed substitute claims 32, 35, and 36 suffer from the same deficiency for the same reasons. Substitute claims 33, 37, and 38 depend from claim 21 and require “a piston rod comprising either an internal or an external fourth thread.” As explained above, Patent Owner does not show adequate support in the '616 application or the GB application for “a piston rod comprising . . . an internal . . . fourth thread,” (i.e., and internally threaded piston rod). Accordingly, substitute claims 33, 37, and 38 lack the necessary written description support.

D. Conclusion

For these reasons, we find that Patent Owner's Corrected Revised Contingent Motion to Amend does not establish adequate support in the '616 application or the GB application for proposed substitute claims 31–38. Thus, we deny Patent Owner's Corrected Revised Contingent Motion to Amend.

IV. ANALYSIS OF PETITIONER'S MOTION TO EXCLUDE

Petitioner moves to exclude the following one hundred and thirty-seven exhibits – Exhibits 2001–2017, 2100–2107, 2109, 2111, 2113–2119, 2121–2152, 2158–2162, 2164–2168, 2173–2201, 2203–2212, 2214–2218, 2223–2225, 2302, 2305, 2306, 2308–2312, 2316, 2323–2325, 2327, and 2332–2334. Mot. 1. Petitioner also moves to exclude “the redirect testimony” in Exhibits 1054 and 1109. *Id.* Petitioner states that corresponding objections to the exhibits sought to be excluded were filed prior to the motion to exclude. *Id.* (citing Papers 24, 37, 38, 68, 91). Petitioner further argues that to the extent any exhibit is not excluded, “use

of the exhibit should be restricted to the use for which it was originally submitted.” *Id.* at 10 (citing Federal Rules of Evidence (“FRE”) 105). Petitioner, as the “moving party,” “has the burden of proof to establish that it is entitled to the requested relief.” 37 C.F.R. § 42.20 (2017).

A. Exhibits 2001–2017

Petitioner moves to exclude Exhibits 2001–2017 pursuant to FRE 402 and 403 because these exhibits are purportedly not relevant to any contested issue in this proceeding and risk confusing the issues. Mot. 1–5. Patent Owner responds that these exhibits “were offered to show information that was relevant to disputed issues raised during the preliminary stage of this proceeding.” Mot. Opp. 1. Patent Owner asserts that these exhibits do not lack relevance, have no risk of confusing the issues, and should therefore remain in the record. *Id.* In reply, Petitioner argues that Patent Owner conceded these exhibits pertain to pre-institution issues and failed to identify any issue remaining in the trial for which they are relevant. Mot. Reply 1. Petitioner further asserts that, if these exhibits are not excluded, “they should be limited to the purpose for which they were submitted.” *Id.* (citing FRE 105).

We are not persuaded that exhibits offered prior to institution of *inter partes* review should be excluded after institution merely because they are no longer relevant to an issue in dispute between the parties. Indeed, the record contains other documents that may similarly be characterized as only relevant prior to institution, such as the preliminary response of the Patent Owner. These exhibits and papers are a part of the record on which institution was based and Petitioner fails to identify any persuasive reasons for their exclusion at this stage of the proceeding. Petitioner shows no risk of confusion by allowing the exhibits to remain in the record. Petitioner also

fails to direct our attention to any prior Board decision that granted a motion to exclude exhibits merely because they were relevant only to the pre-institution phase of an *inter partes* review. Petitioner does not show a persuasive reason to exclude the exhibits or expressly limit their purpose pursuant to FRE 105 over the competing interest of maintaining a full record of the evidence and arguments provided by the parties, including evidence introduced only for purposes relevant to our decision on institution.

B. Exhibits 2100, 2102–2106, 2113–2115, 2118, 2119, 2122, 2124, 2125, 2127, 2129–2135, 2138–2141, 2145–2147, 2151, 2152, 2158–2161, 2164–2166, 2173, 2174, 2176–2183, 2186–2200, 2203–2212, 2214–2218, 2225, 2305, 2306, 2308–2312, 2323, 2324, and 2327

Petitioner contends Exhibits 2100, 2102–2106, 2113–2115, 2118, 2119, 2122, 2124, 2125, 2127, 2129–2135, 2138–2141, 2145–2147, 2151, 2152, 2158–2161, 2164–2166, 2173, 2174, 2176–2183, 2186–2200, 2203–2212, 2214–2218, 2225, 2305, 2306, 2308–2312, 2323, 2324, and 2327 should be excluded pursuant to FRE 402 and 403 “because they were not discussed in the substantive papers, cannot be relevant to them, and consequently serve only to confuse and create prejudice through belated surprise.”²⁰ Mot. 4. Petitioner further contends that Exhibits 2225, 2323, and 2324 should be excluded under FRE 403 and 802 because they “were not cited in any substantive papers and are prejudicial because it risks confusion by diverting attention away from the actual issues under review,” and they are “hearsay without exception.” Mot. 10. Petitioner offers no additional explanation of its arguments specific to Exhibits 2225, 2323, or 2324 to show that they are hearsay. Likewise for all of these exhibits,

²⁰ Exhibits 2147, 2151, 2152, 2206, 2207, 2211, and 2215–2218 are further addressed below (Section V.G.) in light of Petitioner’s additional arguments with respect to these claims.

Petitioner identifies no support for the broad proposition that an exhibit “not discussed in substantive papers” must be excluded, and offers only unsupported bald assertions that the exhibits “cannot be relevant” and “serve only to confuse and create prejudice through belated surprise.” *See* Mot. 4, 10; *see also* Mot. Reply 1–2.

Patent Owner explains that Exhibits 2100 and 2102–2106 are exhibits to the deposition of Mr. Leinsing, that Exhibit 2225 is an exhibit to Mr. McDuff’s deposition, that Exhibits 2100–2103, 2113, 2131, 2134, 2135, 2138, 2147, 2152, 2158–2161, 2164–2166, 2173, 2174, 2176–2183, 2206–2207, 2211, 2214, 2218, 2310, and 2311 are expressly cited in Dr. Slocum’s declaration, that Exhibits 2124, 2145, 2146, 2164, 2186–2199, 2203–2205, and 2208–2210 are expressly cited by Dr. Grabowski, and that Exhibits 2125, 2140, 2141, and 2200 are expressly cited by Dr. Goland. Mot. Opp. 1–2. Patent Owner reasons that these exhibits provide context for understanding the testimony provided by the declarants and are materials they reasonably relied upon in forming their opinions. *Id.*; *see also id.* at 3 (addressing the relevance of Exhibits 2162, 2305, 2306, 2308–2312, 2323, 2324, and 2327). Patent Owner also states that Dr. Slocum relied upon Exhibits 2151 and 2215–2218. *Id.* at 11–12. Petitioner argues in reply that the exhibits should nonetheless be excluded or “limited to the purpose for which they were cited.” Mot. Reply 1–2.

We have considered the parties additional arguments and conclude that Petitioner does not show any persuasive reason any of the exhibits purportedly not “discussed in the substantive papers” should be excluded.

*C. Exhibits 2101, 2116, 2121, 2123, 2126, 2128, 2136,
2137, 2142–2144, 2175, 2184, 2185, and 2201*

Petitioner contends that Exhibits 2101, 2116, 2121, 2123, 2126, 2128, 2136, 2137, 2142–2144, 2175, 2184, 2185, and 2201 “should be excluded under FRE 402 and 403 because the properties for which they are cited (e.g., injection force and ease of use) are not required by any of the Challenged Claims so these exhibits serve only to confuse the issues and create prejudice through needless multiplication of issues.” Mot. 9–10. Patent Owner argues the exhibits are relevant. Mot. Opp. 12–13.

Petitioner offers no explanation or support for the notion that exhibits which pertain to properties *Petitioner alleges* are not required by any of the Challenged Claims should be excluded. Petitioner essentially concedes that the exhibits are relevant to an issue in dispute, but suggests that they be excluded because Petitioner does not agree with Patent Owner’s contentions. That simply is not a sufficient reason for exclusion.²¹

*D. Exhibits 2107, 2302, 2316, 2325, 2332,
1054 (redirect), and 1109 (redirect)*

Petitioner seeks to exclude Exhibits 2107, 2302, 2316, 2325, 2332, 1054 (redirect), and 1109 (redirect) under FRE 702, 703, and 705. Mot. 4–8. Petitioner fails to identify at the outset of its argument what these exhibits correspond to, improperly leaving it to Patent Owner and the Board to fill in the information absent from the motion. Additionally, Petitioner fails to expressly address in any substantive manner Exhibits 2302, 2316, and 2325,

²¹ In reply, Petitioner argues for the first time that these exhibits should be “excluded under FRE 801–804.” Mot. Reply 5. Because this argument was not raised in the Motion, it is improper.

and, accordingly, does not satisfy its burden to show that these exhibits should be excluded.

With respect to Exhibits 2107 and 2332, which are two of the declarations of Dr. Slocum, as well as the deposition redirect examination of Dr. Slocum in Exhibits 1054 and 1109, Petitioner argues that Dr. Slocum did not have personal knowledge of injection pens or the industry during the relevant time period and that Dr. Slocum relied upon Mr. Veasey, one of the named inventors of the '844 patent, for certain data and a model used for various calculations. *Id.* at 4–6. As to Exhibit 2107, Petitioner argues that “it does not provide sufficient facts or data, is not the product of reliable principles and methods, and has not applied the proper principles to the facts of this proceeding.” *Id.* at 7. Petitioner contends, as an example, that Appendices A through F “do not set forth the principles used nor do they demonstrate the calculations used in generating the spreadsheets” and, thus, “should be excluded for failing to disclose the underlying facts and data, and failing to set forth the bases of Dr. Slocum’s opinions.” *Id.* As to Exhibit 2332, Petitioner argues that “it is not supported by sufficient facts of record to qualify as expert testimony.” *Id.*

With respect to Dr. Slocum’s personal knowledge, Patent Owner correctly explains in response that “an expert need not be qualified in the pertinent art at the time of the invention,” and that neither party’s proposed definition of the ordinary level of skill in the art requires specific knowledge of, or experience with, pen injectors. Mot. Opp. 5 (citing Ex. 1011 ¶ 106; Ex. 2107 ¶ 102). Further, Patent Owner asserts that Dr. Slocum acquired knowledge of the pen injector field as of 2003 because he “(i) researched the prior art, (ii) canvassed literature on pre-critical date pen injectors, design considerations, and design standards, and (iii) conversed with those in the

industry (*i.e.*, Mr. Veasey and Dr. Goland).” *Id.* (citing Ex. 2107 ¶¶ 25–61). Patent Owner also contends Dr. Slocum documented his opinions with facts and data in support of what a person of ordinary skill would have known in 2003. *Id.* at 6.

Regarding the information and model obtained from Mr. Veasey, Patent Owner asserts that Dr. Slocum performed his own investigation and research into design considerations and the state of the art, as documented in his declaration. *Id.* at 6–7 (citing Ex. 2107 ¶¶ 25–61). Patent Owner further asserts that much of the information provided by Mr. Veasey is undisputed, including design considerations and that the FlexPen[®] is the commercialization of an embodiment of Steinfeldt-Jensen. *Id.* at 7–8. Moreover, Patent Owner states that it “served as supplemental evidence the native spreadsheets that specify [the] principles and calculations” set forth in Appendices A through F and that “the measurements provided by Mr. Veasey are corroborated, unrebutted, and reliable.” *Id.* at 9–10 (citing Ex. 2226).

In reply, Petitioner offers no persuasive argument in support of its motion, but instead baselessly suggests that Dr. Slocum “objectively failed to act as an expert in this case.” Mot. Reply 2. Petitioner also challenges Dr. Slocum’s acceptance of Mr. Veasey’s data “without question,” contending that Dr. Slocum only did so because “he had no relevant knowledge or experience.” *Id.* at 3. Petitioner also asserts that Patent Owner hid Mr. Veasey’s involvement in Dr. Slocum’s testimony precluding Petitioner from cross-examining Mr. Veasey. *Id.* at 4.

We find that Dr. Slocum is undisputedly an expert in mechanical engineering with knowledge and experience *beyond* the level of ordinary skill in the art as the parties have proposed and we have adopted. *See*

Sundance, Inc. v. DeMonte Fabricating Ltd., 550 F.3d 1356, 1363 (Fed. Cir. 2008) (noting that “[a] witness possessing merely ordinary skill will often be qualified to present expert testimony both in patent trials and more generally”) (citations omitted). Additionally, as both parties acknowledge, there is no requirement that an expert have personal knowledge of the technology during the specific relevant time period in order to qualify as an expert. In this regard, we find that Patent Owner and Dr. Slocum have established sufficient support, as detailed above, as to how he acquired knowledge of the specific technology at issue—the mechanical operation and design of injection pens. Further, Dr. Slocum’s reliance upon other individuals, including Mr. Veasey, to provide information upon which he based his opinions does not render him unqualified to offer an expert opinion.

Petitioner’s assertions that Patent Owner hid Mr. Veasey’s involvement are unfounded. In particular, Dr. Slocum acknowledged in Appendix B of his declaration that the “[i]nput values were provided by Mr. Robert Veasey of DCA Engineering.” Ex. 2107, App. B at 2. Thus, we find that Petitioner could have, but did not, seek to depose Mr. Veasey and therefore Petitioner’s arguments regarding Mr. Veasey’s involvement do not justify excluding Dr. Slocum’s declaration (Ex. 2107) or redirect testimony (Ex. 1054). To the extent the credibility of any of the individuals upon which Dr. Slocum relied may be in doubt, e.g., Mr. Veasey’s potential bias as a named inventor on the ’844 patent, those issues are the proper subject of cross-examination, go to the weight accorded the evidence, and do not justify excluding Dr. Slocum’s testimony on the facts presented here. And, to the extent Petitioner questions the data or model provided by Mr. Veasey, the proper recourse is to probe the bases for such during cross-examination.

Therefore, Petitioner does not show that Dr. Slocum should be disqualified as an expert in this proceeding or that any of Exhibits 2107, 2302, 2316, 2325, 2332, 1054 (redirect), and 1109 (redirect) should be excluded.

E. Exhibit 2109

Petitioner contends that Exhibit 2109, the declaration of Dr. Grabowski should be excluded under FRE 702, 703, and 705 because his opinions are based on data that Petitioner failed to provide in accordance with 37 C.F.R. § 42.65 (“Rule 42.65”). Mot. 8–9. Patent Owner responds that “Petitioner cites no authority that a party must file every single document that an expert considers in forming his opinions,” that it complied with Rule 42.65 by “disclosing Dr. Grabowski’s reliance on IMS Health data,” that “the underlying IMS Health data is voluminous,” and that “Petitioner independently obtained the IMS Health data and moved it into the public record” in related district court litigation. Mot. Opp. 11.

Petitioner replies that Patent Owner does not cite a rule in support of its failure to produce the data underpinning Dr. Grabowski’s testimony merely because it was voluminous, and that, even if Petitioner independently obtained the data, it was unable to “test” whether it was the same as the data relied upon by Dr. Grabowski. Mot. Reply 5. Petitioner, however, does not suggest that it sought an order from the Board requiring Patent Owner to produce the data, and shows no prejudice in light of Petitioner’s ability to obtain the data independently. Petitioner had every opportunity needed to “test” whether it was the same data by deposing Dr. Grabowski. Petitioner does not show any sufficient basis for excluding Exhibit 2109.

F. Exhibit 2111

Petitioner contends that Exhibit 2111, the Declaration of Dr. Robin S. Goland, should be excluded under FRE 702 and 703 because “her

unqualified testimony contrary to her own experience demonstrates a stark failure to provide testimony that ‘is the product of reliable principles and methods.’” Mot. 8 (quoting FRE 702(c)); Mot. Reply 4–5. Petitioner’s argument, on its face, is insufficient to support exclusion. Petitioner offers no explanation for its frivolous assertion that Dr. Goland is unqualified to offer an expert opinion in this proceeding. With regard to her experience, Dr. Goland explains in her declaration the following:

I received a Bachelor of Arts in History from Harvard University in 1976. After completing my undergraduate studies, I went on to obtain an M.D. degree from Columbia University in 1980.

After completing my internship in 1981, I undertook a residency in internal medicine at New York-Presbyterian/Columbia University from 1980-1984. I completed a fellowship in endocrinology at Columbia University College of Physicians and Surgeons in 1987. I am board-certified in Internal Medicine and Endocrinology.

Since completing my residency and fellowship, I’ve held a number of academic positions at Columbia University College of Physicians and Surgeons, including Assistant Professor of Clinical Medicine (1987-1989), Assistant Professor of Medicine (1990-1996), Florence Irving Associate Professor of Medicine (1997-2008), Professor of Clinical Medicine (2008-present), Professor of Clinical Medicine and Clinical Pediatrics (2010-present), and J. Merrill Eastman Professor of Clinical Diabetes (2011-present).

Since 1987, I have been the Chief of the Diabetes Clinic at New York-Presbyterian Hospital/Columbia University. In 1997, I founded the Naomi Berrie Diabetes Center at Columbia University, and I have served the center as co-director ever since. The Naomi Berrie Diabetes Center serves 14,000 patients each year, approximately 40% of which have Type 1 diabetes. In addition, the Center conducts clinical research on diabetes.

During my career, I have authored or co-authored over 80 peer reviewed articles. I am a member of the American Diabetes Association. I also served as a member of the Medical Advisory

Board of the Juvenile Diabetes Foundation, New York Chapter, the Pharmacy and Therapeutics Committee of Merck Health Solutions, and the Medical Advisory Board of the NY Stem Cell Foundation.

I am an experienced clinical investigator and principal investigator in diabetes trials. In 1996-1999, I received the Irving Scholar Award for Clinical Investigation from Columbia University.

Ex. 2111 ¶¶ 2–7. We find Dr. Goland is more than sufficiently qualified to offer an expert opinion in this proceeding. Petitioner fails to show any basis for excluding Exhibit 2111.

G. Exhibits 2117, 2147–2152, 2162, 2167, 2168, 2206, 2207, 2211, and 2215–2218

Petitioner contends that Exhibits 2117, 2147–2152, 2162, 2167, 2168, 2206, 2207, 2211, and 2215–2218 are animations “offered to show animated operations of prior art and non-prior art injection pens” and should be excluded as hearsay pursuant to FRE 801–804 “because they are offered for the truth of their contents without satisfying any of the hearsay exceptions.” Mot. 9. Patent Owner responds that an expert may rely upon hearsay if reasonable to do so in the expert’s field, and that Dr. Slocum relied upon each of these exhibits “to explain the operation of the injector pens in the challenged patents, the prior art, and Petitioner’s proposed modifications to the prior art.” Mot. Opp. 11–12. Petitioner argues in reply that the exhibits are not admissible hearsay merely because they were relied upon by an expert. Mot. Reply 5.

Patent Owner does not dispute that these exhibits constitute hearsay and Petitioner does not dispute that Dr. Slocum was permitted to rely upon these exhibits in formulating his opinions. Accordingly, Exhibits 2117,

2147–2152, 2162, 2167, 2168, 2206, 2207, 2211, and 2215–2218 are limited to the purpose of showing the basis for Dr. Slocum’s testimony.

H. Exhibits 2223 and 2224

Petitioner contends that Exhibits 2223 and 2224 are “offered to show secondary considerations” and should be excluded under FRE 402, 403, 802, and 901 because they are “hearsay without exception, lack authentication, and are unreasonably prejudicial because they are cited for a new purpose.” Mot. 10. Petitioner does not explain what the “new purpose” is, but suggests that Ex. 2223 is a “self-serving advertisement by an interested party.” Petitioner does not identify the purported “interested part.” *Id.* Patent Owner responds with the following explanation of the exhibits at issue:

EX2223 is a press release from DCA, the designer of the SoloSTAR pen at issue in this proceeding, announcing that SoloSTAR won the 2008 Good Design Award from The Chicago Athenaeum: Museum of Architecture and Design. The exhibit is relevant to objective indicia of non-obviousness. Dr. Grabowski obtained the exhibit and cited it in his declaration. *See* EX2109 at n.92. Dr. Grabowski therefore provided the required foundation. Finally, as Dr. Grabowski is permitted to rely upon EX2223 under FRE703, there is no basis to exclude it.

Next, EX2224 was presented without objection to Petitioner’s expert Dr. McDuff during his deposition. *See* EX2318, 73:3-18, 88:7-89:20. The exhibit confirms that an academic journal (EX2116) cited in both Dr. McDuff’s and Dr. Grabowski’s declarations, was double-blind peer-reviewed and thus a reliable source of information. *See* EX1060 at n.127; EX2109 n.53. As Petitioner did not object to this exhibit at deposition, there is no basis to exclude it now.

Mot. Opp. 13–14. Petitioner does not respond to Patent Owner’s arguments in its Reply. *See* Mot. Reply. Petitioner fails to show any sufficient basis for excluding Exhibits 2223 and 2224 because the arguments in the motion are undeveloped, conclusory, and vague.

I. Exhibits 2333 and 2334

Petitioner contends that Exhibits 2333 and 2334 should be excluded under FRE 402 and 403 because they “are not cited in the reply and have no evidentiary value, but instead appear to be illustrated argument,” and are, therefore, “not relevant.” Mot. 9. Petitioner fails to even explain what Exhibits 2333 and 2334 are in its motion. Patent Owner explains the following:

EX2333 and EX2334 are animations of designs discussed at length in Dr. Slocum’s Declaration in Support of Sanofi’s MTA Reply (EX2332). Specifically, Dr. Slocum explains that the designs animated in EX2333 and EX2334 would have been immediately discerned by a [person of ordinary skill in the art] having read the GB [a]pplication. *See* EX2332, ¶ 30 (EX2333), ¶ 36 (EX2334). EX2333 and EX2334 undermine Petitioner’s written description arguments concerning the claimed “piston rod” and “arc shaped body,” and therefore have evidentiary value.

Mot. Opp. 12. Petitioner does not specifically address Exhibits 2333 and 2334 in its Reply outside of grouping them with its argument concerning other exhibits purportedly not cited by Patent Owner. Mot. Reply 1. Petitioner does not show any persuasive reason Exhibits 2333 and 2334 should be excluded merely because they are “not cited in the reply.”

J. Summary

In summary, many of Petitioner’s arguments purportedly supporting its attack on a wide range of exhibits are poorly supported, undeveloped, not credible, and lack on their face the basic information necessary to show Petitioner is entitled to the relief requested, as explained above. Exhibits 2117, 2147–2152, 2162, 2167, 2168, 2206, 2207, 2211, and 2215–2218 are limited to the purpose of showing the basis for Dr. Slocum’s testimony.

V. CONCLUSION

Our final determination in this case is summarized below:²²

Claims	35 U.S.C. §	Reference(s)	Claim(s) Shown Unpatentable	Claims Not shown Unpatentable
21–29	102(a)	Giambattista	21–24, 26–28	25, 29
24–29	103	Giambattista, Steinfeldt-Jensen	24–29	
30	103	Giambattista, Klitgaard	30	
Overall Outcome			21–30	

Motion to Amend Outcome	Claims
Original Claims Cancelled by Amendment	
Substitute Claims Proposed in the Amendment	31–38
Substitute Claims: Motion to Amend Granted	
Substitute Claims: Motion to Amend Denied	31–38
Substitute Claims: Not Reached	

²² Should Patent Owner wish to pursue amendment of the Challenged Claims in a reissue or reexamination proceeding subsequent to the issuance of this decision, we draw Patent Owner’s attention to the April 2019 *Notice Regarding Options for Amendments by Patent Owner Through Reissue or Reexamination During a Pending AIA Trial Proceeding*. See 84 Fed. Reg. 16,654 (Apr. 22, 2019). If Patent Owner chooses to file a reissue application or a request for reexamination of the challenged patent, we remind Patent Owner of its continuing obligation to notify the Board of any such related matters in updated mandatory notices. See 37 C.F.R. § 42.8(a)(3), (b)(2) (2019).

VI. ORDER

In consideration of the foregoing, it is hereby:

ORDERED that claims 21–30 of the '844 patent have been proven to be *unpatentable*;

FURTHER ORDERED that Patent Owner's Corrected Revised Contingent Motion to Amend (Paper 73) is *denied*; and

FURTHER ORDERED that Petitioner's Motion to Exclude (Paper 92) is *denied*; and

FURTHER ORDERED that, because this is a Final Written Decision, the parties to the proceeding seeking judicial review of the Decision must comply with the notice and service requirements of 37 C.F.R. § 90.2.

IPR2018-01680
Patent 9,526,844 B2

FOR PETITIONER:

Richard Torczon
Wesley Derryberry
Douglas Carsten
Jeffrey Guise
Nicole Stafford
Lorelei Westin
Arthur Dykhuis
Tasha Thomas
Elham Steiner
Yahn-Lin Chu

WILSON SONSINI GOODRICH & ROSATI

rtorczon@wsgr.com
wderryberry@wsgr.com
dcarsten@wsgr.com
jguise@wsgr.com
nstafford@wsgr.com
lwestin@wsgr.com
adykhuis@wsgr.com
tthomas@wsgr.com
esteiner@wsgr.com
ychu@wsgr.com

FOR PATENT OWNER:

Elizabeth Stotland Weiswasser
Anish Desai
Sudip Kundu
Kathryn Kantha
Adrian Percer
William Ansley
Matthew Sieger
Brian C. Chang
WEIL, GOTSHAL & MANGES LLP
elizabeth.weiswasser@weil.com
anish.desai@weil.com
sudip.kundu@weil.com
kathryn.kantha@weil.com
adrian.percer@weil.com

IPR2018-01680
Patent 9,526,844 B2

sutton.ansley@weil.com
matthew.sieger@weil.com
brian.chang@weil.com

W. Karl Renner
John Goetz
Joshua Griswold
Matthew Colvin
Kenneth Darby, Jr.
FISH & RICHARDSON P.C.
axf-ptab@fr.com
goetz@fr.com
griswold@fr.com
kdarby@fr.com
colvin@fr.com